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A B S T R A C T
Background
Basal cell carcinoma (BCC) is the commonest cancer aJecting white-skinned individuals, and worldwide incidence is increasing. Although
rarely fatal, BCC is associated with significant morbidity and costs. First-line treatment is usually surgical excision, but alternatives
are available. New published studies and the development of non-surgical treatments meant an update of our Cochrane Review (first
published in 2003, and previously updated in 2007) was timely.
Objectives
To assess the eJects of interventions for BCC in immunocompetent adults.
Search methods
We updated our searches of the following databases to November 2019: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE,
Embase, CINAHL, and LILACS.
Selection criteria
Randomised controlled trials (RCTs) of interventions for BCC in immunocompetent adults with histologically-proven, primary BCC. Eligible
comparators were placebo, active treatment, other treatments, or no treatment.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Primary outcome measures were recurrence at three years and five
years (measured clinically) (we included recurrence data outside of these time points if there was no measurement at three or five years)
and participant- and observer-rated good/excellent cosmetic outcome. Secondary outcomes included pain during and aKer treatment,
early treatment failure within six months, and adverse eJects (AEs). We used GRADE to assess evidence certainty for each outcome.
Main results
We included 52 RCTs (26 new) involving 6690 participants (median 89) in this update. All studies recruited from secondary care outpatient
clinics. More males than females were included. Study duration ranged from six weeks to 10 years (average 13 months). Most studies (48/52)
included only low-risk BCC (superficial (sBCC) and nodular (nBCC) histological subtypes). The majority of studies were at low or unclear
risk of bias for most domains. Twenty-two studies were industry-funded: commercial sponsors conducted most of the studies assessing
imiquimod, and just under half of the photodynamic therapy (PDT) studies.
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Overall, surgical interventions have the lowest recurrence rates. For high-risk facial BCC (high-risk histological subtype or located in the
facial 'H-zone' or both), there may be slightly fewer recurrences with Mohs micrographic surgery (MMS) compared to surgical excision (SE)
at three years (1.9% versus 2.9%, respectively) (risk ratio (RR) 0.64, 95% confidence interval (CI) 0.16 to 2.64; 1 study, 331 participants; low-
certainty evidence) and at five years (3.2% versus 5.2%, respectively) (RR 0.61, 95% CI 0.18 to 2.04; 1 study, 259 participants; low-certainty
evidence). However, the 95% CI also includes the possibility of increased risk of recurrence and no diJerence between treatments. There
may be little to no diJerence regarding improvement of cosmetic outcomes between MMS and SE, judged by participants and observers
18 months post-operatively (one study; low-certainty evidence); however, no raw data were available for this outcome.
When comparing imiquimod and SE for nBCC or sBCC at low-risk sites, imiquimod probably results in more recurrences than SE at three
years (16.4% versus 1.6%, respectively) (RR 10.30, 95% CI 3.22 to 32.94; 1 study, 401 participants; moderate-certainty evidence) and five
years (17.5% versus 2.3%, respectively) (RR 7.73, 95% CI 2.81 to 21.3; 1 study, 383 participants; moderate-certainty evidence). There may
be little to no diJerence in the number of participant-rated good/excellent cosmetic outcomes (RR 1.00, 95% CI 0.94 to 1.06; 1 study, 326
participants; low-certainty evidence). However, imiquimod may result in greater numbers of good/excellent cosmetic outcomes compared
to SE when observer-rated (60.6% versus 35.6%, respectively) (RR 1.70, 95% CI 1.35 to 2.15; 1 study, 344 participants; low-certainty
evidence). Both cosmetic outcomes were measured at three years.
Based on one study of 347 participants with high- and low-risk primary BCC of the face, radiotherapy may result in more recurrences
compared to SE under frozen section margin control at three years (5.2% versus 0%, respectively) (RR 19.11, 95% CI 1.12 to 325.78; low-
certainty evidence) and at four years (6.4% versus 0.6%, respectively) (RR 11.06, 95% CI 1.44 to 84.77; low-certainty evidence). Radiotherapy
probably results in a smaller number of good participant- (RR 0.76, 95% CI 0.63 to 0.91; 50.3% versus 66.1%, respectively) or observer-rated
(RR 0.48, 95% CI 0.37 to 0.62; 28.9% versus 60.3%, respectively) good/excellent cosmetic outcomes compared to SE, when measured at
four years, where dyspigmentation and telangiectasia can occur (both moderate-certainty evidence).
Methyl-aminolevulinate (MAL)-PDT may result in more recurrences compared to SE at three years (36.4% versus 0%, respectively) (RR
26.47, 95% CI 1.63 to 429.92; 1 study; 68 participants with low-risk nBCC in the head and neck area; low-certainty evidence). There were
no useable data for measurement at five years. MAL-PDT probably results in greater numbers of participant- (RR 1.18, 95% CI 1.09 to 1.27;
97.3% versus 82.5%) or observer-rated (RR 1.87, 95% CI 1.54 to 2.26; 87.1% versus 46.6%) good/excellent cosmetic outcomes at one year
compared to SE (2 studies, 309 participants with low-risk nBCC and sBCC; moderate-certainty evidence).
Based on moderate-certainty evidence (single low-risk sBCC), imiquimod probably results in fewer recurrences at three years compared to
MAL-PDT (22.8% versus 51.6%, respectively) (RR 0.44, 95% CI 0.32 to 0.62; 277 participants) and five years (28.6% versus 68.6%, respectively)
(RR 0.42, 95% CI 0.31 to 0.57; 228 participants). There is probably little to no diJerence in numbers of observer-rated good/excellent
cosmetic outcomes at one year (RR 0.98, 95% CI 0.84 to 1.16; 370 participants). Participant-rated cosmetic outcomes were not measured
for this comparison.
AEs with surgical interventions include wound infections, graK necrosis and post-operative bleeding. Local AEs such as itching, weeping,
pain and redness occur frequently with non-surgical interventions. Treatment-related AEs resulting in study modification or withdrawal
occurred with imiquimod and MAL-PDT.
Authors' conclusions
Surgical interventions have the lowest recurrence rates, and there may be slightly fewer recurrences with MMS over SE for high-risk facial
primary BCC (low-certainty evidence). Non-surgical treatments, when used for low-risk BCC, are less eJective than surgical treatments,
but recurrence rates are acceptable and cosmetic outcomes are probably superior. Of the non-surgical treatments, imiquimod has the best
evidence to support its eJicacy.
Overall, evidence certainty was low to moderate. Priorities for future research include core outcome measures and studies with longer-
term follow-up.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for basal cell carcinoma of the skin
Why is this question important?
Basal cell carcinoma (BCC) is the most common form of skin cancer among people with white skin.
BCC is not usually life-threatening but if leK untreated, it can cause important disfigurement, especially on the face.
Surgical removal of the aJected area and surrounding skin is usually the first option for treating BCC. Several diJerent surgical approaches
exist as well as non-surgical treatments, such as radiotherapy (high doses of radiation that kill cancer cells), and anti-cancer creams, gels
and ointments.
We reviewed the evidence from research studies, to find out which treatments work best for BCC.
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How did we identify and evaluate the evidence?
We searched for randomised controlled studies (studies where people are randomly put into one of two or more treatment groups),
because these provide the most robust evidence about the eJects of a treatment. We compared and summarised the evidence from all
the studies. Finally, we rated our confidence in the evidence, based on factors such as study methods and sizes, and the consistency of
findings across studies.
What did we find?
We found 52 studies that involved a total of 6690 adults with BCC. Most studies (48 out of 52) included hospital outpatients with small,
superficial or nodular BCC. Studies lasted for between six weeks and 10 years (average duration: 13 months). Twenty-two studies were
funded by pharmaceutical companies.
Our confidence in the evidence presented here is low to moderate, mainly because many studies were small.
Comparison between dierent surgical treatments
- Mohs micrographic surgery (a specialised surgical approach that removes less skin) may slightly decrease recurrence rates at three and
five years compared to surgical excision (one of the most common surgical treatments for BCC).
-There may be little to no diJerence in how well scars heal between these two surgical treatments according to patients and observers
(one study).
Surgery versus non-surgical treatments
Compared against surgical excision:
- Imiquimod (an anti-cancer cream) probably increases BCC recurrence rates at three and five years. There may be little to no diJerence in
scar healing according to patients, although imiquimod may increase chances of scars healing well when healing is rated by an observer
(one study).
- Radiotherapy may increase BCC recurrence rates at three and four years, and probably decreases chances of scars healing well (one study).
- MAL-PDT, a type of photodynamic therapy (that uses a light source and light-sensitive medicine to kill cancer cells), may increase BCC
recurrence rates at three years. MAL-PDT probably increases chances of scars healing well (two studies).
Comparison of dierent non-surgical treatments
Compared against imiquimod:
- MAL-PDT probably increases BCC recurrence rates at three and five years. There is probably little to no diJerence in scar healing (one
study);
What does this mean?
Overall, the evidence suggests that:
- surgery could reduce chances of BCC recurrence;
- non-surgical treatments such as anti-cancer creams or photodynamic therapy carry an increased chance of BCC recurrence, but could
increase chances of scars healing well compared with surgery.
Complications with surgical treatments include wound infections, skin graK failure and bleeding aKer the procedure. Non-surgical
treatments frequently lead to localised itching, weeping, pain and redness. Treatment-related side eJects that caused modifications to
the study or the withdrawal of participants occurred with imiquimod and MAL-PDT.
How-up-to date is this review?
The evidence in this Cochrane Review is current to November 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Mohs micrographic surgery compared to surgical excision for basal cell carcinoma of the skin
Mohs micrographic surgery compared to surgical excision for high-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from hospitals in the Netherlands
Intervention: Mohs micrographic surgery
Comparison: surgical excision
Anticipated absolute effects* (95% CI)Outcomes












































Although a reported outcome, raw data were not available. The authors of Smeets 2004 state that
overall, cosmetic outcomes did not significantly differ between groups.
The cosmetic outcomes were judged by participants 18 months post-operatively, and photographs
of a selected group of tumours (first 139 primary) were judged retrospectively by a panel of six indi-
viduals.
not estimable (1 RCT) ⊕⊕⊝⊝
LOW 2
-
Pain No study addressed this outcome. not estimable - - -
Early treat-
ment failure
No study addressed this outcome. not estimable - - -
































































































































CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm.




Summary of findings 2.   Imiquimod compared to surgical excision for basal cell carcinoma of the skin
Imiquimod compared to surgical excision for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from hospitals in the UK
Intervention: 5% imiquimod cream
Comparison: surgical excision
Anticipated absolute effects* (95% CI)Outcomes













Study populationRecurrence at 3 years










Study populationRecurrence at 5 years
































































































































































3 years on a 6-point
scale.4
Study populationPain (moderate/severe)





















Early treatment failure No study addressed this outcome not estimable - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI.
2 Downgraded one level for serious imprecision as only a single study with a small sample size and one level for serious risk of bias as unable to truly blind due to the nature of
interventions (i.e. presence or absence of scar will unblind to treatment allocation).
3 Downgraded one level for serious imprecision as only a single study with a small sample size and one level for serious risk of attrition bias as fewer pain data were available
for the surgical excision group.
4 6-point scale: unable to see lesion, very poor, poor, fair, good, excellent.
5 Measured on a scale from: no pain, mild pain, mild-to-moderate pain, moderate pain, moderate-to-severe pain and severe pain.
 
 
Summary of findings 3.   Radiotherapy compared to surgical excision (with or without frozen section margin control) for basal cell carcinoma of the
skin































































































































Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from a single hospital in France
Intervention: radiotherapy
Comparison: surgical excision (with or without frozen section margin control)
Anticipated absolute effects* (95% CI)Outcomes













Study populationRecurrence at 3 years









Study populationRecurrence at 4 years











661 per 1000 502 per 1000
(416 to 601)





4 years on a 3-point













years on a 3-point
scale.4 ITT analysis per-
formed.
Pain No study addressed this outcome. not estimable - - -
Early treatment failure No study addressed this outcome. not estimable - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; ITT: intention-to-treat; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.































































































































Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded two levels for very serious imprecision due to very wide 95% CI (although excludes 1, there is a greater than 100-fold diJerence).
2 Downgraded one level for serious indirectness (outcome outside our pre-specified time-points) and downgraded one level for serious imprecision as only a single study with
a small sample size.
3 Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions.
4 3-point scale: bad, fair, good.
 
 
Summary of findings 4.   MAL-PDT compared to surgical excision for basal cell carcinoma of the skin
MAL-PDT compared to surgical excision for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from hospitals in Brazil, the UK, Germany, Switzerland and Australia
Intervention: MAL-PDT
Comparison: surgical excision
Anticipated absolute effects* (95% CI)Outcomes
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Observer-rated at 1 year on a 4-
point scale.5
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
AEs: adverse effects; CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded two levels for very serious imprecision due to very wide 95% CI (although excludes 1, there is a greater than 100-fold diJerence).
2 Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions.
3 Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm.
4 Downgraded one level for serious imprecision due to small sample size and wide 95% CI.
5 4-point scale: poor (extensive occurrence of scarring, atrophy, or induration), fair (slight to moderate occurrence of scarring, atrophy or induration), good (no scarring, atrophy
or induration and moderate redness or increase in pigmentation compared with adjacent skin), excellent (no scarring, atrophy, or induration and slight or no redness or change
in pigmentation compared with adjacent skin).
 
 
Summary of findings 5.   Imiquimod cream compared to MAL-PDT for basal cell carcinoma of the skin
Imiquimod cream compared to MAL-PDT for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from seven hospitals in the Netherlands
Intervention: 5% imiquimod cream
Comparison: MAL-PDT
Anticipated absolute effects* (95% CI)Outcomes
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Study populationRecurrence at 5
years































During treatment: week of treat-
ment with highest frequency of
reported moderate/severe pain
(week 6 for imiquimod, treat-
ment cycle 2 for PDT).
Study populationEarly treatment
failure









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded one level for serious imprecision as only a single study with a small sample size.
2 Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI.
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B A C K G R O U N D
Description of the condition
Disease definition and burden
Basal cell carcinoma (BCC) is the most common skin cancer
and the most common cancer found in white-skinned individuals
(Dessinioti 2010; Lomas 2012; Madan 2016; Verkouteren 2017).
BCCs are slow-growing, locally invasive, malignant (but not life
threatening), epidermal skin tumours (Roewert-Huber 2007; Wong
2003). Patients with BCC place a considerable burden on healthcare
systems worldwide due to their high, increasing incidence and
associated morbidity. Furthermore, people with BCC are at high risk
of developing further BCCs and other ultraviolet radiation (UVR)-
related skin cancers. As a result, the disability adjusted life years
and healthcare costs of BCCs have risen significantly in recent
decades (Verkouteren 2017).
Clinical features
Clinical appearances and morphology of BCC can be diverse
(more than 26 subtypes have been described), with no universally
accepted classification system. The main clinical subtypes
are: nodular, superficial, ulcerated (rodent ulcer), morphoeic
(sclerodermiform), fibroepithelial (fibroepithelioma of Pinkus) and
advanced BCC (resulting from prolonged neglect) (Madan 2016).
Histopathological patterns are also diverse and include: nodular,
superficial, morphoeic, micronodular, infiltrative, pigmented and
basosquamous or metatypical subtypes (Crowson 2006). Early
BCCs may appear as a small red patch or a scab that fails to heal.
Symptoms such as pain are rare. Nodular BCC (nBCC) is the most
common subtype in the UK, making up to 60% of all BCCs (Scrivener
2002). However, in other countries such as Australia, superficial BCC
(sBCC) is the most common subtype (Raasch 2002). BCCs aJect the
head and neck region in the majority of cases (Scrivener 2002). A
recent UK study of first registered BCCs in the population identified
BCCs aJected the head and neck region around 70% of the time and
the trunk and extremities around 30% of the time (Venables 2019).
Clinicopathological features of the tumours can be used to
diJerentiate them into high-risk and low-risk subtypes, which
has implications on the management approach. High-risk
BCCs include: morphoeic, infiltrative, micronodular histological
subtypes; presence of perineural or perivascular invasion; size > 5
cm; recurrent lesion; centrofacial location, including periocular and
ears and host immunosuppression (Madan 2016). Low-risk BCCs
include: superficial and nodular histological subtypes when they
are located on a low-risk site (e.g. not centrofacial location).
Natural history
BCCs are usually slow-growing tumours that only very rarely
metastasize (spread) to other distant parts of the body (0.0028% to
0.55% of advanced BCCs metastasize) (Ting 2005). In people with
a competent immune system, growth of a BCC is usually localised
to the area of origin. BCCs tend to infiltrate surrounding tissues in
a three-dimensional fashion through the irregular growth of finger-
like projections which may not be apparent clinically (Breuninger
1991; Miller 1991). If leK untreated, or inadequately treated, the
BCC can cause extensive tissue destruction, particularly on the face.
Neglected cases may even infiltrate bone and deeper structures,
like the brain. The clinical course of BCC is unpredictable; it may
remain small for years with little tendency to grow, it may grow
rapidly, or it may proceed by successive spurts of extension of
tumour and partial regression (Franchimont 1982).
Epidemiology and causes
Considerable variation exists in the literature for incidence rates of
BCC. Latitude, sun exposure and skin type of a country's inhabitants
contribute to much of this variation. Additionally, despite being
common tumours, numbers of BCCs recorded in cancer registries
are frequently underestimated due to their high volume and low
perceived risk and oKen they are treated without a confirmatory
biopsy. Depending on the registry, it is estimated that between
30% to 50% of BCCs are unreported (NCIN 2010). However, since
2013 the UK has vastly improved registry data collection and now
records all cases of BCC and squamous cell carcinoma (SCC). This
has greatly improved the accuracy of epidemiological analysis of
keratinocyte cancers and the UK now has the largest population-
based keratinocyte cancer registry in the world (Venables 2019).
From 2013 to 2015, the European age standardised incidence rate
of BCC in the UK was 285 per 100,000 people annually. The highest
BCC rate was observed in Southwest England with 362 per 100,000
people annually.
Direct comparison of incidence rates between countries is limited
by the fact that studies oKen use diJerent standardisation methods
and because each country will have their own registry with
diJerent registration criteria. The highest incidence of BCC is
found in Australia where in Queensland from 1997 to 2006, the
rate was 1813 per 100,000 males annually and 1269 per 100,000
females annually (Verkouteren 2017). Parts of Africa have the
lowest reported incidence rates with less than 1 per 100,000
people annually (Lomas 2012). In mainland Europe, there is large
variation dependent on country and sex with the highest rate of
164.7 per 100,000 males annually found in the Netherlands and
the lowest rate of 24.5 per 100,000 females annually observed in
Croatia (Verkouteren 2017). In the USA, California had the highest
incidence rate of 1069 per 100,000 males annually. Data from
the USA provides compelling evidence for the role of decreasing
geographical latitude on increasing BCC incidence with a rate in
New Hampshire (43 degrees) of 309.9 per 100,000 males annually
(Karagas 1999) whereas in Arizona (35 degrees) the rate is 935.9 per
100,000 males annually (Harris 2001). The studies reporting these
incidence rates both used the same standardisation method.
The incidence of BCC is increasing globally. A systematic review
identified that incidence is increasing in Europe by 5.5% annually
(Lomas 2012), and the study by Venables 2019 calculated a mean
annual percentage increase of 5% between 2013 to 2015 for both
BCC and SCC across the UK. In the USA, the incidence is increasing
by around 2% annually (Verkouteren 2017). The Australian national
surveys have shown that the incidence rate has been increasing
since 1985, but that it may now be reaching a plateau (Lomas
2012). There has been a very large increase in BCC incidence in
young females in Europe and the USA that has led to a reversal of
the male:female ratio, such that the ratio observed now is female
> male in the younger population (Verkouteren 2017). Higher
frequency of tanning bed use and higher likelihood of seeking
medical attention in females are reasons postulated to contribute
to this observed trend.
Risk factors for BCC include: advanced age, male sex, fair skin, low
ability to tan, intense intermittent UVR exposure during childhood,
signs of actinic damage (skin changes due to excessive sun
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exposure), personal/family history of skin cancer, excessive sun bed
use, phototherapy, radiotherapy, systemic immunosuppression
and a genetic predisposition (Verkouteren 2017).
Germ-line mutations can also have a large eJect on the risk of
developing BCC such as those seen in Gorlin syndrome (naevoid
BCC syndrome). This is an autosomal (non-sex determining
chromosome) dominantly inherited condition characterised by
developmental abnormalities and the occurrence of multiple BCCs.
Mutations in people with Gorlin syndrome have been found on
the PTCH1 gene located on chromosome nine, which appears to
be crucial for proper embryonic development and for tumour
suppression (Johnson 1996).
Description of the intervention
The primary aim of treatment is complete removal or destruction
of the BCC lesion to result in cure and minimise the risk of
recurrence. This should also be balanced against the patient's
requirement for a good/acceptable cosmetic result (Madan 2016).
There are numerous interventions currently available for BCC and
the choice of intervention is determined by tumour factors such
as the histological/clinical subtype of BCC, site, size, whether
primary or recurrent tumour, as well as patient factors (e.g. co-
morbidities, importance of cosmesis) and other factors such as
available resources, costs and local health economics. The diJerent
interventions are usually split into surgical and non-surgical
interventions. Generally, surgical interventions are used as first-
line treatments for both high-risk and low-risk BCC subtypes and
non-surgical interventions are usually reserved for low-risk BCC
subtypes where histological margins are less important (Madan
2016). Radiotherapy and electrochemotherapy are the exceptions
as they tend to be used for high-risk BCCs not amenable to surgical
intervention.
Surgical (physical) interventions
• Surgical excision (with predetermined margins)
• Surgical excision (with frozen section margin control)
• Mohs micrographic surgery (MMS - technique that takes
serial horizontal frozen sections intraoperatively to examine
histologically the entire surgical margin to confirm complete
tumour clearance)
• Curettage and cautery (synonymous for electrodesiccation)
• Cryosurgery (synonymous for cryotherapy, delivered by a
variety of methods)







• Intralesional interferon, fluorouracil
• Electrochemotherapy
• Others (solasodine glycosides, sinecatechins, diclofenac,
calcitriol)
How the intervention might work
Surgical (physical) interventions
Surgical excision (SE) with predetermined margins is one of the
most common treatments for BCC and is oKen regarded as the gold-
standard. SE involves excising the tumour under local anaesthetic
with a variable margin of clinically normal surrounding tissue. A
key advantage of SE over non-surgical techniques is that it allows
the histological examination of the excised specimen and therefore
an accurate assessment of the surgical margins. A peripheral
margin of 4 mm to 5mm is usually suggested for well-defined,
small BCC (Wolf 1987, Kimyai-Asadi 2005) and the use of curettage
prior to excision to delineate the margins of the BCC is oKen
performed (Chiller 2000). Excision through subcutaneous fat is
generally advisable for the deep surgical margin, however there is a
lack of evidence informing this. Factors such as the local anatomy,
size and histological subtype of the BCC will influence this decision
(Telfer 2008).
Mohs micrographic surgery (MMS) was pioneered in the 1930s by
Frederic Mohs and is a specialised surgical procedure in which serial
horizontal frozen sections allow the microscopic examination of
the entire surgical margin during surgery (in contrast to the 1% to
2% of the margin asseessed by "bread-loafing" of vertical sections
examined with standard excision), so that the extent of excision can
be defined precisely (Madan 2016). The technique produces very
high cure rates and is oKen used as the gold-standard for high-
risk facial BCC. Another important benefit is that it allows for tissue
sparing as smaller margins than SE can be taken.
Similar to MMS is the technique of surgical excision with frozen
section margin control, which employs a similar serial frozen
section technique but oKen with standard excision margins. Frozen
section margin control also diJers from MMS in that excision of the
tumour and an accompanying annular strip of surrounding tissue is
performed with vertical margins (Nizamoglu 2016; Avril 1997).
Curettage and cautery (C&C) and curettage alone are traditional
surgical BCC treatment methods that are sometimes used for
small, low-risk BCCs. There is wide variation in the protocols and
techniques used, including type of curette used (e.g. Volkmann
spoon curette, disposable loop curette) and the number of
treatment cycles. The procedure normally destroys epidermis and
upper dermis and therefore scarring tends to be mild (Madan 2016).
Curetted tissue is usually histologically examined but assessment
of surgical margins is usually not possible.
Cryosurgery involves the direct application of liquid nitrogen to
freeze a BCC lesion to between -50 °C and -60 °C resulting in
destruction of both the tumour and a margin of surrounding
normal tissue (Telfer 2008). Techniques and liquid nitrogen delivery
methods are variable and protocols diJer including number of
freeze-thaw cycles. Mallon 1996 showed that a double 30-second
freeze-thaw cycle achieved higher cure rates than a single freeze-
thaw cycle for facial BCC, and that a single freeze-thaw cycle
achieves high cure rates for truncal BCC.
Ablative lasers (e.g. carbon dioxide laser) utilise their tissue-heating
properties to destroy BCC with high accuracy but this technique
does not allow any histological examination and consequently it
is not suitable for high-risk lesions. It is therefore not widely used
in the treatment of BCC. There are some data suggesting that,
following ablative laser treatment, recurrent BCC can develop into a
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more aggressive histological subtype (Jung 2011). Pulsed dye laser
is generally used to treat vascular skin lesions and is also used as
a treatment for thin, low-risk BCCs based on the observation that
they are oKen highly vascular with clinically evident telangiectasias
(dilated blood vessels) (Shah 2009).
Non-surgical (medical) interventions
Radiotherapy involves directing ionising radiation to destroy
tumour tissue and a margin of surrounding normal tissue.
Several diJerent techniques and methods are currently used
including conventional X-ray therapy, interstitial brachytherapy
and superficial contact therapy with the choice of technique
dependent on factors such as size and location of the lesion and
performance status of the patient (Telfer 2008). Radiotherapy can
be used for high-risk (including recurrent tumours) and low-risk
BCCs and is oKen the first-line for high-risk BCCs in patients who
do not want surgical intervention. Radiotherapy is usually only
available at specialist hospital centres due to the high costs of
the equipment and need for a clinical oncologist to decide on the
treatment regimen. Usually the treatment is given in a fractionated
regimen which requires multiple hospital visits over several days
to weeks. Importantly, radiotherapy should not be used in the
treatment of previously radiotherapy-treated recurrent BCCs and
is contraindicated in patients with Gorlin syndrome as they have a
increased radiosensitivity and can develop multiple BCCs within a
field of radiation (Kleinerman 2009).
Imiquimod is an immunomodulator topical treatment that works
by stimulating toll-like receptors-7 and -8, present on immune cells,
inducing interferon-α which promotes a Th1 innate and adaptive
cell-mediated immune response. This results in the recognition
and subsequent destruction of tumour cells by the immune system
(Dummer 2003). Imiquimod is licensed in the treatment of low-
risk BCCs up to 2 cm diameter in immunocompetent patients and
the treatment regimen is five times per week for six weeks (sBCC)
or 12 weeks (nBCC). It is fairly common for patients to experience
influenza-like symptoms (due to the interferon release) and local
application-site reactions are common.
5-fluorouracil (5-FU) is a pyrimidine analogue that disrupts DNA and
RNA synthesis by inhibiting the enzyme thymidylate synthetase,
thereby preventing purine and pyrimidine (DNA/RNA building
blocks) from becoming incorporated into DNA during the cell-cycle
(Sloan 1990). 5-FU cream is commonly used in the treatment of
pre-malignant actinic keratosis (AK) and Bowen disease and is less
commonly used in the treatment of small, low-risk BCC. Application
site reactions are common. 5-FU can also be administered
intralesionally to treat low-risk BCC.
Photodynamic therapy (PDT) is a procedure that involves the
application of a photosensitiser to BCC lesions and surrounding
normal skin. It relies on the principle that the sensitiser
accumulates in higher concentration within rapidly proliferating
malignant cells compared to cells in adjacent normal tissues. The
photosensitiser is activated by visible light of certain wavelengths
which produces cytotoxic oxygen species and free radicals that
selectively destroy the tumour cells (Fritsch 1998). Systemic PDT
is utilised for some solid organ tumours, however in dermatology
the mainstay of PDT is topical using the photosensitisers 5-
aminolevulinic acid (ALA; Levulan® Kerastick®, Ameluz® and
Alacare®), the methyl ester of ALA, methyl aminolevulinate
(MAL; Metvix®/Metvixia®) and more recently hexylaminolevulinate
(HAL, Hexvix®) has been used. These photosensitisers utilise the
principles of the haem biosynthesis pathway, acting as pro-drugs
that enter and accumulate in cells and are metabolised to form
protoporphyrin IX which accumulates in the target tissue (Ibbotson
2016). Protoporphyrin IX is a potent and eJicient photosensitiser
when it is present in high concentration and can be activated by
light of the appropriate wavelengths (Ibbotson 2016).
Ingenol mebutate is a topical treatment derived from the plant
Euphorbia peplus and is licensed in the treatment of AK. It has
a dual mechanism of action whereby it destroys epidermal cells
within hours and induces production of antibodies that result in
neutrophils targeted to kill any residual dysplastic epidermal cells
(Rosen 2012).
Intralesional interferon utilises the principles of the naturally
occurring interferon family of proteins. These proteins are secreted
by cells in response to viral infections and function by binding to
promote Th1 innate and adaptive cell-mediated immune responses
than can be harboured to destroy tumour cells (Tucker 2006). The
treatment usually needs to be delivered over multiple sessions and
is expensive which limits its widespread use. Systemic side-eJects
are common (Madan 2016).
Electrochemotherapy (ECT) involves permeating cytotoxic agents
(classically bleomycin) into the tumour using short electric pulses
(a process known as electroporation), resulting in a direct cytotoxic
eJect (Campana 2017).
Zycure cream is a mixture of 0.005% solasodine glycosides (mainly
solasonine and solamargine) found in solanaceous plants of
the nightshade family, such as aubergine (Punjabi 2008). The
mechanism of action of these compounds is thought to involve
direct cell lysis and induction of apoptosis with selectivity towards
tumour cells (van der Most 2006).
Sinecatechin ointment contains epigallocatechin-3-gallate (EGCG)
which is an active constituent of green tea. It is licensed in the
treatment of genital warts and has been shown to have cytotoxic
eJects on tumours cells through inhibition of cell growth, induction
of apoptosis and possible inactivation of β-catenin signalling
through the Wingless (Wnt) pathway (Singh 2013).
Sonic hedgehog pathway inhibitors target the approximate 90% of
BCC that have mutations in genes causing unregulated activation
of the sonic hedgehog pathway. Oral hedgehog pathway inhibitors
(vismodegib and sonidegib) are licensed for the treatment of
metastatic BCC and locally advanced BCC not appropriate for
surgery or radiotherapy (Madan 2016). Trials are under way
assessing the safety and eJicacy of topical hedgehog inhibitors for
BCCs in Gorlin syndrome patients, but none of these studies met
our inclusion criteria.
Intervention outcomes
The ideal outcome of any intervention to treat a BCC would be
to achieve complete clearance with no recurrence at follow-up,
and to fulfil satisfactory cosmetic results with minimal risk of
discomfort or adverse eJects before or aKer the intervention. All
interventions have the potential to fall short of these expectations
to varying degrees. The more complete the removal or destruction
of the lesion, the lower the risk of recurrence, but both modes of
tumour eradication unfortunately cause localised tissue damage.
The resultant inflammation can lead to adverse eJects such as pain,
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erythema, bleeding, crusting, vesicles, oedema, and paraesthesia.
Pain of varying degrees is one of the more common adverse
eJects, and therefore has the potential to influence the patient’s
treatment choice and/or adherence. AKer the initial inflammatory
phase lasting a week or so, a healing wound undergoes a three-
week proliferation stage during which collagen is deposited and a
scar begins to form. This is followed by a remodelling stage lasting
a year, during which collagen cross-linking occurs and the scar
matures (Mulholland 2012). Other undesired post-inflammatory
cosmetic outcomes include hypo- and hyper-pigmentation.
Why it is important to do this review
BCC is common, continuously rising in incidence and is associated
with significant morbidity and costs to healthcare systems.
Although there are a wide variety of treatment modalities used in
the management of BCCs, and the vast majority of the tumours
are successfully treated, little research is available which accurately
compares these diJerent treatment modalities.
It is essential for both healthcare providers and patients to have
the best available evidence so that they can weigh up the risks and
benefits of the available treatments; to allow and promote shared
decision making.
Since the publication of the previous version of this review
(Bath-Hextall 2007), the results of several long-term studies on
interventions for BCC have become available and several novel,
non-surgical treatments have been developed and entered into
clinical trials making this update timely and necessary.
O B J E C T I V E S
To assess the eJects of interventions for basal cell carcinoma (BCC)
in immunocompetent adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised controlled
trials (RCTs) of interventions for basal cell carcinoma (BCC).
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Types of participants
All immunocompetent adults who have one or more histologically-
proven, primary BCC, who were eligible for randomisation to either
active treatment, placebo, other treatment or no treatment were
included. Persistent (where a number of treatments have been tried
with no success) or recurrent tumours have been excluded. Studies
including participants with Gorlin syndrome (basal cell naevus
syndrome), organoid naevi or other genetic syndromes have been
excluded. Excluding such patients from trials is commonplace as
the aetiology of the BCCs are diJerent and treatments are known
to work diJerently (for example radiotherapy can increase risk
of developing further BCCs in Gorlin syndrome) and with large
numbers of lesions, confounding of results can occur.
Types of interventions
Treatments for BCC including the following.
1. Surgical (physical)
• Surgical excision
• Mohs micrographic surgery
• Curettage and cautery
• Cryosurgery










• Others (solasodine glycosides, tazarotene, valproic acid,
sinecatechins, diclofenac, calcitriol)
Types of outcome measures
Primary outcomes
1. Recurrence at three years and five years, measured clinically
(to reflect what actually happens in clinical practice). Rather than
exclude potentially clinically useful data, we included recurrence
data that fell outside our primary outcome time points if data were
not available for three and five years.
2. Cosmetic outcome (participant- and observer-rated). We have
included any validated method for assessing cosmetic outcome
including the four-point scale, the Vancouver scar scale and the
Patient and Observer Scar Assessment Scale (POSAS) (Mosterd
2013). We did not pre-specify a time point for our cosmetic outcome
but aimed to include outcomes measured aKer at least one year
(minimum time taken for a scar to mature). If multiple time points
were reported, we reported the closest time point to one year (but
not less than one year).
Secondary outcomes
1. Pain during treatment and thereaKer. We included any pain
reported, but prioritised outcomes that included a measure of
severity e.g. 'moderate/severe pain' reported by participants as
well as pain measured by visual analogue scale (VAS). We did not
specify how long aKer treatment to measure the pain outcome but
included any pain measurement if it was recorded in the follow-up
period. Due to the varied nature of pain and manner in which it is
recorded, we also collated pain data into Table 1.
2. Early treatment failure within six months, measured
histologically.
3. Adverse eJects (AEs). We did not perform numerical analyses on
AEs but provided a narrative synthesis in the results and expanded
on this in Table 2.
Due to the large number of studies included in this review update
and to improve the overall readability of the review, we have
excluded studies that did not measure any of our outcomes of
interest.
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Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
For this update, we revised our search strategies in line with current
Cochrane Skin practices, and expanded our list of disease terms.
Details of the previous search strategies are available in Bath-
Hextall 2007.
The Cochrane Skin Information Specialist searched the following
databases up to 19 November 2019:
• the Cochrane Skin Group Specialised Register using the search
strategy in Appendix 1;
• the Cochrane Central Register of Controlled Trials (CENTRAL)
in the Cochrane Library (2019, Issue 11) using the strategy in
Appendix 2;
• MEDLINE via Ovid (from 1946) using the strategy in Appendix 3;
• Embase via Ovid (from 1974) using the strategy in Appendix 4;
• CINAHL via EBSCO (from 1981) using the strategy in Appendix 5;
and
• LILACS (Latin American and Caribbean Health Science




Two review authors (SH and JT) searched the following trials
registers up to 3 March 2019 using the term "basal cell carcinoma":
• the ISRCTN registry (www.controlled-trials.com);
• ClinicalTrials.gov (www.clinicaltrials.gov);
• the Australian New Zealand Clinical Trials Registry
(www.anzctr.org.au);
• the World Health Organization International Clinical Trials
Registry Platform (ICTRP) (apps.who.int/trialsearch/); and
• the EU Clinical Trials Register (www.clinicaltrialsregister.eu/).
Published and unpublished trials
We checked the reference lists of included studies for further
references to eligible trials.
We contacted corresponding authors of study publications to
request information on ongoing, unpublished or published trials
where we needed additional information.
Adverse e ects
We did not perform a separate search for adverse eJects of
interventions for BCC. However, we did examine data on adverse
eJects from the included studies we identified, and we extracted
these data into a table (see Table 2).
Data collection and analysis
Selection of studies
Three review authors (FB, JT, SH) checked the titles and abstracts
identified from the searches and independently assessed the
full text of all RCTs of possible relevance. The review authors
decided which trials fitted the inclusion criteria and recorded
their methodological quality. Any disagreements were resolved by
discussion between the review authors. Where there were missing
data from the trial reports attempts were made to obtain that data
by contacting the trial author.
Data extraction and management
Three review authors (FB, JT, SH) independently performed data
extraction, using a pre-derived data extraction form for consistency.
Discrepancies were resolved by a fourth review author (HW).
Missing data were obtained from the trial authors where possible.
Three review authors (FB, JT, SH) checked and entered the
data. Data recorded included: demographics, sites, clinical types,
histological diagnosis, inclusion criteria, treatment modalities and
regimens, rates of recurrence, cosmetic outcomes, pain outcomes,
early treatment failure rates, adverse eJects data, setting and
funding sources.
Assessment of risk of bias in included studies
The Cochrane 'Risk of bias' assessment framework (Higgins 2011)
was used to evaluate the internal validity of studies, covering the
main sources of bias across the following components:
a) the method of generation of the randomisation sequence
(selection bias)
b) the method of allocation concealment - we considered it
'adequate' if the assignment could not have been foreseen
(selection bias)
c) who was blinded or not blinded (participants, clinicians, outcome
assessors) (performance bias and detection bias)
d) how many participants were lost to follow-up in each arm
(attrition bias)
e) if there was selective outcome reporting (reporting bias)
Two authors (JT, SH) independently assessed risk of bias in
included studies. Any disagreements were resolved through
discussion between the authors including a third author (HW).
The overall 'Risk of bias' assessment for each study's bias sources
(presented in the Characteristics of included studies table) was
performed in relation to our recurrence rate primary outcomes.
Measures of treatment e<ect
We expressed the results as risk ratio (RR) with 95% confidence
intervals (CIs) for dichotomous outcomes, and diJerence in means
(MD) with 95% CIs for continuous outcomes.
Unit of analysis issues
The unit of analysis in the included studies was based on
either participants or lesions. Where possible, data at participant
level were used in preference. Where there were multiple
intervention groups within a trial, we made pair-wise comparisons
of similar active interventions versus placebo, or another
active intervention. We analysed internally-controlled trials using
appropriate techniques for paired designs (for example, for
continuous outcomes using Wilcoxon Signed Ranks test or paired
t-test; or for dichotomous data using McNemars test), where
available, and we did not pool them with studies of other designs.
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Where dichotomous data permitted, we estimated paired odds
ratios (OR) with 95% CIs. Where paired data could not be extracted
from the papers, we presented the data narratively.
Dealing with missing data
If participant dropout led to missing data we conducted an
intention-to-treat analysis, as reported in the publications of the
trials. We contacted trial authors to provide missing statistics, such
as standard deviations (SDs), where appropriate.
Assessment of heterogeneity
We assessed statistical heterogeneity using the I2 statistic.
Assessment of reporting biases
Study registrations and protocols were identified where available
and any diJerences between registered and reported outcomes
were flagged as potential reporting bias. We did not test publication
bias as none of the comparisons in our review had the minimum
number of 10 studies required in a meta-analysis to apply tests for
funnel plot asymmetry (Page 2019).
Data synthesis
We calculated a weighted treatment eJect (using random eJects)
across trials since the treatment eJects for interventions are likely
to vary by participant and methodological variations between
studies, as per the standard methods used within Cochrane Skin.
The results were expressed as RR and 95% CI for dichotomous
outcomes. All analyses were conducted using RevMan 5.4.
Wherever possible, a meta-analysis was conducted to assess the
overall intervention eJect of diJerent primary research studies
that considered the eJectiveness of the same intervention. This
approach has the benefits of improving the accuracy of the results
and addressing disputes between studies (Higgins 2011).
Where we performed a meta-analysis, we calculated a weighted
treatment eJect across trials, using a random-eJects model. Where
it was not possible to perform a meta-analysis, we summarised the
data for each trial and have only presented forest plots. If raw data
could not be extracted, we extracted the results from appropriate
statistical analyses presented in the paper and reported these in the
review. We considered a P value < 0.05 as statistically significant.
Subgroup analysis and investigation of heterogeneity
Due to insuJicient studies being included across the comparisons,
we were unable able to perform any subgroup analyses.
Sensitivity analysis
We planned to conduct sensitivity analyses to examine the eJects
of excluding studies with a moderate or high risk of bias (Higgins
2011), but insuJicient numbers of studies were included in meta-
analyses.
Summary of findings and assessment of the certainty of the
evidence
'Summary of findings' tables were produced for the outcomes that
we determined to be the most clinically relevant. This was based on
the experiences of study authors and an electronic survey sent to
clinicians in our centre, on what were felt to be the most important
outcomes and comparisons to patients and clinicians.
For 'Summary of findings' tables we included the following
comparisons.
• MMS (Mohs micrographic surgery) versus SE (surgical excision)
• Imiquimod cream versus SE
• Radiotherapy versus SE (with or without frozen section margin
control)
• MAL-PDT versus SE
• Imiquimod cream versus MAL-PDT
MMS versus SE was our main comparison based on our authors'
own clinical experiences and the fact that this issue has been
debated for years between dermatologists and plastics surgeons.
Additionally, the experience of our centre also suggested this was
the most important comparison which we established through our
electronic survey.
All of our pre-defined outcomes were reported in each 'Summary of
findings' table except adverse eJects data which were not included.
Instead these were presented as a narrative synthesis within the
results and discussion sections and collated into Table 2.
'Summary of findings' tables are based on the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) principles (Schünemann 2013), and we used GRADEpro
to assess the certainty of evidence for each review outcome.
Evidence from the included RCTs was downgraded from 'high
certainty' by one level for each serious study limitation found in the
domains: risk of bias, inconsistency, indirectness, imprecision, and
publication bias. Where confidence intervals included important
benefit and serious harm (i.e. > 1.25 and < 0.75), we rated down
two levels for very serious imprecision as described in the GRADE
handbook (Schünemann 2013). We also rated down two levels for
imprecision if there was a very wide confidence interval (more than
100-fold diJerence) even if it excluded no eJect (RR of 1.0). We
rated down three levels when confidence intervals were so wide
that we cannot have any certainty in the results and defined this as
a confidence interval that includes no eJect with a more than 100-
fold diJerence.
Other
A consumer (an experienced patient representative) was consulted
throughout, particularly for readability and understanding of the
plain language summary.
R E S U L T S
Description of studies
For a full description of the studies please see the Characteristics of
included studies tables.
Results of the search
The database searches (see Electronic searches) for this update
retrieved a total of 4566 records. We did not identify any records of
trials from our scanning of reference lists or correspondence with
pharmaceutical companies (see Searching other resources). AKer
removing 179 duplicates, we had 4387 records. We screened these
and excluded 4309 records based on titles and abstracts.
We obtained the full text of the remaining 78 records. Twenty-eight
studies did not meet our inclusion criteria and were excluded (see
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Characteristics of excluded studies). One study included from the
previous review (Lui 2004) was also excluded as we identified that
not all lesions included were histologically proven and it included
a large number of Gorlin syndrome patients.
Six studies were not classified as we did not have enough
information to decide if they met our eligibility criteria despite
attempts to contact the authors to obtain the full study details for
review (Bunker 2000; IRCT 2017 030732933N1; ISRCTN 92678315;
Kang 2018; Ma 2018; RPCEC00000147; see Studies awaiting
classification). Three studies are ongoing with no results available
yet (EudraCT 2016-002255-25; NCT02242929; NCT03573401).
This leK us with 41 records. Nine of these were related to studies
included in the previous version of this review. The remaining 32
records reported 26 new studies which we included. We combined
them with 26 included studies (reported in 43 references) from the
previous version of the review. We then had a total of 52 included
studies reported in 75 references (see Characteristics of included
studies). We recorded the selection process in suJicient detail to
complete a PRISMA flow diagram (Moher 2009) (Figure 1).
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Figure 1.   PRISMA study flow diagram.
 
We contacted 21 corresponding authors to obtain further
information. The authors of Clover 2016 and Kuijpers 2007 kindly
responded and provided further information.
Included studies
Nine papers were identified from our search that had follow-
up data from earlier studies: Basset-Seguin 2008; Punjabi 2008;
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Rhodes 2004; Smeets 2004 (four references), Kuijpers 2007 (was
Thissen 2000); Foley 2009a; Foley 2009b (was Tope 2005).
Design
All studies were prospective, RCTs with a parallel-group design.
Eight RCTs were reported as pilot studies (Abd El-Naby 2019;
Beutner 1999; Choi 2016; Eimpunth 2014; Haak 2015; Kuijpers 2006;
Romagosa 2000; Tran 2012). The most common comparators were
non-surgical treatments, with 20 RCTs comparing a non-surgical
treatment against another non-surgical treatment. Fourteen RCTs
compared a non-surgical treatment against placebo. Eighteen RCTs
had a surgical treatment comparator, with 10 RCTs comparing
a surgical treatment against a non-surgical treatment, five RCTs
comparing a surgical treatment against a surgical treatment, and
three RCTs comparing a surgical treatment against placebo.
Twenty-six of our included studies compared an intervention
against at least one active treatment (head-to-head studies), 13
compared diJerent regimens of the same active treatment, and 13
compared against placebo/vehicle/sham/no treatment. Seventeen
studies had multiple intervention arms (three or four arms).
All intervention groups were deemed to be relevant in these multi-
arm studies, but due to the large number of comparisons in the
review, we only presented the active treatment-arm comparisons.
The duration of the included studies ranged from six weeks to
10 years, with an average of 13 months. Just under half of the
studies were multi-centre (24/52), with 26/52 single-centre studies.
We were unable to ascertain the number of study centres for two
studies.
Setting
All of the studies included in this review recruited participants from
secondary care clinics, with the vast majority being dermatology
outpatient clinics. The studies were conducted in many parts of the
world. Thirty-two studies were conducted in Europe, 11 in North
America, five in Australasia, three in Asia/middle East and one in
South America.
Participants
A total of 6690 participants were randomised across the 52 RCTs
included in this review. Studies recruited participants ranging in age
from 20 to 95 years old with a median age of 64.9 years. Twelve
studies did not provide data on the age of participants. Ten studies
did not provide data on the gender of participants. Based on the
studies that did provide data on gender, there were more male
participants than females (ratio 1.48 males:1 female).
The vast majority (48/52) of studies exclusively included basal
cell carcinomas (BCC) of low-risk histological subtypes (nodular,
superficial). Only four studies included high-risk histological
subtypes (Alpsoy 1996; Avril 1997; Clover 2016; Smeets 2004), but
none of these exclusively included high-risk histological subtypes
and the majority of BCCs in these studies were low-risk histological
subtypes.
Most studies (27/52) included BCCs located on the head, neck and
body regions. Six studies excluded BCCs located on the head and
neck region (Karsai 2015; Kessels 2017; Romagosa 2000; Salmivuori
2019; Spelman 2014; Tran 2012). Nine studies included BCCs only
located on the head and neck region (Abbade 2015; Abd El-Naby
2019; Avril 1997; Garcia-Martin 2011; Haak 2015; Kuijpers 2007;
Landthaler 1989; Salmanpoor 2012; Smeets 2004). Three studies
included BCCs exclusively on high-risk facial sites (H-zone of the
face) (Smeets 2004; Haak 2015; Garcia-Martin 2011). Ten studies did
not report the location of BCCs (Choi 2016; Clover 2016; Edwards
1990; Eimpunth 2014; Marks 2001; Punjabi 2008; Rogozinski 1997;
Siller 2010; Soler 2000; 2005-001474-27).
Sample sizes
The number of participants randomised in each study ranged from
13 (Romagosa 2000) to 724 (Geisse 2004) with a median of 89
participants. We did not re-count the participants in the follow-
up studies, and therefore there were a total of 6690 participants
randomised in the 52 primary RCTs included in this review. Thirty-
eight RCTs used participants as the unit of analysis, and 14 RCTs
used lesions as the unit of analysis. A total of 7241 lesions were
included in this review.
Funding
Overall, 22 studies were industry funded, with studies of imiquimod
and photodynamic therapy being over-represented in this group.
Seventy-nine per cent of studies (11/14) assessing imiquimod were
funded by the same company (3M), and seven out of 16 PDT studies
were industry-funded (five by PhotoCure/Galderma).
Interventions
The trials fell into 15 broad therapeutic categories. For a full
description of the studies, please see the Characteristics of included
studies table. *Denotes study new to this update.
1. Surgical excision (SE)
Ten RCTs.
• Mohs micrographic surgery versus SE (Smeets 2004)
• Imiquimod versus SE (Bath-Hextall 2014*)
• Radiotherapy versus SE (with option for frozen section margin
control) (Avril 1997)
• Curettage versus curettage and cautery versus SE (Salmanpoor
2012*)
• Curettage and cryosurgery versus SE (Kuijpers 2007*)
• MAL-PDT versus SE (Abbade 2015*; Rhodes 2004; Szeimies 2008)
• ALA-PDT versus SE (Mosterd 2008*)
• Electrochemotherapy versus SE (Clover 2016*)
2. Radiotherapy
Four RCTs.
• Radiotherapy versus SE (Avril 1997)
• Imiquimod versus radiotherapy (Garcia-Martin 2011*)
• Low dose versus high-dose radiotherapy (Landthaler 1989*)
• Radiotherapy versus cryosurgery (Hall 1986)
3. Cryosurgery
Four RCTs.
• Radiotherapy versus cryosurgery (Hall 1986)
• Curettage and cryosurgery versus SE (Kuijpers 2007)
• PDT versus cryosurgery (Wang 2001; Basset-Seguin 2008*)
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4. Curettage and cautery (C&C)
One RCT.
• Curettage versus curettage and cautery versus SE (Salmanpoor
2012*)
5. Photodynamic therapy (PDT)
Sixteen RCTs.
• MAL-PDT versus SE (Abbade 2015*; Rhodes 2004; Szeimies 2008)
• ALA-PDT versus SE (Mosterd 2008*)
• ALA-PDT versus MAL-PDT (Kuijpers 2006*)
• MAL-PDT versus HAL-PDT versus BF200-ALA-PDT (Salmivuori
2019*)
• BF-200 ALA-PDT versus MAL-PDT (Morton 2018*)
• Two-fold ALA-PDT versus conventional MAL-PDT (Kessels 2018*)
• PDT versus cryosurgery (Wang 2001; Basset-Seguin 2008)
• Imiquimod cream versus MAL-PDT (Arits 2013*)
• 5-FU cream versus MAL-PDT(Arits 2013*)
• Laser ALA-PDT versus broadband halogen light ALA-PDT (Soler
2000)
• Ablative fractional laser-assisted MAL-PDT versus MAL-PDT (Choi
2016*; Haak 2015*)
• MAL-PDT versus placebo (Foley 2009a; Foley 2009b)
6. Imiquimod (5% cream unless otherwise stated)
Fourteen RCTs.
• Imiquimod versus MAL-PDT (Arits 2013*)
• Imiquimod versus 5-FU cream (Arits 2013*)
• Imiquimod versus SE (Bath-Hextall 2014*)
• Imiquimod versus radiotherapy (Garcia-Martin 2011*)
• Dose response trial of imiquimod with and without occlusion for
BCC - one trial for sBCC and one trial for nBCC (Sterry 2002a;
Sterry 2002b)
• Five diJerent doses of imiquimod for sBCC and nBCC versus
vehicle (Beutner 1999)
• Open-label dose response trial of imiquimod for primary
superficial BCC (Marks 2001)
• Open-label dose response trial of imiquimod for nBCC (Shumack
2002a)
• Dose response trial of imiquimod versus vehicle for sBCC (Geisse
2002; Geisse 2004; Schulze 2005; Shumack 2002b)




• 5-FU cream versus MAL-PDT (Arits 2013*)
• Imiquimod cream versus 5-FU cream (Arits 2013*)
• 5-FU cream in phosphatidyl choline versus 5-FU cream in
petrolatum (Romagosa 2000)




• Electrochemotherapy versus SE (Clover 2016*)
9. Ingenol mebutate
Two RCTs.
• Ingenol mebutate gel 0.0025% versus ingenol mebutate gel
0.01% versus ingenol mebutate gel 0.05% versus vehicle gel
(Siller 2010*)
• Ingenol mebutate gel + full occlusive aluminium disk versus
ingenol mebutate gel and semi-occlusive dressing with Opsite or
Ingenol mebutate gel with no occlusion (Spelman 2014*)
10. Solasodine glycosides
One RCT.
• Solasodine glycoside (Zycure) cream versus matching vehicle
(Punjabi 2008)
11. Topical valproic acid gel and tazarotene gel
One RCT.
• Valproic acid (Baceca®) gel followed by Tazarotene gel versus
placebo gel followed by Tazarotene gel (placebo cross-over aKer
eight weeks) (2005-001474-27*)
12. Topical diclofenac and vitamin D
One RCT.
• Diclofenac-3% gel versus calcitriol 3ug/g ointment versus
diclofenac-3% gel plus calcitriol 3ug/g ointment versus no
topical treatment (Brinkhuizen 2016*)
13. Pulsed dye laser (PDL)
Four RCTs.
• PDL versus sham (Karsai 2015*)
• PDL single session versus PDL two sessions (Abd El-Naby 2019*)
• PDL 7mm spot-size, single pulses versus PDL 10mm spot-size,
stacked pulses (Tran 2012*)
• PDL 10mm spot-size, one stacked pulse session versus no
treatment (Eimpunth 2014*)
14. Intralesional interferon (IFN) therapy
Four RCTs.
• IFN alpha-2a, 2b or alpha-2a and 2b (Alpsoy 1996)
• IFN alpha 2b versus vehicle (Cornell 1990)
• Number of dosages of IFN alpha 2b (Edwards 1990)
• IFN beta versus placebo (Rogozinski 1997)
15. Topical sinecatechins
One RCT.
• Sinecatechin 10% ointment versus vehicle (Kessels 2017*)
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Outcomes
Out of the 52 comparisons, only 21% (11/52) reported our 3-
year recurrence primary outcome and only 17% (9/52) reported
our 5-year recurrence primary outcome. Cosmetic outcome data
were reported for 37% (19/52) of the comparisons (14/52 had data
available for analysis). Early treatment failure was reported in 75%
(39/52) of comparisons. Pain data were reported in 46% (24/52) of
the comparisons (10/52 had data available for analysis). Adverse
eJects data were reported for most comparisons (81%, 42/52), but
due to their heterogeneity we did not perform any analyses and
instead summarised these data in Table 2.
Excluded studies
We excluded 29 studies due to the following reasons: no outcomes
of interest measured (8); not all lesions histologically proven (7); not
an RCT (8); not all lesions primary, untreated BCC (3); inclusion of
Gorlin syndrome participants (3) and a study on adjuvant treatment
(1). Please see the Characteristics of excluded studies tables for
further details.
Studies awaiting classification
We were unable to make a final decision on whether to include
or exclude six studies despite attempts to contact the study
investigators. See the Studies awaiting classification tables for
further details.
Ongoing studies
Three studies were identified that are currently ongoing and had
no data available for us to include in this review. See the Ongoing
studies tables for further details.
Risk of bias in included studies
In order to objectively assess risk of bias, we used Cochrane
'Risk of bias' methods (Higgins 2011). Occasionally, our ability to
assess risk was hampered by limited reporting of data. Where
there was inadequate information to make a judgement, for
example abstract-only studies, attempts to contact the authors
were made in order to get access to the data needed. Please see
the Characteristics of included studies tables for full details. Figure
2 and Figure 3 summarise the overall data.
 
Figure 2.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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2005-001474-27 ? ? + + + -
Abbade 2015 + ? ? ? ? ?
Abd El-Naby 2019 + + ? + + ?
Alpsoy 1996 ? ? ? ? + ?
Arits 2013 + + ? + ? ?
Avril 1997 ? ? ? ? + ?
Basset-Seguin 2008 + ? ? ? ? -
Bath-Hextall 2014 + + ? ? + +
Beutner 1999 ? ? + + + ?
Brinkhuizen 2016 + + ? ? ? +
Choi 2016 + ? ? + + ?
Clover 2016 + + ? ? ? ?
Cornell 1990 + ? ? ? ? ?
Edwards 1990 ? ? ? ? + ?
Eigentler 2007 ? ? + ? ? ?
Eimpunth 2014 ? ? ? ? + ?
Ezughah 2008 + + ? + + ?
Foley 2009a + + + + + ?
Foley 2009b + + + + + ?
Garcia-Martin 2011 - - ? ? + ?
Geisse 2002 + ? + + + ?
Geisse 2004 + + + ? ? ?
Haak 2015 + + ? + ? +
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Figure 3.   (Continued)
Geisse 2004 + + + ? ? ?
Haak 2015 + + ? + ? +
Hall 1986 ? ? ? ? ? ?
Karsai 2015 + + + ? + ?
Kessels 2017 + + + + + +
Kessels 2018 + + ? + + +
Kuijpers 2006 ? ? + + + ?
Kuijpers 2007 + + ? ? ? ?
Landthaler 1989 ? ? ? ? + ?
Marks 2001 ? ? ? ? + ?
Miller 1997 ? ? ? ? ? ?
Morton 2018 + + ? + + +
Mosterd 2008 + + ? ? ? ?
Punjabi 2008 ? ? + + - ?
Rhodes 2004 + + ? ? ? ?
Rogozinski 1997 ? ? ? ? ? ?
Romagosa 2000 ? ? + + + ?
Salmanpoor 2012 ? ? ? ? ? ?
Salmivuori 2019 ? ? ? ? ? ?
Schulze 2005 + + + + + ?
Shumack 2002a ? ? ? ? ? ?
Shumack 2002b ? ? ? ? + ?
Siller 2010 + + ? + + ?
Smeets 2004 + + ? ? + ?
Soler 2000 ? + ? ? + ?
Spelman 2014 ? ? ? ? ? ?
Sterry 2002a + ? ? ? + ?
Sterry 2002b + ? ? ? + ?
Szeimies 2008 + + ? ? + ?
Tran 2012 ? ? + + + ?
Wang 2001 + + ? ? + ?
 
Allocation
Random sequence generation and concealment of allocation
The randomisation process in general and concealment of
allocation are the most important and sensitive indicators that bias
has been minimised in a clinical trial (Schulz 1995).
Twenty-nine studies had a low risk of bias for random sequence
generation and 22 studies had an unclear risk of bias. Twenty-three
studies had a low risk of bias for allocation of concealment whereas
28 studies had an unclear risk of bias. Only one study (Garcia-Martin
2011) had a high risk of bias for random sequence generation and
allocation of concealment.
Blinding
Only 14 studies were rated as having a low risk of bias for blinding
of participants/personnel with the remaining 38 studies being
assessed as having an unclear risk of performance bias. Unclear risk
of bias was chosen in three situations: 1) if the blinding method was
not clearly stated by the study authors 2) the study was unblinded 3)
the study was blinded but due to the nature of the interventions it is
likely that participants/personnel would be aware of the treatment
allocation. The reason we decided to rate all these situations as
"unclear" is that it is unclear how lack of blinding would impact our
outcomes of interest.
Only 19 studies were assessed as low risk of bias for blinding of
the outcome assessor. Thirty-three studies were assessed as having
unclear risk of detection bias. We rated the bias as unclear for the
same situations as detailed above for performance bias. Even if
studies reported that outcome assessors were blinded, for all the
studies comparing a surgical intervention against a non-surgical
intervention, we felt that it was not possible to truly blind due to
the nature of the interventions and again we were unclear whether
being unblinded would bias the assessing of clinical response
with regards to recurrence rates. However we decided that being
unblinded would bias the rating of cosmetic outcomes and in this
situation we consider the risk of bias to be high. As recurrence
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rate is our primary outcome the risk of bias rating displayed in the
Characteristics of included studies table relates to this.
Incomplete outcome data
Analysis should be performed according to intention-to-treat
principle to minimise risk of attrition bias (Fergusson 2002).
However, in many of the trials analysis of outcome was carried
out only in those participants who completed the trial. Thirty-
two studies had a low risk of bias for incomplete outcome data.
Nineteen studies had an unclear risk and one study (Punjabi 2008)
had a high risk of attrition bias as there was a large diJerence
in the number of participants that withdrew from the study
between groups and the authors used the "last observation carried
forward" method to deal with missing data which is an imputation
method that fails to acknowledge uncertainty in the imputed values
(Higgins 2011).
Selective reporting
To minimise the risk of selective outcome reporting bias, outcomes
for studies should all be specified prior to recruitment in a
time-stamped, publicly available trial registry. This has been
a prerequisite for publication since 2005 for publication in
International Committee of Medical Journal Editors (ICMJE)
member journals. Only 11 studies prospectively registered their
primary outcomes and of these only six were rated as low risk of
selective reporting bias which is a concerningly low number. Forty-
four studies were rated as unclear risk of bias and two studies were
reported as having a high risk of reporting bias: 2005-001474-27 and
Basset-Seguin 2008.
E<ects of interventions
See: Summary of findings 1 Mohs micrographic surgery compared
to surgical excision for basal cell carcinoma of the skin; Summary
of findings 2 Imiquimod compared to surgical excision for basal
cell carcinoma of the skin; Summary of findings 3 Radiotherapy
compared to surgical excision (with or without frozen section
margin control) for basal cell carcinoma of the skin; Summary of
findings 4 MAL-PDT compared to surgical excision for basal cell
carcinoma of the skin; Summary of findings 5 Imiquimod cream
compared to MAL-PDT for basal cell carcinoma of the skin
Not all of the comparisons measured or reported all primary and
secondary outcomes. If an outcome has not been reported under a
comparison, this means it was not measured by any study.
1. Surgical excision
Mohs micrographic surgery (MMS) versus surgical excision (SE)
One study (Smeets 2004) compared SE against MMS in 374
participants (408 lesions) with high-risk facial primary basal cell
carcinomas (BCCs) (high-risk histological subtype or located in
the ‘H-zone’ of the face or both). The study also randomised 204
recurrent facial BCCs but we have not included these data as we
are only interested in primary BCC. The study used 3 mm margins
for both treatments to standardise the two modalities (smaller
margins are usually used for MMS). If the defect margins were
found to be positive aKer SE, a re-excision with a 3 mm margin
was done. If the margins remained positive aKer a second excision
then MMS was undertaken. The primary outcome was recurrence
at 30 months (which we have considered to be approximately three
years). Recurrence at five years and 10 years were published in two
further papers. See Summary of findings 1.
Primary outcomes
Recurrence
There may be slightly fewer recurrences with MMS and SE at three
years (1.9%, 3/160 versus 2.9%, 5/171, respectively) (risk ratio (RR)
0.64, 95% confidence interval (CI) 0.16 to 2.64; Analysis 1.1), and at
five years (3.2%, 4/125 versus 5.2%, 7/134, respectively) (RR 0.61,
95% CI 0.18 to 2.04; Analysis 1.2). We rated the certainty of evidence
as low for both these outcomes, rating down two levels for very
serious imprecision due to the very wide 95% CIs. This CI indicates
that the true MMS recurrence rate may represent an important
improvement or worsening of recurrence rates when compared to
SE.
Cosmetic outcome (participant- and observer-rated).
The authors state that overall, participant- and observer-rated
cosmetic outcomes did not significantly diJer between MMS and SE
when measured at 18 months. We rated the certainty of evidence
as low, rating down two levels for very serious indirectness as
although the authors did compare the cosmetic outcomes between
the two groups, they did not present the data for analysis.
Secondary outcomes
Adverse e<ects
The study reported in their text that there was quote: "no diJerence
in post-operative complications between SE and MMS"; however
raw data were not presented for this outcome to verify this. See
Table 2 for further adverse eJect (AE) data from this study.
Imiquimod cream versus surgical excision (SE)
One study (Bath-Hextall 2014) compared imiquimod to SE in 501
participants with nodular BCC (nBCC) or superficial BCC (sBCC) at
low-risk sites in a non-inferiority trial design with five-year follow-
up. Participants randomised to imiquimod treatment applied the
cream daily for six weeks (sBCC) or 12 weeks (nBCC). The licensed
imiquimod regimen for sBCC is five days a week for six weeks and
for nBCC is five days a week for 12 weeks. SE margins were 4 mm.
See Summary of findings 2.
Primary outcomes
Recurrence
Imiquimod probably results in more recurrences (16.4%, 35/213)
than SE (1.6%, 3/188) at three years corresponding to a 10-fold
increased risk of recurrence with imiquimod (RR 10.30, 95% CI
3.22 to 32.94; Analysis 2.1). We rated the certainty of evidence as
moderate, rating down for serious imprecision due to the wide 95%
CI and because this was only a single study.
By five years, imiquimod may result in more recurrences (17.5%,
36/206) compared with SE (2.3%, 4/177) with a nearly 8 fold
increased risk of recurrence (RR 7.73, 95% CI 2.81 to 21.30; Analysis
2.2). We rated the certainty of evidence as moderate, rating down
for imprecision (wide 95% CI, single study).
Cosmetic outcome (participant- and observer-rated)
Cosmetic outcome was assessed at six months and three years by
participants and two independent dermatologists using a six-point
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scale (unable to see lesion, very poor, poor, fair, good, excellent).
Our analyses focused on using data from three-year follow-up due
to the reasons outlined in the methods section.
When participant-rated, there may be little to no diJerence
between imiquimod (91.9%, 147/160) and SE (92.2%, 153/166) on
the rate of good/excellent cosmetic outcomes (RR 1.00, 95% CI
0.94 to 1.06; Analysis 2.3). When dermatologist-rated, imiquimod
may improve rate of good/excellent cosmetic outcomes (60.6%,
103/170) compared to SE (35.6%, 62/174), corresponding to a 70%
increase rate for imiquimod (RR 1.70, 95% CI 1.35 to 2.15; Analysis
2.3). We rated the certainty of evidence as low for both these
comparisons, rating down for serious risk of bias (unable to truly
blind due to nature of interventions) and serious risk of imprecision
(only one study).
Secondary outcomes
Pain during and aLer treatment
Patient diaries were used to record information about the level of
pain felt before and aKer the lesion was treated. During treatment,
imiquimod probably worsens the risk of moderate/severe pain
compared to SE (30%, 72/242 versus 22%, 44/201, respectively)
corresponding to a 36% increased risk with imiquimod (RR 1.36,
95% CI 0.98 to 1.88; Analysis 2.4). We rated the certainty of evidence
as low, rating down for serious imprecision (wide 95% CI, including
the null eJect which indicates there may be no diJerence between
the two treatments) and serious risk of attrition bias.
However, during the 16-week follow-up period imiquimod probably
reduces the risk of moderate/severe pain compared to SE (9%,
22/233 versus 20%, 41/206) corresponding to a 53% decreased risk
with imiquimod (RR 0.47, 95% CI 0.29 to 0.77; Analysis 2.4). We rated
the certainty of evidence as low, rating down for serious risk of
imprecision (only one study) and serious risk of attrition bias. See
Table 1 for further pain data from this study.
Adverse e<ects
There were slightly more mild/moderate AEs reported during the
first six months of treatment in the imiquimod group compared
to the SE group (94% of participants versus 88%, respectively).
Itching at the tumour site was frequently reported (85%, 211/249
imiquimod versus 56%, 129/229 SE), but weeping at the tumour
site was also common (64%, 160/249 for imiquimod versus 35%,
81/229 for SE). Five participants treated with imiquimod withdrew
from the study because of AEs related to the treatment whereas
no participants withdrew because of AEs related to SE. Thirty-eight
(15%) of participants needed a dose reduction in the imiquimod
group due to AEs. See Table 2 for further AE data.
Radiotherapy versus surgical excision (SE) with or without
frozen section margin control
One study (Avril 1997) involving 347 participants (347 lesions)
compared SE (at least 2 mm margin with the option of frozen
section margin control) against radiotherapy in primary BCCs
of the face, involving tumours less than 4 cm in diameter.
BCCs included nodular, ulcerated, superficial and pagetoid and
morphoeaform. The main outcome measure was histologically-
confirmed persistent tumour or recurrent disease at four years.
Three radiation techniques were used: interstitial brachytherapy
(n = 95), superficial contact therapy (n = 50) and conventional
radiotherapy (n = 20). See Summary of findings 3.
Primary outcomes
Recurrence
At three years the recurrence rates were 5.2% (9/173) and 0%
(0/174) for radiotherapy and SE, respectively. (RR 19.11, 95% CI
1.12 to 325.78; Analysis 3.1). We rated the certainty of evidence
as low, rating down two levels for very serious imprecision due to
the very wide 95% CI, which although does not include the null
eJect, indicates that radiotherapy may lead to a slight or markedly
increased risk of recurrence when compared to SE.
As the study set their primary outcome of recurrence at four years,
we have included these data. By four years, radiotherapy may result
in a higher risk of recurrence compared to SE with a recurrence rate
of 6.4% (11/173) versus 0.6% (1/174), respectively (RR 11.06, 95%
CI 1.44 to 84.77; Analysis 3.2). We rated the certainty of evidence
as low, rating down for serious indirectness as the outcome was
measured outside our three-year and five-year time points and for
serious imprecision due to the wide 95% CI.
Cosmetic outcome (participant- and observer-rated)
Comparing the rate of participant-reported good cosmetic
outcomes (three-point scale: bad, fair or good) at four years
between the groups, radiotherapy probably worsens the rate of
good cosmetic outcome compared to SE frozen (RR 0.76, 95% CI
0.63 to 0.91; Analysis 3.3). At four years, radiotherapy probably
worsens the rate of dermatologist-assessed cosmesis based on the
scar (bad, clearly marked or slightly visible) compared to SE (RR
0.48, 95% CI 0.37 to 0.62; Analysis 3.3). We rated the certainty of
evidence for both these outcomes as moderate, rating down for
serious risk of bias (high risk of blinding bias). We performed an
intention-to-treat analyses on both these outcomes (as detailed in




AKer radiotherapy, dyspigmentation and telangiectasia (which may
aJect the cosmetic appearance) developed in more than 65% of
the participants by four years. Radiodystrophy aJected 41% of the
participants at four years and 5% of the patients in the radiotherapy
group had necrosis. These AEs were exclusive to the radiotherapy
group. The main characteristics of surgical scars were deformations
and constrictions and although these decreased with time they still
aJected 25% and 5% of participants, respectively at four years. See
Table 2 for further AE data for this study.
2. Radiotherapy
Low-dose versus high-dose radiotherapy
Landthaler 1989 compared low-dose (48 Gy) against high-dose
radiotherapy (60 Gy) in 319 participants with 290 BCCs (unclear
subtype) and 44 SCCs located on the face.
Secondary outcomes
Early treatment failure
There may be little to no diJerence in the risk of early treatment
failure between low dose radiotherapy (8.1%, 12/148) and high
dose radiotherapy (9.6%, 14/142) (RR 0.82, 95% CI 0.39 to 1.72;
Analysis 7.1). The certainty of evidence was low due to very serious
imprecision where the 95% CI indicates that low dose might lead to
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One study (Hall 1986) of 93 participants (93 lesions) compared
radiotherapy against cryosurgery (unclear subtype, but lesions on
nose/ears were excluded). Radiotherapy was applied with 130 kV
X-rays and fractionation depended on lesion size. Cryosurgery was
performed with two freeze-thaw cycles each lasting one minute.
Primary outcomes
Recurrence
Radiotherapy may reduce the risk of recurrence (4.1%, 2/49)
compared to cryosurgery (38.6%, 17/44) at 2 years follow-up (RR
0.11, 95% CI 0.03 to 0.43; Analysis 8.1). However, we rated the
certainty of evidence as low, rating down for serious indirectness
(as the outcome was measured at two years) and serious
imprecision (single study with a fairly wide 95% CI).
Cosmetic outcome (participant- and observer-rated)
The study reported that there was no statistically significant
diJerence in cosmetic outcomes between the interventions;
however, the raw data were not presented to verify this.
Secondary outcomes
Pain during and aLer treatment
The study reported that the degree of pain reported by patients
(on questionnaires given during follow-up) was not statistically
significant between the two interventions; however, the data were
not presented for further analyses.
Adverse e<ects
Hypopigmentation was more common than hyperpigmentation
with both modes of treatment (81% of those in the radiotherapy
group and 88% of those in the cryosurgery group). Seven
participants treated with radiotherapy developed some radiation
telangiectasia. Hypopigmentation and telangiectasia tend to be
lifelong. Five participants treated with cryosurgery developed milia
- these all resolved by one year. See Table 2 for further AE data from
this study.
Curettage and cryosurgery versus surgical excision
One study (Kuijpers 2007) compared curettage and cryosurgery
against SE in 88 participants with 100 low-risk BCCs on the head
and neck region (96 nBCC, four sBCC) with five years follow-up.
Cryosurgery was performed with two 20-second freeze-thaw cycles
using a neoprene cone to give a free margin of 5 mm around the
tumour. Surgery was performed with 3 mm margins. See Table 3.
Primary outcomes
Recurrence
At three years, curettage and cryosurgery may slightly increase
the risk of recurrence compared to SE (13.7%, 7/51 versus 4.1%,
2/49, respectively) (RR 3.36, 95% CI 0.73 to 15.40; Analysis 9.1).
We rated the certainty of evidence as low, downgrading two levels
for very serious imprecision (very wide 95% CI that indicates both
important benefit and harm).
At five years cryosurgery probably increases the risk of recurrence
compared to SE (23.7% versus 8.5%) (RR 2.78, 95% CI 0.93 to
8.34; Analysis 9.2). We rated the certainty of evidence as moderate,
downgrading one level for serious imprecision (wide 95% CI that
includes important benefit and little to no diJerence).
Cosmetic outcome (participant- and observer-rated)
Cosmetic outcomes were assessed by observers and patients at one
year post treatment on a three-point scale (bad, fair, good). When
participant-rated, curettage and cryosurgery may slightly decrease
the rate of good cosmetic outcomes compared with SE (RR 0.88,
95% CI 0.78 to 0.98; Analysis 9.3).
When dermatologist-rated, curettage and cryosurgery may
decrease the rate of good cosmetic outcome compared to SE (RR
0.28, 95% CI 0.16 to 0.47; Analysis 9.3). We rated the certainty
of evidence as low for both of these outcomes rating down for
serious risk of blinding bias (unable to truly blind due to nature of
interventions) and serious risk of imprecision (single study).
Secondary outcomes
Adverse e<ects
Secondary wound infection, treated with systemic antibiotics, was
seen in 5.9% (3/51) participants in the curettage and cryosurgery
group. In the SE, group systemic antibiotics were needed for
secondary wound infection in 8.2% (4/49) of participants in the first
and second weeks aKer treatment. No further AE data from this
study were available.
4. Currettage and cautery
Curettage and cautery versus curettage versus surgical excision
One small study of 55 participants with 69 BCCs on the face
and scalp (majority nBCC) compared: curettage and cautery (C&C)
versus SE, curettage versus SE and curettage versus curettage and
cautery with just two years follow-up (Salmanpoor 2012).
Primary outcomes
Recurrence
It is uncertain whether the risk of recurrence is improved for
curettage versus SE (RR 2.40, 95% CI 0.49 to 11.77; Analysis 4.1), C&C
versus SE (RR 0.96, 95% CI 0.15 to 6.28; Analysis 5.1), and curettage
versus C&C (RR 0.40, 95% CI 0.08 to 1.97; Analysis 6.1). We rated the
certainty of evidence as very low for all these comparisons, rating
down for very serious imprecision (very wide 95% CIs) and also for
serious indirectness as the study only measured recurrence up to
two years.
5. Photodynamic therapy (PDT)
PDT versus surgical excision (SE)
Four studies compared PDT with SE, three of which used
the photosensitiser methyl aminolevulinate (MAL-PDT) (Rhodes
2004; Szeimies 2008; Abbade 2015), and one which used the
photosensitiser 5-aminolevulinate (ALA-PDT) (Mosterd 2008).
Rhodes 2004 compared MAL-PDT against SE for nBCC of the face
in 103 participants (118 lesions) with five years follow-up. Abbade
2015 compared MAL-PDT against SE in 57 participants (68 lesions)
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with nBCC in the head and neck area with follow-up over three
years.
Szeimies 2008 was a non-inferiority study that compared MAL-PDT
with SE in 196 participants with 246 sBCCs (between 8 mm and
20 mm located anywhere except mid-face) with one year follow-
up. The inferiority margin was set at a diJerence of 15% in terms
of per cent reduction in lesion count three months aKer the last
treatment.
Mosterd 2008, compared fractionated ALA-PDT with SE in 171
primary nBCCs (149 participants) with five years follow-up.
All the MAL-PDT studies followed the standard European PDT
protocol which defines one cycle as two PDT sessions separated
by a one-week interval. The ALA-PDT (Mosterd 2008) study did
two illuminations on the same day separated by 60 minutes
and any incomplete responses were re-treated surgically. Rhodes
2004 and Szeimies 2008 performed a gentle curettage of lesions
to remove scale/crust and allowed a second PDT cycle if there
was not a complete response when assessed clinically at three
months follow-up. Mosterd 2008 and Abbade 2015 debulked/
shaved tumours under anaesthetic prior to PDT treatments. See
Summary of findings 4 and Table 4.
Primary outcomes
Recurrence
Although Rhodes 2004 followed-up patients for five years, they
presented the per protocol population data and the denominators
to be included for our analyses could not be determined for three-
year and five-year recurrence rates. Abbade 2015 showed that at
three years, MAL-PDT may increase the risk of recurrence compared
to SE (36.36%, 12/33 versus 0%, 0/35) (RR 26.47, 95% CI 1.63 to
429.92; Analysis 10.1). We rated the certainty of evidence as low,
rating down two levels for very serious imprecision (very wide
95% CI which indicated a slight increase or very large increase in
recurrence risk).
Mosterd 2008 showed that ALA-PDT probably increases the risk
of recurrence compared to SE at three years (24.7%, 21/85
versus 2.3%, 2/88, respectively) (RR 10.87, 95% CI 2.63 to 44.95;
Analysis 11.1). By five years, ALA-PDT probably increases the
risk of recurrence compared to SE (27.1%, 23/85 versus 2.3%,
2/88, respectively) (RR 11.91, 95% CI 2.90 to 48.95; Analysis 11.2).
We rated the certainty of evidence for both these outcomes as
moderate, rating down for serious imprecision (wide 95% CIs and
only one study).
Cosmetic outcome (participant- and observer-rated)
Pooling cosmetic results from Szeimies 2008 and Rhodes 2004, we
found that when measured at one year, MAL-PDT probably slightly
reduces the rate of participant-rated good/excellent cosmetic
outcomes compared to SE (RR 1.18, 95% CI 1.09 to 1.27, I2=0%;
Analysis 10.2). When investigator-rated at one year, MAL-PDT
probably increases the rate of investigator rated good/excellent
cosmetic outcomes compared to SE (RR 1.87. 95% CI 1.54 to 2.26, I2
= 0%; Analysis 10.2). We rated the certainty of evidence as moderate
for both these outcomes, rating down for serious risk of bias (unable
to truly blind due to nature of interventions).
Secondary outcomes
Pain during and aLer treatment
Rhodes 2004 recorded the frequency of patient reported "pain
in skin" and "burning sensation of skin" during treatment and
follow-up as part of their AE data. MAL-PDT may result in a higher
frequency of pain in the skin than SE (13.4%, 7/52 versus 6.1%,
3/49, respectively) (RR 2.20, 95% CI 0.60 to 8.03; Analysis 10.3). We
rated the certainty of evidence as low due to the very wide 95% CI.
Szeimies 2008 reported pain during and aKer treatment as part of
a "photosensitivity reaction" which included all expected reactions
to PDT such a "skin discomfort, burning sensation, stinging and
erythema". See Table 1 for further pain data from these studies.
Early treatment failure
At six months follow-up, it is uncertain whether MAL-PDT increases
early treatment failures compared to SE as the certainty of evidence
is very low due to the very wide 95% CI that meant we rated down
three levels for very serious imprecision (RR 11.65, 95% CI 0.67
to 202.74; Analysis 10.4). Rhodes 2004 and Szeimies 2008 did not
histologically confirm their early treatment failures and these data
were therefore not extracted.
Mosterd 2008 showed that SE may improve the risk of early
treatment failures for nBCCs compared to ALA-PDT (7.2%, 6/83
versus 2.3%, 2/88) (RR 3.18, 95% CI 0.66 to 15.32; Analysis 11.3).
We rated the certainty of evidence as low, rating down for very
serious imprecision (very wide 95% CI that indicates important
improvement or worsening in early treatment failures).
Adverse e<ects
Based on Rhodes 2004, more participants treated with MAL-PDT
than SE reported AEs 52% versus 29%, (P = 0.03, Fisher exact test).
Most of the AEs were transient local reactions commonly associated
with PDT, such as burning sensation of the skin, pain in the skin
or erythema. Szeimies 2008 had similar findings (37% versus 14%
reported AEs, respectively). Wound infections were reported in
three SE participants in Rhodes 2004, one ALA-PDT participant from
Mosterd 2008 and one severe wound infection was reported aKer
SE in Szeimies 2008.
See Table 2 for further AE data from the respective studies.
MAL-PDT versus ALA-PDT
One small pilot study (Kuijpers 2006) compared the topical
photosensitisers MAL and ALA in 43 participants with a nBCC
(< 20 mm diameter) with eight weeks follow-up. Half of the
tumours were debulked prior to PDT and conventional treatment
protocols were followed (two PDT sessions one week apart). All
treated tumours were excised eight weeks following treatment.
A second, non-inferiority study (Morton 2018) compared a newer,
stable nanoemulsion ALA formulation (BF-200 ALA gel) against MAL-
PDT in 231 participants with 275 sBCC and nBCC with one year
follow-up. Conventional treatment protocols were followed for
both arms. A third study (Salmivuori 2019) compared BF-200 ALA-
PDT, hexylaminolevulinate (HAL)-PDT and MAL-PDT in 95 lesions
(sBCC and thin nBCCs) with a non-inferiority trial design.
A fourth study (Kessels 2018) compared two-fold ALA-PDT with
conventional MAL-PDT in 162 participants with sBCC over a one-
year follow-up. The two-fold group were treated with ALA 20%
ointment with both PDT treatments done on the same day,
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separated by two hours. The MAL-PDT group had the two PDT
treatments separated by one week.
Primary outcomes
Recurrence
Morton 2018 and Kessels 2018 had only one-year follow-up and
Salmivuori 2019 is still ongoing therefore no three- or five-year
recurrence rates reported. As one year is closer to our early
treatment failure time point we have just reported this.
Cosmetic outcome (participant- and observer-rated)
In Morton 2018, a blinded investigator assessed cosmetic outcome
at one year using a five-point scale (impaired, unsatisfactory,
satisfactory, good, very good). Only complete responders were
included in the analysis. There is probably little to no diJerence
between BF-200 ALA-PDT (73.2%, 41/56) and MAL-PDT (68.4%,
39/57) on the rate of good/very good cosmetic outcomes (RR
1.07, 95% CI 0.84 to 1.36; Analysis 12.1). We rated the certainty of
evidence as moderate, rating down for serious imprecision (wide
95% CI that indicates important improvement and worsening of
cosmetic outcome).
Kessels 2018 used two blinded investigators to assess cosmetic
outcome on the standard four-point scale. Two-fold ALA-PDT
probably slightly increases the rate of good/excellent cosmetic
outcomes compared to MAL-PDT (RR 1.19, 95% CI 0.98 to 1.46;
Analysis 12.1). We rated the certainty of evidence as moderate,
rating down for serious imprecision (wide 95% CI). The outcomes
from these two studies were not pooled as they used diJerent
cosmetic outcome scales.
Secondary outcomes
Pain during and aLer treatment
We pooled the pain data from Morton 2018 and Kuijpers 2006 as
they had similar PDT protocols and used the same visual analogue
scale (VAS). For both studies, VAS scores were slightly higher during
cycle two and mean VAS scores ranged over both cycles from 2.4
to 4.8. During cycle one, there is probably little to no diJerence
between ALA-PDT and MAL-PDT on the risk of pain, measured
using VAS (mean diJerence (MD) 0.56, 95% CI -0.76 to 1.88, I 2
= 57%; Analysis 12.2). We rated the certainty of evidence as low,
rating down for serious imprecision due to the fairly wide 95% CI
and serious inconsistency as I2 suggests substantial heterogeneity.
During cycle two, there is probably little to no diJerence between
ALA-PDT and MAL-PDT on the risk of pain (MD 0.43, 95% CI -0.18 to
1.05; I2 = 0%; Analysis 12.2). We rated the certainty of evidence as
moderate, rating down for serious imprecision.
Based on Kessels 2018, there is probably little to no diJerence in
numerical pain scores (0-10) between two-fold ALA-PDT and MAL-
PDT during cycle one (MD -0.37, 95% CI -1.13 to 0.39; Analysis 12.3).
For cycle 2, there is probably a slightly higher numerical pain score
with twofold ALA-PDT over MAL-PDT (3.36 +/- 2.57 versus 2.48 +/-
2.57, respectively) (MD 0.88, 95% CI 0.09 to 1.67; Analysis 12.3).
We rated the certainty of evidence as moderate for both these
outcomes, rating down for serious imprecision.
See Table 1 for further pain data.
Early treatment failure
In Kuijpers 2006, at eight weeks there may be little to no diJerence
between MAL-PDT and ALA-PDT on the risk of early treatment
failure rates (28.6%, 6/21 versus 27.3%, 6/22, respectively) (RR
0.95, 95% CI 0.37 to 2.49; Analysis 12.4). We rated the certainty
of evidence as low due to very serious imprecision (very wide
95% CI that indicates important benefit and harm). Based on
Salmivuori 2019, there may be fewer early treatment failures at 3
months with MAL-PDT compared to BF-200 ALA-PDT (3.2%, 1/31
versus 9.1%, 3/33, respectively) (RR 2.82, 95% CI 0.31 to 25.68;
Analysis 13.1). We rated the certainty of evidence as low due to
very serious imprecision (very wide 95% CI that indicates important
improvement or worsening in early treatment failures). Morton
2018 did not histologically confirm early treatment failures and we
have not extracted these data.
Based on Kessels 2018, there may be slightly more early treatment
failures with MAL-PDT compared with two-fold ALA-PDT (5.1%,
4/79 versus 3.8%, 3/79, respectively) (RR 0.75, 95% CI 0.17 to 3.24;
Analysis 12.4). We rated the certainty of evidence as low due to
very serious imprecision (very wide 95% CI that indicates important
improvement or worsening in early treatment failures).
Adverse e<ects
In Morton 2018, the most frequently reported AEs were mild-to-
moderate pain, erythema, pruritus and oedema and frequencies
were comparable between the two groups. Two-fold ALA-PDT
resulted in more post-treatment AEs compared with MAL-PDT. See
Table 2 for further AE data.
HAL-PDT versus MAL-PDT
Early treatment failure
Based on Salmivuori 2019 (detailed above), we are uncertain
whether there is any diJerence in the three-month early treatment
failure rate between HAL-PDT and MAL-PDT (6.5%, 2/31 versus 3.2%,
1/31, respectively) because the certainty of evidence was rated as
very low due to a very wide 95% CI that meant we rated down three
levels for imprecision (RR 2.00, 95% CI 0.19 to 20.93; Analysis 14.1).
HAL-PDT versus BF-200 ALA-PDT
Early treatment failure
Based on Salmivuori 2019 (detailed above), there may be fewer
early treatment failures at three months with HAL-PDT compared
to BF-200 ALA-PDT(6.5%, 2/3 versus 9.1%, 3.33) (RR 0.71, 95% CI
0.13 to 3.97; Analysis 15.1). We rated the certainty of evidence as
low (very wide 95% CI that indicates important improvement or
worsening in early treatment failures).
Adverse e<ects
Severity of post-treatment reactions were visually assessed (on
a scale: none/minimal/mild/moderate/severe). HAL-PDT had 12
lesions with a moderate reaction and 13 lesions with a severe
reaction. BF-200 ALA-PDT had 13 moderate and 11 severe reactions.
MAL-PDT had 13 moderate and nine severe reactions. Overall, there
was no significant diJerence between the three groups P = 0.49).
There was one treatment-related withdrawal from the trial, as
one patient from the MAL group experienced remarkable swelling,
oedema, erythema and haematoma in the treatment area.
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PDT versus cryosurgery
Two studies compared PDT against cryosurgery. One study (Basset-
Seguin 2008) compared a single session of MAL-PDT against
cryosurgery in 118 participants with 219 sBCCs over 5 years follow-
up. A second study (Wang 2001) compared a single session of ALA-
PDT (against cryosurgery) in 88 participants with nBCC and sBCC
over 1 year follow-up. The standard European protocol for PDT is
two PDT sessions separated by 1 week and therefore the single PDT
sessions performed in these studies would no longer be considered
the standard of care. See Table 5.
Primary outcomes
Recurrence
There may be little to no diJerence between MAL-PDT and
cryosurgery on the risk of recurrence at three years (22%, 22/100
versus 19.4%, 18/93) (RR 1.14, 95% CI 0.65 to 1.98; Analysis 16.1). We
rated the certainty of evidence as low, rating down for very serious
imprecision (very wide 95% CI that indicates important benefit and
harm).
At five years there may be little to no diJerence between MAL-PDT
and cryosurgery on the risk of recurrence (22%, 22/100 versus 20%,
19/93, respectively) (RR 1.08, 95% CI 0.62 to 1.86; Analysis 16.2). We
rated the certainty of evidence as low for very serious imprecision
(very wide 95% CI that indicates important benefit and harm).
Cosmetic outcome (participant- and observer-rated)
When participant-rated at one year on a four-point scale, MAL-
PDT probably increases the rate of good/excellent cosmetic
outcomes compared to cryosurgery (100%, 51/51 versus 81.3%,
39/48, respectively) (RR 1.23, 95% CI 1.07 to 1.41; Analysis 16.3).
When investigator-rated on a four-point scale, MAL-PDT probably
increases the rate of good/excellent cosmetic outcomes compared
to the cryosurgery (89%, 45/51 versus 61%, 29/48, respectively)
(RR 1.46, 95% CI 1.14 to 1.88; Analysis 16.3). Wang 2001 assessed
cosmetic outcome based on hypo- and hyperpigmentation, scar
and tissue defect and then gave an overall investigator rated
assessment based on a four-point scale. The study showed that
ALA-PDT probably increases the rate of good/excellent cosmetic
outcomes at one year compared to cryosurgery (92.8%, 39/42
versus 54.1%, 20/37) (RR 1.72, 95% CI 1.26 to 2.34; Analysis 17.1). We
rated the certainty of evidence as moderate for all these outcomes,
rating down for serious risk of blinding bias due to the nature of the
interventions.
Secondary outcomes
Pain during and aLer treatment
Basset-Seguin 2008 presented pain data within the adverse eJects
data. There may be little to no diJerence between MAL-PDT and
cryosurgery on the risk of pain reported as an AE (33%, 19/58
versus 37%, 22/60, respectively) (RR 1.12, 95% CI 0.68 to 1.84;
Analysis 16.4). We rated the certainty of evidence as low (very
wide 95% CI that indicates important benefit and harm). Wang
2001 measured pain during and the first week aKer treatment
by providing participants with a self-registration VAS form which
ranged from 0 mm (no pain) to 115 mm (unbearable pain). Raw
data with standard deviations were available for the mean during
treatment VAS scores which showed that ALA-PDT probably results
in slightly more pain than cryosurgery (MD 11.00, 95% CI -1.12
to 23.12; Analysis 17.2). We rated the certainty of evidence as
moderate rating down for serious imprecision (only one study and
wide 95% CI). In the first week aKer treatment,
See Table 1 for further pain data.
Early treatment failure
At three months, there may be slightly fewer early treatment
failures with MAL-PDT compared to cryosurgery (2.9%, 3/103 versus
5.1%, 5/98, respectively) (RR 0.57, 95% CI 0.57 to 2.33; Analysis
16.5). We rated the certainty of evidence as low, rating down for
very serious imprecision (very wide 95% CI that indicates important
benefit and harm).
Adverse e<ects
See Table 2 for further AE data.
Imiquimod cream versus MAL-PDT
One study (Arits 2013) assessed whether imiquimod cream and 5-
FU cream were non-inferior to MAL-PDT in 601 participants with a
single sBCC (anywhere except high-risk face/scalp) in a three-arm
RCT with five years follow-up. A pre-specified non-inferiority margin
of 10% was used. See Summary of findings 5.
Primary outcomes
Recurrence
Imiquimod cream probably reduces the risk of recurrence at three
years compared to MAL-PDT (22.8%, 34/149 versus 51.6%, 66/128,
respectively) (RR 0.44, 95% CI 0.32 to 0.62; Analysis 18.1). We rated
the certainty of evidence as moderate, rating down for serious
imprecision as this was a single study.
At five years, imiquimod cream probably reduces the risk of
recurrence compared to MAL-PDT (28.6%, 36/126 versus 68.6%,
70/102) (RR 0.42, 95% CI 0.31 to 0.57; Analysis 18.2). We rated
the certainty of evidence as moderate, rating down for serious
imprecision (only one study).
Cosmetic outcome (participant- and observer-rated)
A blinded observer-rated cosmetic outcome at one year on a
four-point scale. There is probably little to no diJerence between
imiquimod and MAL-PDT on the rate of good/excellent cosmetic
outcomes (RR 0.98, 95% CI 0.84 to 1.16; Analysis 18.3). We rated the
certainty of evidence as moderate (only one study).
Secondary outcomes
Pain during and aLer treatment
Maximum pain was recorded on VAS for all interventions at the end
of each week of treatment. The scores were then interpreted as
absent/mild (0-3), moderate (4-6) and severe (7-10). We selected
the week or treatment cycle (presented for PDT only) with the
highest reported moderate/severe pain to overcome diJerences
in timing of reported pain with the diJerent interventions. Week
six had the highest reported pain for imiquimod (18% of patients
reported moderate/severe pain) and treatment cycle two for MAL-
PDT (31% of patients reporting moderate/severe pain). Our analysis
showed that imiquimod probably reduces the risk of moderate/
severe pain compared to MAL-PDT (RR 0.60, 95% CI 0.41 to 0.87;
Analysis 18.4). We rated the certainty of evidence as moderate,
rating down for serious imprecision (only one study). See Table 1
for further pain data from this study.
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Early treatment failure
At three months, there may be little to no diJerence between
imiquimod and MAL-PDT on the risk of early treatment failures
(10.1%, 19/189 versus 15.8%, 31/196) (RR 0.64, 95% CI 0.37 to 1.09;
Analysis 18.5). We rated the certainty of evidence as moderate,
rating down for serious imprecision (wide 95% CI, including the null
eJect which indicates there may be an important diJerence or no
diJerence between the two treatments).
Adverse e<ects
Participants treated with imiquimod more oKen reported moderate
to severe local swelling, erosion, crust formation and itching of
skin compared to the MAL-PDT group. There were no unexpected
serious adverse reactions in the MAL-PDT group, but 4.8% (nine
participants) were reported to have a suspected unexpected
serious adverse reaction (SUSAR) in the imiquimod group for
influenza-like symptoms (n = 8) and a local wound infection;
however, none of the participants were admitted to hospital. See
Table 2 for further AE data from this study.
5-fluorouracil cream versus MAL-PDT
One study (Arits 2013) assessed the eJects of 5-FU cream versus
MAL-PDT; this study is described above in section 5. See Table 6.
Primary outcomes
Recurrence
5-FU cream probably reduces the risk of recurrence compared
to MAL-PDT at three years (34.2%, 50/146 versus 52.4%, 66/126,
respectively) (RR 0.65, 95% CI 0.49 to 0.86; Analysis 19.1). We rated
the certainty of evidence as moderate, rating down for serious
imprecision (only one study).
Similar findings were also seen at five years, where 5-FU cream
probably reduces the risk of recurrence compared to MAL-PDT
(46%, 57/124 versus 68.7%, 70/102, respectively) (RR 0.67, 95% CI
0.53 to 0.84; Analysis 19.2). We rated the certainty of evidence as
moderate, rating down for serious imprecision (only one study).
Cosmetic outcome (participant- and observer-rated)
There is probably little to no diJerence between 5-FU cream and
MAL-PDT on the rate of good/excellent cosmetic outcomes (RR
0.92, 95% CI 0.78 to 1.09; Analysis 19.3). We rated the certainty of
evidence as moderate, rating down for serious imprecision (only
one study).
Secondary outcomes
Pain during and aLer treatment
The maximum recorded pain for 5-FU cream was recorded during
week four (final week) of treatment with 12% of patients reporting
moderate/severe pain. 5-FU cream probably reduces the risk of
moderate/severe pain compared to MAL-PDT (RR 0.41, 95% CI
0.26 to 0.63; Analysis 19.4). We rated the certainty of evidence as
moderate, rating down for serious imprecision (only one study). See
Table 1 for further pain data.
Early treatment failure
There may be little to no diJerence between 5-FU cream and MAL-
PDT on the risk of early treatment failure (12.1%, 24/198 versus
15.8%, 31/196) (RR 0.77, 95% CI 0.47 to 1.26; Analysis 19.5). We
rated the certainty of evidence as low, rating down two levels for
very serious imprecision (very wide 95% CI that indicates important
benefit and harm).
Adverse e<ects
Unexpected serious adverse reactions were reported in 2.1% (four
participants) in the 5-FU cream group: two local wound infections,
one case of erysipelas of the leg and one leg ulcer. See Table 2 for
further AE data.
Laser ALA-PDT versus broadband halogen light ALA-PDT
One study (Soler 2000) of 83 participants (245 lesions) with sBCC
compared two diJerent light sources: laser or broadband lamp
light with ALA-PDT. The study only had six months follow-up. The
laser light was 630 nm from a copper vapour dye laser with doses
ranging between 100 J/cm2 to 150 J/cm2. The broadband light used
a halogen bulb and a filter to produce red light (570 nm to 740 nm)
with a dose ranging between 150 J/cm2 to 200 J/cm2 as well as
infrared radiation (1180 nm to 2700 nm).
Primary outcomes
Cosmetic outcome (participant- and observer-rated)
At six months, cosmetic outcome was rated by two observers (only
one blinded) on a four-point scale (poor, fair, good, excellent). Only
tumours that had completely responded were scored leading to
an unequal attrition rate between the groups. There may be little
to no diJerence on the rate of good/excellent cosmetic outcomes
between the two light sources (RR 0.91, 95% CI 0.82 to 1.01; Analysis
20.1). We rated the certainty of evidence as low, rating down for
serious imprecision (only one study) and serious risk of attrition
bias.
Secondary outcomes
Pain during and aLer treatment
There is probably little to no diJerence between laser ALA-PDT and
broadband light ALA-PDT on the frequency of pain (reported as any
type of discomfort) during and immediately aKer treatment (83%,
34/41 versus 76%, 32/42) (RR 1.09, 95% CI 0.87 to 1.35; Analysis
20.2). In the first week aKer treatment, there is probably little to
no diJerence in the frequency of pain reported between the two
light sources (RR 0.93, 95% CI 0.70 to 1.22; Analysis 20.2). We rated
the certainty of evidence for both these outcomes as moderate,
rating down for serious imprecision (only one study). See Table 1
for further pain data from this study.
Early treatment failure
The study did not histologically confirm clinical treatment failures;
therefore, we have not extracted the data for this outcome.
Adverse e<ects
Some discomfort during and aKer illumination was reported by
83% of participants receiving laser ALA-PDT and 76% of those
receiving broadband PDT. No serious AEs were reported during the
6-month follow-up. See Table 2 for further AE data from this study.
Ablative fractional laser (AFXL) MAL-PDT versus MAL-PDT
Two small pilot studies compared ablative fractional laser (AFXL)
pre-treatment prior to MAL-PDT against conventional MAL-PDT with
one year follow-up. This is based on the rationale that AFXL pre-
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treatment increases uptake of MAL deeper into the tumour. One
study (Haak 2015) randomised 32 participants with facial nBCC and
the other (Choi 2016) randomised 39 participants (42 lesions) with
facial nBCC. The first study used a fractional CO2 laser and the
second an erbium:YAG laser.
Primary outcome
Cosmetic outcome (participant- and observer-rated)
Cosmetic outcomes were assessed by a blinded investigator in both
studies at one year using a four-point scale. The pooled results
from both studies showed there may be little to no diJerence
between AFXL-PDT and MAL-PDT on the rate of good/excellent
cosmetic outcomes (RR 1.12, 95% CI 0.54 to 2.31, I2 = 66%; Analysis
21.1). We rated the certainty of evidence as low, rating down two
levels for very serious imprecision (very wide 95% CI that indicates
important benefit and harm). Haak 2015 presented participant
reported cosmetic outcomes, showing that there is probably little
to no diJerence between AFXL-PDT and MAL-PDT on the rate of
good/excellent cosmetic results (RR 0.94, 95% CI 0.75 to 1.17;
Analysis 21.1). We rated the certainty of evidence as moderate,
rating down for serious imprecision (only one study).
Secondary outcomes
Pain during and aLer treatment
Pain was recorded using VAS for both studies but individual data
were not presented. Both studies reported in their text that there
was “no statistically significant diJerence” in pain scores between
the treatment groups. See Table 1 for further pain data from these
studies.
Early treatment failure
A pooled analysis of both studies showed that AFXL-PDT probably
reduces the risk of early treatment failures compared to MAL-PDT at
three months (RR 0.38, 95% CI 0.17 to 0.84, I2 = 0%; Analysis 21.2).
We rated the certainty of evidence as moderate, rating down for
serious imprecision (fairly wide 95% CI).
Adverse e<ects
See Table 2 for further AE data from these studies.
MAL-PDT versus placebo
Two RCTs with the "same design and procedures" (Foley 2009a
and Foley 2009b) randomised 131 participants (160 nBCC) to MAL-
PDT versus placebo. We have presented the data analyses as one
study under Foley 2009a as the data from the separate studies
were not available. All tumours were debulked prior to treatment
and all treatment sites were excised at three months (clinical
non-responders) or six months (clinical responders) aKer the last
treatment.
Primary outcomes
Cosmetic outcome (participant- and observer-rated)
Only the complete clinically/histologically clear lesions were
assessed for cosmetic outcome. The authors only presented the
investigator-rated data (four-point scale). There is probably little to
no diJerence between MAL-PDT and placebo on the rate of good/
excellent cosmetic outcomes (RR 1.05, 95% CI 0.91 to 1.21; Analysis
22.1). We rated the certainty of evidence as moderate, rating down
for serious imprecision (fairly wide 95% CI).
Secondary outcomes
Pain during and aLer treatment
Frequency of "burning sensation of skin", "pain in skin" and
"stinging of skin" were reported as part of treatment-related local
adverse eJects. MAL-PDT probably increases the risk of "pain in
skin" compared to placebo (RR 3.94, 95% CI 1.17 to 13.32; Analysis
22.2). We rated the certainty of evidence as moderate, rating down
for serious imprecision (fairly wide 95% CI). See Table 1 for further
pain data from this study.
Early treatment failure
MAL-PDT may reduce the risk of early treatment failures compared
to placebo (RR 0.36, 95% CI 0.24 to 0.54; Analysis 22.3). We rated
the certainty of evidence as low, rating down for serious imprecision
(only one study).
Adverse e<ects
See Table 2 for further AE data from this study.
6. Imiquimod cream
Imiquimod cream versus 5-fluorouracil cream
One study (Arits 2013) assessed the eJects of imiquimod cream




Imiquimod probably reduces the risk of recurrence compared to
5-FU cream at three years (23.4%, 34/145 versus 34.2%, 50/146,
respectively) (RR 0.68, 95% CI 0.47 to 0.99; Analysis 23.1). We rated
the certainty of evidence as moderate, rating down for serious
imprecision (only one study).
Imiquimod probably reduces the risk of recurrence compared
to 5-FU cream at five years (28.6%, 36/126 versus 46%, 57/124,
respectively) (RR 0.62, 95% CI 0.44 to 0.87; Analysis 23.2). We rated
the certainty of evidence as moderate, rating down for serious
imprecision (only one study).
Cosmetic outcome (participant- and observer-rated)
When blinded observer-rated at 1 year, there is probably little to
no diJerence between imiquimod and 5-FU cream on the rate of
good/excellent cosmetic outcomes (61.4%, 113/184 versus 57.5%,
111/193, respectively) (RR 1.07, 95% CI 0.90 to 1.26; Analysis 23.3).
We rated the certainty of evidence as moderate, rating down for
serious imprecision (only one study).
Secondary outcomes
Pain during and aLer treatment
We compared the week with the highest frequency of reported
of moderate/severe pain during treatment for each intervention
(week six for imiquimod and week 4 for 5-FU cream). There is
probably a slightly increased risk of moderate/severe pain with
imiquimod compared with 5-FU cream (18.2%, 33/181 versus
12.5%, 23/184) (RR 1.46, 95% CI 0.89 to 2.34; Analysis 23.4). We
rated the certainty of evidence as moderate, rating down for serious
imprecision (wide 95% CI that indicates increased pain or slightly
less pain). See Table 1 for further pain data from this study.
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Early treatment failure
There may be little to no diJerence between imiquimod and 5-FU
cream on the risk of early treatment failures (10%, 19/189 versus
12.1%, 24/198 ) (RR 0.83, 95% CI 0.47 to 1.46; Analysis 23.5). The
certainty of evidence is low due to very serious imprecision with a
wide 95% CI that indicates there may be an important reduction or
an important increase in early treatment failures.
Adverse e<ects
See Table 2 for further AE data from this study.
Imiquimod cream versus radiotherapy
One small study (Garcia-Martin 2011) randomised 27 participants
with nBCC of the eyelid to either imiquimod (five days a week for
six weeks) or conventional radiotherapy with two years follow-up.
The study was at high risk of selection bias due to the method of
randomisation (based on birthday of participant).
Primary outcomes
Recurrence
There were no recurrences in either group during the follow-up
period and therefore we were unable to assess eJect size.
Cosmetic outcome (participant- and observer-rated)
Cosmesis was patient-rated on a three-point scale (bad, good,
excellent), but this was only measured at 6 weeks following
treatment. Observer-rated cosmetic outcomes were also recorded
on a three-point scale, but the data were not presented in the
paper. All participants in the imiquimod group rated the cosmetic
result as excellent and all those in the radiotherapy group rated
the cosmetic result as good. There may be more participant-rated
excellent cosmetic outcomes at 6 weeks with imiquimod compared
to radiotherapy (RR 25.19, 95% CI 1.66 to 382.13; Analysis 24.1). We
rated the certainty of evidence as low due to the very wide 95% CI.
Secondary outcomes
Pain during and aLer treatment
Blink discomfort was reported in 60% (9/15) of participants in the
imiquimod group and blink discomfort and dry eye were reported
in 50% (6/12) participants in the radiotherapy group. Intense
conjunctival irritation occurred in 13.3% (2/15) of participants in the
imiquimod group.
Early treatment failure
There were no early treatment failures at six weeks following
treatment and therefore no eJect size was estimable.
Adverse e<ects
All participants in the radiotherapy group presented with loss of
eyelashes in one or both eyelids, 16.6% (2/12) of participants had
inferior eyelid retraction with secondary ectropion, and three of
the participants reported dry eye symptoms aKer radiotherapy.
Tolerability during treatment was better in the radiotherapy group.
Seven of the 15 participants in the imiquimod group reported 'bad'
tolerability, but these symptoms disappeared when the period of
cream application ended. Only one patient in the radiotherapy
group rated 'bad' tolerability. See Table 2 for further AE data and
Table 1 for pain data from this study.
Imiquimod with occlusion versus imiquimod without occlusion
Two similar dose-response studies ( Sterry 2002a; Sterry 2002b)
examined imiquimod cream with or without occlusion in sBCC
(93 participants; Sterry 2002a) and nBCC (90 participants; Sterry
2002b). Patients were randomised to one of four groups to apply
imiquimod 5% cream two or three days per week either with
or without occlusion for six weeks. At the end of the six-week
treatment period, the entire target tumour area was excised and
histologically examined for evidence of residual tumour. Size and
location of lesions were not given.
Secondary outcomes
Early treatment failure
Pooling the data from both studies (we also combined the diJerent
dosing regimen group as the number of participants was small)
found there may be little to no diJerence between the occlusion
and no occlusion groups (38.2%, 34/89 versus 41.5%, 39/94) on the
risk of early treatment failures (RR 0.91, 95% CI 0.64 to 1.33; Analysis
25.1, I2 = 0%). We rated the certainty of evidence as low due to very
serious imprecision (wide 95% CI that indicates that includes the
possibility of important benefit or harm).
Adverse e<ects
See Table 2 for further AE data from these studies.
Imiquimod versus placebo
One trial (Beutner 1999) randomised 35 participants with sBCC
and nBCC to imiquimod cream or vehicle cream in one of
five dosing regimens for up to 16 weeks. Another trial of 128
participants (Geisse 2002) compared imiquimod twice daily, once
daily, five days per week or three days per week versus vehicle
for sBCCs. Marks 2001 compared diJerent dosages of imiquimod
cream applied for six weeks in 99 Australian participants with
primary sBCCs. Geisse 2004 randomised 724 participants with
sBCC to imiquimod cream daily either five times per week or
seven times per week for six weeks versus vehicle. One further
study (Schulze 2005), randomised 166 participants with sBCC to
imiquimod cream or vehicle, once a day for six weeks. Another two
similar studies (Shumack 2002a; Shumack 2002b) randomised 99
and 92 participants with nBCC, respectively to four diJerent dosing
regimens (three or seven days per week or twice daily for three or
seven days per week) of imiquimod cream or vehicle over 12 and six
weeks, respectively. All these studies were industry sponsored.
Early treatment failure
Pooled analysis of the five studies showed that imiquimod reduces
the risk of early treatment failures compared to vehicle by 75% (RR
0.25, 95% CI 0.19 to 0.32, I2 = 57%; Analysis 26.1). We rated the
certainty of evidence as high.
Dose-ranging studies
One study (Ezughah 2008) compared the tolerability of two
regimens of imiquimod for the treatment of sBCC with one
year follow-up: five weeks of once-daily dosing with a one-week
interval in the middle of the course (R1) versus eight weeks of
treatment with once-daily dosing for alternate weeks (R2). One
study (Eigentler 2007) compared imiquimod three times a week
over eight weeks versus three times a week over 12 weeks in 102
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participants with nBCC up to 1.5 cm, located anywhere on the body
(except close to the eyes).
Primary outcomes
Recurrence
Ezughah 2008 only followed up patients for one year and as we have
not included the early treatment failure data (as not histologically
confirmed) we have included these data. R2 imiquimod dosing may
result in fewer recurrences than R1 imiquimod dosing (12.5%, 2/16
versus 57.1%, 8/14, respectively) (RR 4.57, 95% CI 1.16 to 18.05;
Analysis 27.1). We rated the certainty of evidence as moderate,
rating down for serious imprecision due to the wide 95% CI and the
small numbers of participants.
Secondary outcomes
Early treatment failure
Based on Eigentler 2007, at eight weeks post-treatment there may
be little to no diJerence in early treatment failure rates between
imiquimod three times a week over eight weeks and three times
a week over 12 weeks (35.6%, 16/45 versus 37.8%, 17/45) (RR
0.94, 95% CI 0.55 to 1.62; Analysis 28.1). We rated the certainty of
evidence as low, rating down two levels for very serious imprecision
(very wide 95% CI that indicates important benefit and harm).
Pain during and aLer treatment
In Ezughah 2008, a weekly VAS for tolerability was measured using
a 10 cm line scale ranging from 0 cm (not unpleasant) to 10
cm (absolutely intolerable). There may be little to no diJerence
between the eight-week and five-week treatment groups on the
mean composite VAS scores at eight weeks (median score 0.85 cm
versus median score 0.30 cm; 95% CI for diJerence in medians:
20.40 to 0.9 cm, P = 0.39), as reported in the paper. Eigentler 2007
did not present pain data separately for the two treatment arms.
See Table 1 for further pain data from these studies.
Adverse e<ects
See Table 2 for AE data from these studies.
7. 5-Fluorouracil
Phosphatidyl choline versus petrolatum vehicle
One small pilot study (Romagosa 2000) compared 5-FU cream
in petrolatum with 5-FU cream in phosphatidyl choline (a
transepidermal carrier to aid penetration) in 13 participants (17
lesions, non sBCC, at least 0.7cm diameter, facial lesions excluded).
Participants underwent excision of the treated BCC site at week-16.
Secondary outcomes
Early treatment failure
There may be fewer early treatment failures with 5-FU cream in
phosphatidyl choline compared to 5-FU cream in petrolatum (10%,
1/0 versus 42.9%, 3/7, respectively) (RR 0.23, 95% CI 0.03 to 1.81;
Analysis 29.1). We rated the certainty of evidence as low, rating
down two levels for very serious imprecision (very wide 95% CI that
indicates important benefit and harm).
Adverse e<ects
In the Romagosa 2000 study, local irritation, erythema, ulceration
and tenderness were common reactions but were reported to be
well-tolerated by the participants. Minimal itching and discomfort
were experienced by some of the participants in both treatment
arms. See Table 2 for further AE data from this study.
Intralesional 5-fluorouracil/epinephrine gel
One study (Miller 1997) compared six treatment regimens of
intralesional 5-FU/epinephrine gel in 122 participants with sBCC
and nBCC located on the head, upper and lower extremities: 1 mL
versus 0.5 mL both once a week for six weeks; 1 mL versus 0. 5mL
both twice a week for three weeks; 0.5 mL twice a week for four
weeks versus 0.5 mL three times a week for two weeks.
Early treatment failure
There may be fewer early treatment failures with 1 mL intralesional
5-FU compared with 0. 5mL intralesional 5-FU when given twice a
week for three weeks (5.6%, 1/18 versus 21.1%, 4/19, respectively)
(RR 0.26, 95% CI 0.03 to 2.14; Analysis 31.1). We rated the certainty of
evidence as low, rating down two levels for very serious imprecision
(very wide 95% CI that indicates important benefit and harm). It is
uncertain whether there is any diJerence between the other two
intralesional regimens as we rated the certainty of evidence for
these comparisons as very low due, rating down three levels for
very serious imprecision (Analysis 30.1; Analysis 32.1).
Adverse e<ects
All participants had transient, moderate to severe stinging, burning
or pain at the time of injection. Local tissue reactions were
confined to the treatment site and included erythema, swelling,
desquamation, erosions and eschar in most participants. See Table
2 for further AE data from this study.
8. Electrochemotherapy
Electrochemotherapy versus surgical excision
One study (Clover 2016) compared bleomycin
electrochemotherapy (ECT) to SE in 100 participants with 117
low-risk and high-risk BCC (superficial, nodular, infiltrative and
morphoeic subtypes). Noduar and nodular/infiltrative BCC were
the most common subtype. Location of lesions was not described.
Follow-up was for five years. The author of the abstract was
contacted and unpublished data were obtained.
Primary outcomes
Recurrence
ECT may result in more recurrences (10.5%, 4/38 versus 2.8%, 1/36,
respectively) than SE at three years (RR 3.79, 95% CI 0.44 to 32.32;
Analysis 33.1) and 5 years (13.5%, 5/37 versus 2.8%, 1/36) (RR
4.86, 95% CI 0.60 to 39.63; Analysis 33.2). We rated the certainty of
evidence for both these outcomes as low rating down two levels
for the very wide 95% CI that includes the possibility of important
benefit or harm.
Cosmetic outcome (participant- and observer-rated)
When assessed with the Vancouver scar scale by four blinded plastic
surgeons 18 months aKer treatment, the authors reported there
was no significant diJerence between ECT and SE; however the raw
data were not available for further analysis.
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9. Ingenol mebutate
Day 1 and 2 versus day 1 and 8 regimens
One study (Siller 2010) randomised 60 participants with sBCC to
one of two diJerent treatment regimens (days 1 and 2 dosing
or days 1 and 8 dosing) and then randomised again within each
group to treatment with one of three diJerent concentrations of
ingenol mebutate gel (0.0025%, 0.01% and 0.05%), or vehicle. The
main outcome measures were the incidence and severity of adverse
eJects and local skin responses.
Secondary outcomes
Pain during and aLer treatment
Intensity of pain data were not presented. Within the adverse
eJects data, only two patients reported application site pain and
these were in the highest dose ingenol group (0.05%) in the days 1
and 8 regimen. See Table 1 for further pain data from this study.
Early treatment failure
At week-12, in the day 1 and 2 dosing group, ingenol 0.05% gel
probably results in fewer early treatment failures than vehicle
gel (37.5%, 3/8 versus 100%, 6/6, respectively) (RR 0.42, 95% CI
0.18 to 0.97; Analysis 34.1). We rated the certainty of evidence
as moderate, rating down for serious imprecision. For the lower
ingenol concentration in the day 1 and 2 dosing group, as well as all
concentrations in the day 1 and 8 dosing group, there may be little
to no diJerence between ingenol and vehicle (see analysis Analysis
35.1 and Analysis 36.1 for RRs). We rated the certainty of evidence as
low for both these outcomes, rating down for serious imprecision
due to the wide 95% CIs and low numbers of participants involved.
Adverse e<ects
See Table 2 for further AE data from this study.
Occlusion versus no occlusion
One study (Spelman 2014) compared ingenol mebutate 0.05% gel
given on three consecutive days with full occlusion (aluminium disk
dressing) versus semi-occlusion (Opsite™ Disk) and no occlusion in
75 participants with sBCC (4 mm-15 mm to diameter) on the trunk/
extremities in a phase two RCT with four months follow-up.
Secondary outcomes
Early treatment failure
At four months, ingenol with full occlusion may reduce the risk
of early treatment failures compared to no occlusion (29.6%, 8/27
versus 45.5%, 11/24, respectively) (RR 0.65, 95% CI 0.31 to 1.34;
Analysis 36.1), and semi-occlusion may increase the risk of early
treatment failures compared to no occlusion (62.5%, 15/24 versus
45.8%, 11/24, respectively) (RR 1.36, 95% CI 0.80 to 2.33; Analysis
36.1). We rated the certainty of evidence as low for both these
outcomes, rating down for serious imprecision due to the wide 95%
CI and low numbers of participants involved.
Adverse e<ects
The percentage of participants with AEs were similar across all
three treatment groups. The most common AE was application site
pain. See Table 2 for further AE data from this study.
10. Solasodine glycosides
One study (Punjabi 2008) of 94 participants compared solasodine
glycoside (Zycure) cream to matching vehicle in BCCs at least 0.5cm
diameter (excluding morphoeic BCC). Lesions were treated twice
daily under occlusion with solasodine glycoside cream or vehicle
for 8 weeks.
Primary outcomes
Cosmetic outcome (participant- and observer-rated)
Cosmetic outcome was evaluated by an assessment of scarring
during the follow-up (categorized as none, mild, moderate,
severe). The authors reported there was no statistically significant
diJerence between the treatment groups; however, raw data were
not presented for further analysis.
Secondary outcomes
Early treatment failure
At the end of 8 weeks of treatment, a 2 mm punch biopsy was
performed on all lesions. Solasodine glycoside cream probably
reduces the risk of early treatment failures compared to vehicle
(33.9%, 21/62 versus 75%, 24/32, respectively) (RR 0.45, 95% CI
0.30 to 0.67; Analysis 37.1). We rated the certainty of evidence as
moderate, rating down for serious imprecision (only one study).
Adverse e<ects
No major treatment-related adverse eJects were reported. See
Table 2 for further AE data from this study.
11. Topical valproic acid and tazarotene
One study (2005-001474-27) randomised 50 participants (subtype
not stated, located anywhere except eyelids, nose, lips, anogenital)
to topical valproic acid (Baceca® 3% gel) and tazarotene (Zorac®
0.1% gel) against placebo gel and tazarotene. Treatment lasted
eight weeks and involved applying valproic acid or placebo gel
before bedtime and 15 to 30 minutes later tazarotene was applied.
Participants in both groups that did not show a complete clearance
aKer eight weeks, completed a further eight weeks of treatment
with valproic acid and tazarotene (cross-over design).
Early treatment failure
At three months follow-up, there may be slightly fewer early
treatment failures in the valproic acid gel and tazarotene group
compared with the placebo gel and tazarotene group (31%, 8/25
versus 52%, 13/25, respectively) (RR 0.62, 95% CI 0.31 to 1.22;
Analysis 38.1). We rated the certainty of evidence as low, rating
down one level for serious imprecision ( wide 95% CI that indicates
important benefit and slight harm).
Adverse e ects
Erythema, itching, ulceration and localised pain were the most
frequently reported AEs across both groups. There were no drug-
related severe AEs. See Table 2 for further AE data from this study.
12. Topical diclofenac gel and calcitriol ointment (vitamin D)
One study (Brinkhuizen 2016) of 128 participants (64 sBCC and 64
nBCC) compared diclofenac 3% gel (SolarazeTM), calcitriol 3 μg/g
ointment (Silkis®), a combination of both or no topical treatment.
The active treatments were applied twice daily under occlusion for
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Early treatment failure was measured at eight weeks of treatment.
Diclofenac gel monotherapy may reduce the risk of early treatment
failures compared to calcitriol ointment (53.3%, 16/30 versus 97%,
31/32, respectively) (RR of 0.55, 95% CI 0.39 to 0.77; Analysis 39.1).
We rated the certainty of evidence as moderate, rating down for
serious imprecision (only one study).
There may be little to no diJerence between diclofenac gel
monotherapy and combination treatment of diclofenac and
calcitriol on the risk of early treatment failures (53.3%, 16/30 versus
61.3%, 19/31, respectively) (RR 0.87, 95% CI 0.56 to 1.35; Analysis
40.1). We rated the certainty of evidence as low, rating down for
very serious imprecision due to the 95% CI that indicates important
benefit and harm.
Calcitriol ointment may increase the risk of early treatment failures
compared to combination treatment of diclofenac and calcitriol
(97%, 31/32 versus 61.3%, 19/31, respectively) (RR 1.58, 95% CI
1.19 to 2.11; Analysis 41.1). We rated the certainty of evidence as
moderate, rating down for serious imprecision (only one study).
Adverse e<ects
In all intervention groups mild to moderate application-site
reactions were reported. See Table 2 for further AE data from this
study.
13. Pulsed dye laser (PDL)
One session versus two sessions
One small pilot study (Abd El-Naby 2019) randomised 22
participants with 22 BCCs (17 nBCCs, three sBCC, one pigmented
BCC and one cystic BCC located on the face/scalp) to treatment with
one or two sessions (two weeks apart) of PDL (595 nm, fluency 7




Four weeks aKer the last treatment all lesions were excised and
early treatment failure rates were very high. Two sessions of PDL
may slightly reduce the rate of early treatment failures compared to
one session of PDL (81.9%, 9/11 versus 100%, 11/11, respectively)
(RR 0.83, 95% CI 0.60 to 1.13; Analysis 42.1). We rated the certainty of
evidence as moderate, rating down for serious imprecision ( small
numbers involved in study and wide 95% CI).
Adverse e<ects
The paper reported the technique was tolerable and safe with
minimal side eJects but no further data were given.
7mm spot size single pulses versus 10 mm spot size stacked
pulses
One small pilot study (Tran 2012) randomised 17 participants
with 20 BCCs (13 nBCCs, 6 multifocal BCCs, one superficial BCC
located on trunk/limbs) into three treatment groups: a control (no
treatment) group; PDL (595 nm, fluency 15 J/cm2, pulse width 3 ms)
using 7 mm spot size and single pulses and PDL (595 nm, fluency 7.5
J/cm2, pulse width 3 ms) using 10 mm spot size and double-stacked
pulses. All lesions were treated with a 4 mm margin of clinically
normal skin. The rationale for increasing spot size and stacking
pulses is to increase the depth of penetration of the laser. Three
SCC-in-situ lesions were also treated and we have excluded these
from our analyses. We have not analysed the control group data as
no placebo/sham treatment was given.
Secondary outcomes
Early treatment failure
Six weeks aKer treatment, all treated lesions were excised. PDL with
a 10 mm spot-size and stacked pulses may reduce early treatment
failure rates compared to PDL with a 7 mm spot-size and single
pulses (28.6%, 2/7 versus 85.7%, 6/7, respectively) (RR 0.33, 95%
CI 0.10 to 1.12; Analysis 43.1). We rated the certainty of evidence
as moderate, rating down for serious imprecision (small numbers
involved in study and wide 95% CI).
Adverse e<ects
Mild scarring occurred in both treatment arms and by five months
post-treatment hypopigmentation was noted. See Table 2 for
further AE data from this study.
PDL versus control (sham laser or no treatment)
One study (Karsai 2015) randomised 39 participants (100 sBCC on
trunk/extremities) to PDL (wavelength 595 nm; fluence 8 J cm2;
pulse duration 0.5 ms; spot size 10 mm) or sham treatment with six
months follow-up. A total of four treatment sessions at three-week
intervals were conducted by a dermatologist experienced in laser
therapy. Another small pilot study (Eimpunth 2014) randomised 24
participants (24 sBCC or nBCC) to PDL or no treatment. The PDL
treatment was one session of double-stacked pulses of PDL using
10 mm spot size, 3 ms pulse width and a fluence of 7.5 J/cm2
with a 6 mm margin of normal skin around the clinically apparent
tumour also treated. Lesions were all subsequently excised and
histologically assessed.
Secondary outcomes
Pain during and aLer treatment
Pain was recorded on VAS (0-10) during treatment. Data presented
did not allow for analysis; however, the authors reported that the
maximum median score for PDL was 4/10 and for sham was 0/10.
See Table 1 for further pain data from this study.
Early treatment failure
At six months, PDL probably reduces the risk of early treatment
failures compared to sham laser (21.4%, 12/56 versus 95%, 42/44,
respectively) (RR 0.22, 95% CI 0.14 to 0.37; Analysis 44.1). We rated
the certainty of evidence as moderate, rating down for imprecision
(only one study). PDL may improve the risk of early treatment
failure compared to no treatment RR 0.36, 95% CI 0.15 to 0.86;
Analysis 45.1). We rated the certainty of evidence as moderate,
rating down for serious imprecision due to wide CI and small
sample size.
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Adverse e<ects
The main AEs in the PDL group were crusts, hyper- and hypo-
pigmentation. See Table 2 for further AE data from this study.
14. Intralesional interferon therapy
Four trials met our inclusion criteria comparing diJerent dosages of
interferon and placebo. There were no active comparator studies.
Interferon versus placebo injections
One study (Cornell 1990) of 165 participants (sBCC and nBCC)
compared interferon alpha-2b (1.5 million units three times weekly
for three weeks) against vehicle with one-year follow-up. Patients
were randomised in a 3:1 ratio, interferon:placebo. Another study
(Rogozinski 1997) compared recombinant interferon beta (1 million
units three times weekly for three weeks) compared to placebo in
35 participants (subtype, size and location of BCC not reported).
Secondary outcomes
Early treatment failure
Based on the Cornell 1990 study, when measured at week 20,
interferon alpha-2b probably reduces the risk of early treatment
failures compared to intralesional placebo (14.2%, 17/120 versus
71.4%, 30/42, respectively) (RR 0.20, 95% CI 0.12 to 0.32; Analysis
46.1). We rated the certainty of evidence as moderate, rating down
for imprecision (only one study). Based on the Rogozinski 1997
study, interferon beta probably reduces the risk of early treatment
failures compared to intralesional placebo (53%, 8/15 versus 100%,
18/18) (RR 0.55, 95% CI 0.34 to 0.87; Analysis 47.1). We rated the
certainty of evidence as moderate, rating down for imprecision
(only one study).
Adverse e<ects
In the Cornell 1990 study, influenza-like symptoms occurred more
commonly in the interferon-treated group than the vehicle group.
In the Rogozinski 1997 study, inflammation at the injection site was
found in 11 out of 16 participants in the treatment group and four
out of 18 receiving placebo. See Table 2 for further AE data from
these studies.
Interferon alpha-2a and interferon alpha-2b versus single
interferon
One study (Alpsoy 1996) compared interferon alpha-2a, interferon
alpha-2b or both interferon alpha-2a and interferon alpha-2b in 45
participants (sBCC, nBCC and morphoeic BCCs located on the head
and trunk) with two years follow-up.
Secondary outcomes
Early treatment failure
Interferon alpha-2a and -2b may slightly reduce the risk of early
treatment failure compared to interferon alpha-2a (RR 0.80, 95% CI
0.27 to 2.41; Analysis 48.1). Interferon alpha-2a and -2b may slightly
reduce the risk of early treatment failure compared to interferon
alpha-2B (RR 0.80, 95% CI 0.27 to 2.41; Analysis 49.1). There may
be no diJerence in risk of early treatment failures when comparing
interferon alpha-2b with interferon alpha-2a (RR 1.0, 95% CI 0.36 to
2.75; Analysis 50.1). We rated the certainty of evidence as low for all
these comparisons due to very serious imprecision (very wide 95%
CI that indicated important benefit or harm).
Adverse e<ects
Pain was experienced at the injection site and all participants had
influenza-like symptoms (fever, chills, headaches, fatigue, myalgia)
especially within the first two weeks aKer the initiation of therapy.
See Table 1 and Table 2 and for further pain data and AE data from
this study.
Sustained release interferon alpha-2b
One study (Edwards 1990) compared diJerent dosing schedules
of sustained release interferon (protamine zinc chelate interferon
alpha-2b) in 65 participants with nBCC and sBCC (location not
reported). Participants were randomised to a single dose of 10




The three times weekly injection treatment group probably reduces
the risk of early treatment failures compared with the single dose
arm (20%, 6/30 versus 48.5%, 16/33, respectively) (RR 0.41, 95% CI
0.19 to 0.92; Analysis 51.1). We rated the certainty of evidence as
moderate rating down for serious imprecision (wide 95% CI and
only one study).
Adverse e<ects
All participants experienced at least one adverse reaction. Side
eJects were similar for both single and repeated dosage groups,
and were those common to interferon. See Table 2 for further AE
data from this study.
15. Topical Sinecatechins
One study (Kessels 2017) compared treatment with 10%
sinecatechin ointment (Veregen®) with vehicle in 42 participants
with sBCC over eight weeks follow-up.
Secondary outcomes
Early treatment failure
There is probably little to no diJerence in the risk of early treatment
failures between topical sinecatechin ointment (95.2%, 20/21) and
placebo (90.5%, 19/21) (RR 1.05, 95% CI 0.89 to 1.25; Analysis 52.1).
We rated the certainty of evidence as moderate, rating down for
serious imprecision (only one study).
Adverse e<ects
See Table 2 for further AE data from this study.
Summary of pain data
Pain was reported on a variety of diJerent scales, for example visual
analogue and three point scales. Occasionally, qualitative data was
captured; pain could be reported as burning, stinging, throbbing,
irritation, lingering, tingling, tenderness or blinking discomfort.
Pain was rarely reported distal to the treatment site for example
pharyngolaryngeal pain aKer ingenol mebutate gel usage (Siller
2010). Depending on the study, patients could be asked to report
any pain during or aKer treatment; this could be as an isolated
assessment or could be done at intervals. Burning was the most
common type of pain reported with PDT (Ezughah 2008; Arits 2013;
Foley 2009a and Foley 2009b). Some authors reported supplying
pre-treatment analgesia before PDT (Choi 2016, Haak 2015) or SE
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(Rhodes 2004). Others reported that physical measures to induce
analgesia during PDT were permitted (Morton 2018; Szeimies 2008;
Wang 2001). Post-treatment analgesia was occasionally permitted
aKer SE (Bath-Hextall 2014), imiquimod, radiotherapy (Garcia-
Martin 2011) and sinecatechin applications (Kessels 2017). Pain
and tenderness during treatment with imiquimod was expected,
and participants were frequently allowed a rest period if needed
in order to complete the treatment course (Bath-Hextall 2014;
Ezughah 2008; Geisse 2002; Geisse 2004; Shumack 2002a; Shumack
2002b; Sterry 2002a and Sterry 2002b) with occasional participants
unable to complete the treatment due to pain despite this
(Ezughah 2008; Shumack 2002b). In total five patients discontinued
treatment due to pain; four aKer imiquimod application (Ezughah
2008; Shumack 2002a; Shumack 2002b) and one aKer MAL-PDT
(Rhodes 2004). For further details see Table 1 and Table 2.
Summary of adverse e<ects data
Patient-reported adverse eJects did not always align with those
reported by the observer (Eigentler 2007). The most commonly
reported adverse eJects were due to application site reactions seen
in the non-surgical interventions. These manifested as localised
inflammation resulting in: itching, weeping, crusting, scabbing,
flaking, erythema, blistering, vesicles, eschar, erosions, burning,
pain, purpura or swelling. Localised inflammation was reported in
13 of the 14 papers on imiquimod usage (Arits 2013; Bath-Hextall
2014; Eigentler 2007; Ezughah 2008; Garcia-Martin 2011; Geisse
2002; Geisse 2004; Marks 2001; Schulze 2005; Shumack 2002a;
Shumack 2002b; Sterry 2002a;Sterry 2002b).
Other treatment modalities resulting in localised inflammation
include AFXL-PDT (Haak 2015), intralesional 5-FU (Romagosa 2000),
PDL (Eimpunth 2014; Karsai 2015; Tran 2012), radiotherapy (Garcia-
Martin 2011), sinecatechins (Kessels 2017), laser/broadband
light ALA-PDT (Soler 2000), tazarotene and valproic acid
(2005-001474-27) and placebo/vehicle (Foley 2009a; Foley 2009b;
Geisse 2002; Kessels 2017; Siller 2010).
Local wound infection or suppuration were reported aKer surgical
treatments such as SE (Kuijpers 2007; Rhodes 2004; Smeets 2004;
Szeimies 2008), cryosurgery (Basset-Seguin 2008; Kuijpers 2007;
Wang 2001), cryosurgery and curettage (Kuijpers 2007) as well
as non-surgical interventions: imiquimod (Arits 2013), 5-FU (Arits
2013), ALA-PDT (Mosterd 2008), but not aKer MAL-PDT (Rhodes
2004; Szeimies 2008).
Dyspigmentation was seen aKer treatment with PDL (Abd El-Naby
2019; Eimpunth 2014; Karsai 2015, Tran 2012), imiquimod (Eigentler
2007; Schulze 2005), AFXL-PDT, MAL-PDT (Haak 2015) and in 83% of
treated with intralesional 5-FU (Miller 1997).
Reports of radiodystrophy and necrosis decreased over time aKer
radiotherapy treatment (Avril 1997). Necrosis (of graKs) was also
seen aKer SE (Smeets 2004). Scarring was seen aKer the use of
PDL (Eimpunth 2014), AFXL-PDT, MAL-PDT (Haak 2015) and ingenol
mebutate gel (Siller 2010). "Adverse" scarring was noted aKer SE
(Avril 1997).
Headache was statistically more prevalent aKer treatment with
certain imiquimod regimens (five times per week) than in placebo
groups (Geisse 2004). Imiquimod also induced influenza-like
symptoms (Bath-Hextall 2014; Schulze 2005; Shumack 2002a;
Shumack 2002b; Sterry 2002a) and deranged haematology results
(Geisse 2004). Biochemical abnormalities were seen with ingenol
mebutate gel usage (Siller 2010).
Withdrawal from study, discontinuation of therapy, interrupted
therapy regimens or dose reduction due to treatment-related
adverse eJects occurred with imiquimod (Bath-Hextall 2014;
Ezughah 2008; Geisse 2002, Geisse 2004; Marks 2001; Schulze 2005;
Shumack 2002a; Shumack 2002b; Sterry 2002a; Sterry 2002b),
diclofenac with or without calcipotriol (Brinkhuizen 2016), MAL-
PDT (Foley 2009a; Foley 2009b; Morton 2018; Rhodes 2004), BF
200 ALA-PDT (Morton 2018), solasodine glycosides (Punjabi 2008)
and ingenol mebutate gel with or without occlusion (Siller 2010;
Spelman 2014).
Serious adverse eJects requiring hospitalisation due to treatment
were not specifically reported in any treatment group but the
influenza-like symptoms and wound infections that were seen
with small numbers treated with imiquimod and 5-FU in the Arits
2013 study were classed as suspected unexpected serious adverse
reactions. More details regarding reaction severity, duration of
adverse events and changes over treatment course can be found in
Table 2.
D I S C U S S I O N
Summary of main results
Basal cell carcinoma (BCC) is the most common skin cancer
with several diJerent interventions available for high- and low-
risk histological subtypes. We aimed to assess the eJectiveness
of these interventions for primary BCC in immunocompetent
individuals and found 52 randomised controlled trials (RCTs)
(26 new to this review update) that randomised a total of
6690 participants. We synthesised the data into a total of 52
comparisons. All studies included a majority of BCCs of low-risk
histological subtypes (nodular (nBCC), superficial (sBCC)), with only
four studies including a minority of high-risk histological subtypes.
No studies exclusively studied high-risk histological subtypes and
we were unable to retrieve the raw data specific to the high-risk
BCCs for full outcome assessment. Consequently, there was not
enough information to draw any conclusions about the eJects of
interventions on histologically high-risk BCC.
Of the included studies, pooling of the data was feasible for
only a very limited number of the reported outcomes, and
the largest number of studies we were able to pool was four.
Many comparisons were evaluated by only one study, preventing
meta-analysis. We considered surgical excision (SE) versus Mohs
micrographic surgery (MMS) as the main comparison in this review.
However, only one study (Smeets 2004), which provided only low-
certainty evidence, assessed MMS, even though this is oKen used as
the gold-standard for high-risk facial BCC.
Broadly, non-surgical interventions were more commonly assessed
than surgical interventions: more than double the number of
trials assessed non-surgical compared to surgical interventions.
The most assessed interventions were photodynamic therapy
(PDT) (24 studies); topical imiquimod (14 studies); and surgical
excision, which is oKen regarded as the gold-standard treatment
for BCC (10 studies). Eleven studies assessed MAL-PDT; 6, ALA-
PDT; 2, ablative fractional laser MAL-PDT, and single studies
assessed HAL-PDT, laser and broadband ALA-PDT. Between two
or four studies assessed radiotherapy, cryosurgery, fluorouracil,
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intralesional interferon, pulsed dye laser, and ingenol mebutate.
No more than one study assessed curettage and cautery,
electrochemotherapy, solasodine glycosides, valproic acid and
tazarotene gel, sinecatechins, calcitriol and diclofenac.
Safety was the most commonly-evaluated outcome, with 81% of
the comparisons assessing adverse eJects. Seventy-five per cent
of comparisons assessed early treatment failure, 21% reported 3-
year recurrence, 17% reported 5-year recurrence, 37% reported on
cosmetic outcomes (27% had data for analysis), and 46% reported
on pain (19% had data for analysis).
Surgical excision (SE)
Surgical interventions have the lowest rates of recurrence at three-
and five- year follow-up.
We found that for high-risk facial BCC, there may be slightly fewer
recurrences with MMS compared to SE at three years and five years
(low-certainty evidence). However, the 95% confidence interval
(CI) also includes the possibility of an increased risk of recurrence
and no diJerence between treatments. There may be little to no
diJerence regarding improvement of participant- and observer-
rated cosmetic outcomes (low-certainty evidence) measured at 18
months post-operatively; however, no raw data were available for
this outcome.
Smeets 2004 has been criticised for performing MMS with
a standardised 3 mm margin as normally smaller margins
are used and this larger margin may have diminished the
tissue-preserving benefit of MMS, potentially worsening the
cosmetic outcome (Muller 2009). The study included high-risk
facial BCCs, defined as high-risk histological subtypes (infiltrative,
micronodular, morphoeic, BCC with squamous diJerentiation) or
BCCs located in the 'H-zone' of the face, or both.
The study followed up participants for over 10 years, and although
our primary outcome was recurrence at three years and five years,
it is important to note that during the five- to 10-year follow-
up period there were an additional 14 recurrences (four in the
MMS group and 10 in the SE group), which means that only
44% of BCC recurrences occurred during five years of follow-up.
This is important as clinicians and patients should be aware that
recurrences are possible up to 10 years following treatment.
For further details see Summary of findings 1.
Imiquimod
Evidence for low-risk sBCC and nBCC found that imiquimod
probably results in more recurrences than SE at three years (10-
fold increased risk, moderate-certainty evidence) and at five years
(eight-fold increased risk, moderate-certainty evidence). This was
a non-inferiority study and imiquimod was found to be inferior to
SE as it failed to meet the study's pre-defined inferiority margin
of 0.87. When measured at three years, there may be little to no
diJerence between imiquimod and SE in the number of participant-
rated good/excellent cosmetic outcomes (low-certainty evidence),
but when this outcome is observer-rated, imiquimod may increase
good/excellent cosmetic outcomes (low-certainty evidence). This
discrepancy between participant- and observer-rated cosmetic
outcomes may be important and should be highlighted to patients.
Although inferior to SE in terms of reducing recurrence rates,
imiquimod's performance is still clinically acceptable to patients
and clinicians and it is probably the best non-surgical treatment
option for low-risk BCC. Another important benefit of imiquimod
resides in the fact that it can be administered by patients at
home, oJering the opportunity to manage low-risk BCCs in
the community. With the trend for patients presenting younger
and with increasing numbers of BCCs, some now advocate the
possibility of general practitioners diagnosing and managing
low-risk BCCs with imiquimod cream and reserving SE for the
approximate 1/5 BCCs that relapse, with the majority found to
relapse within the first year following treatment (Kelleners-Smeets
2017).
Side eJects of imiquimod cream comprise application site
reactions including pain, weeping, itching, redness and swelling
and were reported more oKen in the imiquimod group than in
the SE group. The licensed treatment regimen is five days per
week dosing for six weeks (sBCC) or 12 weeks (nBCC). Bath-Hextall
2014 used daily dosing (the discrepancy may have occurred as
imiquimod was licensed for BCC aKer the study had commenced)
and therefore more adverse eJects may have been recorded during
the study than would be expected in clinical practice. Recurrences
recorded at five years compared with three years were small, with
one additional recurrence for a sBCC treated with imiquimod and
one aKer SE.
Out of 14 studies assessing imiquimod, 11 were funded by the
science-based technology company 3M.
For further details see Summary of findings 2.
Radiotherapy
In comparison against SE with the option of frozen section margin
control for facial BCCs (including high- and low-risk subtypes),
radiotherapy may result in increased recurrences at three years
(low-certainty evidence) and at four years (low-certainty evidence).
When measured at four years, radiotherapy probably results in a
lower number of good cosmetic outcomes (irrelevant of whether
the outcome was participant- or observer-rated) compared
to SE (moderate-certainty evidence), as dyspigmentation and
telangiectasia can occur in people treated with radiotherapy.
DiJerent radiation techniques exist (such as conventional X-ray
therapy, interstitial brachytherapy and superficial contact therapy)
with the choice of technique dependent on factors such as size
and location of the lesion and performance status of the patient.
In practice, radiotherapy is usually reserved for cases where lesions
are not amenable to surgery. When deciding whether to choose
radiotherapy or SE, patients need to consider that radiotherapy will
probably involve numerous visits to the radiotherapy department
up to five times a week, usually for several weeks. It should be
noted that the RCTs for radiotherapy were all conducted decades
ago. Since these studies were carried out, radiotherapy technology
and protocols have improved and therefore these results may not
be representative of modern radiotherapy outcomes. New studies
comparing modern radiotherapy against other interventions are
needed.
For further details see Summary of findings 3.
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Photodynamic therapy (PDT)
PDT was studied in 16 RCTs against various surgical and non-
surgical interventions. Out of 16 PDT studies, seven were industry-
funded (five by PhotoCure/Galderma).
Based on participants with low-risk nBCC on the head and neck
region, MAL-PDT may result in more recurrences than SE at three
years (low-certainty evidence); there were no usable data for
assessment at five years. MAL-PDT probably has slightly more
participant- and observer-rated good/excellent cosmetic outcomes
at one year compared to SE, based on participants with low-risk
nBCC and sBCC (moderate-certainty evidence). For further details
see Summary of findings 4.
Based on participants who each had a single low-risk sBCC,
imiquimod probably results in fewer recurrences at three years and
five years compared to MAL-PDT (moderate-certainty evidence),
and there is probably little to no diJerence in observer-rated
good/excellent cosmetic outcomes measured at one year between
MAL-PDT and imiquimod (moderate-certainty evidence). This
comparison did not measure participant-rated cosmetic outcomes.
For further details see Summary of findings 5.
There is wide variation in PDT protocols with diJerences in
photosensitising agent, use of prior debulking curettage, timing,
source and amount of light irradiation and number of PDT cycles.
MAL-PDT predominates in Europe and Australasia; physicians in the
USA mainly use ALA-PDT. The standard European protocol defines
one cycle as two PDT sessions separated by a one-week interval.
MAL-PDT is significantly more expensive than ALA-PDT. 5-ALA,
however is disadvantaged by the need to prepare the cream fresh
prior to use whereas MAL is available in a standardised preparation
which makes it easier to use. The newer, stable nanoemulsion ALA
formulation (BF-200 ALA gel) is now licensed in the EU. HAL has
been used for years in bladder cancer detection and its use in BCC
treatment has now been investigated. Further studies are required
to inform which protocol is most eJective.
Arits 2013 identified that MAL-PDT probably leads to fewer
recurrences compared to imiquimod for sBCC treatment, in one
subgroup of patients only: older patients with sBCC on the lower
extremities.
Adverse e<ects
Adverse eJects with surgical interventions included wound
infections, necrosis of graKs and post-operative bleeding. Local
adverse eJects such as itching, weeping, pain and redness occurred
frequently with non-surgical interventions. Treatment-related
adverse eJects resulting in study modification or withdrawal
occurred with imiquimod and MAL-PDT.
For further details see Table 4, Table 5, Table 8, Table 3, Table 7, and
Table 6.
Overall completeness and applicability of evidence
This systematic review has included the full spectrum of
interventions for primary BCC by including 52 RCTs (52
comparisons) of varying methodological quality. The evidence we
have identified addressed our primary and secondary outcomes
to varying degrees. Only 21% of the comparisons we included
presented at least three-year recurrence data, and 17% of
comparisons reported 5-year recurrence data. Given that the
majority of recurrences are expected to occur by three years,
this means that almost 80% of studies were not able to address
our primary recurrence rate outcomes due to inadequate follow-
up time. This threatens the applicability and external validity of
the evidence presented. Histologically-confirmed early treatment
failure data were available for all but 13 comparisons. This outcome
benefits from not requiring a long follow-up period and was
frequently used as a primary outcome in small, pilot phase 1/2
studies but is generally of limited use when informing decisions in
clinical practice.
The finding in Smeets 2004 that 56% of recurrences of high-risk
facial BCC occur between five and 10 years following surgery
suggests that longer follow-up times are needed for studies on BCC
and may represent a flaw in our review methodology. However,
a large retrospective review of long-term BCC recurrence rates
identified that only 18% of recurrences occurred between five and
10 years with 67% found to occur within the first three years (Rowe
1989). This study informed our original review's three-year time
point. Further retrospective studies have reported that 18% to 20%
of recurrences occur beyond five years (GriJiths 2005; Hruza 1994;
Randle 1996).
Nineteen comparisons had cosmetic outcome data, of which 14 had
data for analysis. There was heterogenous reporting of cosmetic
outcomes, using diJerent time points, scales and rater (e.g.
participant, observer or both). Observers were generally medically
trained (e.g. dermatologist, surgeon), but some studies used non-
medical observers. Histologically-confirmed early treatment failure
was available for all but 13 comparisons. Although 24 studies
reported on pain, we were only able to perform analyses on pain
data for 10 comparisons; the severity and analgesia required were
not routinely reported, and the modes of assessment ranged from
patient diaries to rating scales or visual analogue scores. Most
studies presented this in their adverse eJects data, and due to the
heterogeneity, we have collated adverse eJects and pain data into
additional tables (Table 1 and Table 2).
The diversity of the outcome data generated by these trials
impacted our ability to make direct comparisons between the
studies; therefore, these data are occasionally not reported.
The discrepancy in reported outcomes and the inconsistency in
reported time points underscores the importance of the work being
done to create core outcome sets based on the needs of the
stakeholders for clinical trials in BCC (Schlessinger 2017).
Thirteen comparisons involved a placebo/vehicle/sham/no
treatment arm, and imiquimod was over-represented in this
group, with five studies comparing imiquimod against vehicle,
involving 1145 participants. This allowed one of the few meta-
analyses included in this review. It should also be noted that all
of these imiquimod studies were industry-funded. BCC is a disease
associated with significant local tissue destruction and therefore
the harm of non-treatment is not insignificant. It is for this reason
that most placebo-controlled studies had short follow-up periods
and usually excised the treatment area at the end of the study.
Twenty-six comparisons were head-to-head, and such studies are
more applicable to clinical practice as they answer more pragmatic
and clinically relevant questions.
We do not have suJicient evidence to determine the eJects
of treatment for histologically high-risk BCC, because only four
of our included studies assessed this subtype and no studies
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exclusively included high-risk histological subtypes. Only three
studies exclusively assessed BCCs located at high-risk sites (H-zone
of the face), and so there was insuJicient evidence to determine the
eJects of treatment for these BCCs.
The vast majority of participants were elderly with a median age
of 64.9 years old. Although participants as young as 20 were
included, separate data on younger participants were not available
and therefore we do not have suJicient evidence to determine if
outcomes are diJerent in younger participants.
Only one study provided evidence for our main comparison of
surgical excision versus MMS. Non-surgical interventions were most
widely evaluated by our included studies, which correlates with the
inclusion of low-risk histological BCC subtypes by all of the studies.
Three types of treatment were disproportionately represented
compared to the rest of the treatments considered: 48 trials
assessed PDT, topical imiquimod, and surgical excision, whereas
almost half of that number (26 studies), in total, assessed the
following: radiotherapy, cryosurgery, fluorouracil, intralesional
interferon, pulsed dye laser, ingenol mebutate, curettage and
cautery, electrochemotherapy, solasodine glycosides, valproic acid
and tazarotene gel, sinecatechins, and diclofenac.
Most of the evidence for the outcomes presented for each of
the interventions has come from relatively small, single studies,
which meant that meta-analysis was largely not possible (the
exceptions being PDT versus SE, imiquimod versus vehicle and
AFXL-PDT versus PDT). The majority of these single studies were
multi-centre, but many were limited by small sample sizes, and
consequently, many of the outcomes reported in this review have
wide confidence intervals. This means there is a large amount of
imprecision in the results, and therefore, several of our results have
low-certainty evidence which threatens their external validity and
reproducibility.
Despite these limitations, our study is the most up-to-date and
extensive systematic review on interventions for BCC. It can be used
globally to inform guidelines and to aid clinicians and patients in
weighing up the risks and benefits of the various treatment options
available for primary BCC.
Certainty of the evidence
The GRADE approach was used to rate the certainty of all the
evidence in our review (as outlined in the Methods section). There
was a wide variation in the certainty with most outcomes being
rated as moderate to low certainty. A few outcomes were rated as
very low-certainty, although these were assessed by comparisons
not considered key. The main reasons for rating down the certainty
of evidence related to serious risk of bias in the studies (for instance,
high risk of selection bias) and serious imprecision with small
sample sizes and wide confidence intervals. Where confidence
intervals included important benefit and serious harm (i.e. > 1.25
and < 0.75), we rated down two levels for very serious imprecision.
A few comparisons had such wide 95% CIs (including 1- and more
than 100-fold diJerence) that we rated them down three levels for
imprecision.
Only 19 studies were assessed as low risk of bias for blinding of the
outcome assessor. For the studies that were unblinded we did not
rate down the certainty of evidence for recurrence outcomes as it
was unclear if being unblinded would bias the assessments. We did
rate down certainty of evidence for high risk of bias when there was
unblinded assessment of cosmetic outcomes.
Only one study was identified as having a high risk of selection
bias, but 22 studies were rated as unclear risk of bias due to the
method of random sequence generation not being clearly stated
by the study authors. Twenty-eight studies had unclear risk of bias
due to the method of allocation concealment not being stated. All
these studies stated that they randomised their participants, and
therefore, we have had to assume that they did this correctly and
we have not rated down the certainty of evidence for an unclear risk
of selection bias assessment. Only six studies were deemed to be
at low risk of selective outcome reporting bias, and only 11 studies
prospectively registered. This number is very low, and selective
outcome reporting may have occurred in studies rated as 'unclear'
risk of bias, but we decided not to rate the certainty of evidence
down for this. This stresses the importance of having pre-specified
outcomes and prospectively registering studies.
The majority of included studies used participants as the unit of
analysis; however, 27% of studies reported results based on lesions.
Therefore, there is the potential of under-estimating the variation
in the intervention eJect from using results which are based on
the same people contributing with multiple lesions. However, the
majority of these studies included small numbers of people with
multiple lesions; therefore, we anticipate that the likely impact
on our results is minimal. Additionally, all of the latter studies
aimed to treat the lesions individually, rather than using a systemic
treatment.
Potential biases in the review process
We attempted to conduct a comprehensive search for studies.
Review authors independently assessed eligibility of studies to
minimise bias in the study selection process. As we were working
from an old protocol, we did decide to make some changes to
our methods that have been clearly described in the DiJerences
between protocol and review section. Changes to our protocol were
made at the start of the review process and were approved by
Cochrane Skin editorial team. Bias may have been introduced by
the time points chosen for some of our outcomes. For instance,
when faced with cosmetic outcome data with a range of time
points, we had to make a decision on which time point to include
for the diJerent comparisons. We attempted to minimise this bias
by asking HW to decide on what should be the best time point to
include. HW decided we should select a time point at least one
year following treatment. The rationale being that scars oKen take
around one year to heal and for the colour to settle. He was not
aware of the included studies or any of the results when making
this decision, so the risk of bias should be minimal, but ideally
this should have been pre-specified in the protocol. For the SE
versus radiotherapy study cosmetic outcome, we reported the time
point with the biggest diJerence between interventions which was
four years aKer treatment which may have introduced selective
outcome reporting bias. The reason we reported this time point is
because it is well documented that radiotherapy has deteriorating
cosmetic outcomes over years and this would not be appreciated if
we reported the one-year time point. Selective outcome reporting
bias may also have been introduced by us selecting the maximum
pain score recorded during treatment for interventions. We felt
this was necessary as pain experienced during treatments is highly
variable and depends on the treatment modality. For example,
comparing pain on day one for a surgical treatment against a non-
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surgical treatment like imiquimod would be meaningless as the
surgical intervention will have produced a painful wound whereas
imiquimod will likely not have had any eJect on day one.
Agreements and disagreements with other studies or
reviews
There have been a few systematic reviews assessing interventions
for BCC published since our last update. Most recently, Drucker
2018 published a comprehensive systematic review and network
meta-analysis (NMA) on treatments for primary BCC. This study only
included English-language publications, and their search yielded
fewer randomised controlled trials (RCTs) whilst also including
non-randomised studies. This study also did not specify a time
point for recurrence before performing the NMA. Despite these
diJerences, our conclusion that surgical interventions have the
lowest recurrence rates for BCC is consistent with theirs. Collier
2018 published a systematic review of PDT for BCC. This study
included 15 RCTs and had similar outcome measures as our study,
except recurrence at one year and five years were their chosen
time points. Our review largely agrees with the results from this
review. A systematic review and meta-analysis on PDT for BCC
by Wang 2015 identified eight RCTs, of which seven are included
in our review. This review pooled the results of all these studies
regardless of PDT method including photosensitising agent (e.g.
MAL versus ALA). We decided against pooling all types of PDT as the
pharmacology for the photosensitising compounds is diJerent and
the evidence for their similar eJicacy is of low quality. We disagree
with the Wang study where they report that PDT is as eJective as
pharmacologic treatment (imiquimod and 5-FU creams). The Wang
study combined both imiquimod and 5-FU in their analyses, and by
doing so, they masked imiquimod's probable superior eJicacy to
PDT in terms of reducing recurrences.
Risk of transformation with non-invasive treatments?
We thought it was important to address the fairly recent literature
that has suggested that topical therapies and PDT may cause non-
aggressive sBCCs to "transform" to more aggressive subtypes (e.g.
nodular, infiltrative or morphoeaform subtypes). This is an area of
contention and others have argued that apparent transformation
is more likely the result of sampling error from the diagnostic
biopsies. The Arits 2013 study (MAL-PDT versus imiquimod versus
5-FU cream) data were used for a separate observational study
to address the question of whether non-invasive therapies cause
sBCCs to transform to higher risk subtypes (van DelK 2019). The
study found that of 166 treatment failures (38.6%) were a non-
superficial subtype and the proportion with a more aggressive
subtype than the primary tumour were 51.3% (38.74) for early
and 28.3% (26/92) for later treatment failures. The authors
conclude that more aggressive treatment failure recurrences aKer
noninvasive therapy for sBCC occur most oKen within the first three
months following treatment, probably indicating sampling error
and consequent under-diagnosis of more aggressive components
in the primary tumour rather than transformation.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The overall quality of research on interventions for basal cell
carcinoma (BCC) has improved since our 2007 review with the
publication of several randomised controlled trials (RCTs) with
long-term follow-up, but many of the included studies have
provided low- or moderate-certainty evidence that should be
interpreted with caution.
The majority of studies have been performed on low-risk
histological BCCs, located on low-risk sites, the results of which
are probably not applicable to high-risk tumours. Only four studies
have looked at high-risk histological subtypes, and three studies
looked at BCCs at high-risk facial sites. More studies or subgroup
analyses are required for morphoeic tumours.
Surgery remains the most eJective treatment modality for BCC in
terms of reducing recurrences, and there may be a slightly reduced
recurrence rate with Mohs micrographic surgery (MMS) compared
to surgical excision (SE); however, the 95% CI also includes the
possibility of both increased risk and no diJerence between
treatments (low-certainty evidence). With regard to improvement
of participant- and observer-rated cosmetic outcomes, there may
be little to no diJerence between MMS and SE (low-certainty
evidence); however, no raw data were available for this outcome.
Radiotherapy is eJective but probably worse than surgery (under
frozen section margin control) in terms of the number of good
cosmetic outcomes (moderate-certainty evidence) and is therefore
best reserved for tumours not amenable to surgery. Radiotherapy
may also lead to increased recurrence compared to SE (low-
certainty evidence).
Non-surgical treatments are less eJective, but the evidence
suggests that recurrence rates are acceptable and they are
important options to oJer patients. Imiquimod probably results in
more recurrences than SE (moderate-certainty evidence) and there
is probably little to no diJerence between groups in the number of
participant-rated good/excellent cosmetic outcomes (low-certainty
evidence). However, imiquimod may increase the number of
observer-rated good/excellent cosmetic outcomes compared to SE
(low-certainty evidence). Overall, imiquimod has the best evidence
to support its eJicacy out of the non-surgical treatments.
Moderate-certainty evidence indicates that imiquimod probably
leads to fewer recurrences than MAL-PDT and there is probably
little to no diJerence between these treatments in terms of
observer-rated good/excellent cosmetic outcomes (participant-
rated cosmetic outcomes were not measured in this comparison).
MAL-PDT may result in more recurrences at three years than
SE (low-certainty evidence; no useable data for measurement at
five years), but probably increases the number of good/excellent
cosmetic results (moderate-certainty evidence).
Adverse eJects with surgical interventions include wound
infections, graK necrosis and post-operative bleeding. Local
adverse eJects such as itching, weeping, pain and redness occur
frequently with non-surgical interventions. Treatment-related
adverse eJects resulting in study modification or withdrawal
occurred with imiquimod and MAL-PDT.
The six studies in Studies awaiting classification may alter the
conclusions of the review once assessed.
Implications for research
Currently, there is only low-certainty evidence informing us on
the eJicacy of MMS against SE, with only one study assessing
MMS against SE that met our inclusion criteria. Given this is
the main comparison of our review, further studies assessing
these treatments against each other are needed. Future studies
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exclusively assessing interventions for high-risk BCC (high-risk
histological subtypes and high-risk locations) are needed. As a
minimum, future studies should present data on high-risk tumours
in subgroup analyses.
Cost:benefit ratios have an important impact on clinical practice
and guidelines and so future systematic reviews on interventions
for BCC should also include cost-analyses as an outcome measure.
This will allow us to answer important questions such as whether
the higher operative costs and procedure times of MMS oJset the
potential higher number of recurrences seen with SE over time. It
will also be important for imiquimod and 5-FU cream as there is a
big cost diJerence between these treatments, which may oJset the
diJerences in eJicacy so defining this further will be important in
future research to impact clinical practice.
Given that the radiotherapy studies included were all conducted
over 20 years ago, and based on the fact that radiotherapy
techniques and protocols have changed a lot since then, up-to-
date studies assessing the eJicacy of radiotherapy using current
methods are needed, as these older studies may not be reflective
of modern radiotherapy outcomes.
One of the key problems with RCTs on interventions for BCC is
the lack of an agreed set of core outcome measures and also the
lack of longer-term outcomes for many of the studies which are
now standard for most other cancer studies (for example, clinical
recurrence at five years). An international group, in collaboration
with the Core Outcome Measures in EJectiveness Trials (COMET)
initiative and Cochrane Skin Group- Core Outcome Set Initiative
(CSG-COUSIN) have begun the task of developing broad consensus
for a core outcome set for BCC intervention trials, which will
be essential to improve the evidence we have for BCC in the
future (Schlessinger 2017). For example, core outcome sets would
determine whose opinion should be sought for assessing cosmetic
outcomes (dermatologist, participant, or both), and when or how
best to report it. BCC research should benefit greatly from this
initiative, but future studies must also ensure that all outcomes are
pre-specified and registered prospectively to mitigate against the
risk of selective outcome reporting bias.
Only a fiKh of included RCTs followed participants up for at least
three years and given that the majority of BCCs are likely to recur
during the first three years aKer treatment, future studies should
have follow-up periods of at least three years. Further research
is needed into what the optimal length of follow-up should be
as there is conflicting evidence documenting recurrences beyond
five years. If at least 20% of recurrences occur beyond five years,
then studies should follow up participants for up to 10 years. This
will also impact the time points used for our primary outcome
measures in future reviews.
Moreover, inadequate reporting of study methodology leads to
biased estimates of treatment eJects (Schulz 1995). Future studies
on interventions for BCC must be well-designed RCTs and should
include a power calculation to ensure that suJicient numbers
of participants are recruited to avoid problems with imprecision.
Studies must also be rigorously reported and conform to the
Consolidated Standards of Reporting Trials (CONSORT) statement
(Schulz 2010). This will ensure a fair interpretation of the results and
allow accurate appraisal and judgements to be made about the risk
of bias and the overall certainty of evidence.
Given that curettage and cautery is commonly used in the
treatment of low-risk BCC, more evidence is needed to assess
its eJicacy as currently we only have one small study with only
two years follow-up that compared curettage and cautery with
SE. Further RCTs with long-term follow-up are needed to assess
its eJicacy against other interventions including non-surgical
interventions. Further RCTs with long-term follow-up are needed
for solasodine glycosides, ingenol mebutate, topical valproic acid,
tazarotene, diclofenac, calcitriol and sinecatechin. These non-
surgical interventions should be compared against other non-
surgical interventions with established eJicacy in treating BCC,
such as imiquimod.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Single-centre, double-blinded, parallel-group, phase IIa RCT. ITT analysis.
Participants Denmark.
Inclusion criteria: adults with easily identifiable and treatable HP BCC with clearly defined borders
measuring between 0.5 cm2 and 4 cm.
Exclusion criteria: BCCs located on the eyelids, lips, nose, mucosa, or in the anogenital area.
Age: not stated.
Gender: not stated.
Interventions Sample size: 50 participants.
Period of inclusion: October 2005 to April 2008.
T1: Week 1 – 8: placebo gel followed by tazarotene gel (n = 25), if not clear after 8 weeks, further 8 week
treatment with Baceca® gel followed by tazarotene gel.
T2: Week 1 – 8: Baceca® gel followed by Tazarotene gel (n = 25), if not clear after 8 weeks, further 8 week
treatment with Baceca® gel followed by tazarotene gel.
Outcomes Clinical evaluation at 8 weeks +/- histological assessment.
Response rate at 12 weeks and histological assessment at 16 weeks.
Patient-reported and safety measurements.
Notes Sponsored by TopoTarget A/S
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
2005-001474-27 
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Allocation concealment
(selection bias)





Low risk Patients were blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Only two participants lost to follow-up.
Selective reporting (re-
porting bias)
High risk Study prospectively registered. Complete remission (assessed histologically) 8
or 16 week time points (i.e. after each treatment cycle) were registered as the
time points for the primary outcome but only reported data for response rate





Methods Single-centre, randomised, parallel RCT - abstract only.
Participants Brazil.
Inclusion criteria: primary nodular HP BCC in the head and neck with a diameter up to two inches.
Exclusion criteria: Gorlin syndrome, contraindication to surgical resection or PDT.
Age: not stated.
Gender: not stated.
Interventions Sample size: 57 participants. 68 HP nodular BCC.
Period of inclusion: not stated.
T1: Standard protocol MAL-PDT (n = 33, two treatment sessions with 1-week interval, lesions shaved
prior to treatment)
T2: SE (n = 35, 4 mm margin)
Outcomes Clinical response at 3 months, confirmed histologically if deemed necessary.
Histologically-confirmed relapse at 6, 12 and 18+ months.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Abbade 2015 
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Random sequence genera-
tion (selection bias)
Low risk Quote: "treatment was decided by random drawing."
Allocation concealment
(selection bias)





Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Unclear if blinded but we felt that unable to truly blind due to the nature of the




Unclear risk Insufficient information to make judgement.
Selective reporting (re-
porting bias)





Methods Single-centre, randomised, parallel RCT.
Participants Egypt.
Inclusion criteria: HP BCC.
Exclusion criteria: wound healing abnormalities, immunosuppressive or dermatological disease, un-
dergoing chemical peel / dermabrasion / radiotherapy, cutaneous infection.
Age: not stated.
Gender: not stated.
Interventions Sample size: 22 participants.
Period of inclusion: May 2015 to May 2016.
T1: One stacked PDL session (n = 11).
T2: Two stacked PDL sessions, two weeks apart (n = 11).
Outcomes Clinical and histological assessment for recurrence at 1 month.
Safety and tolerability assessments.
Recurrence at 6 months (unclear how assessment was made).
Notes There are no conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated list.
Allocation concealment
(selection bias)
Low risk Sequentially-numbered opaque-sealed envelopes.
Abd El-Naby 2019 
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Unclear risk No blinding of participants and personnel during the study but unclear if this
would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk No loss to follow-up.
Selective reporting (re-
porting bias)






Methods Single-centre, parallel-group RCT. ITT analysis - abstract only.
Participants Turkey.
Inclusion criteria: HP BCC.
Exclusion criteria: recurrent lesions, genetic or nevoid conditions, deep tissue involvement.
Age range 38-74, (mean in years): T1 = 58.7, T2 = 63.6, T3 = 60.3
Gender: male = 23, female = 22
Interventions Total: 45 participants, 45 BCCs.
Period of inclusion: not stated.
Intralesional interferon given three times weekly in all groups (10 injections):
T1: IFN alfa-2a (n = 15)
T2: IFN alfa 2b (n =15)
T3: IFN alfa 2a and 2b (n = 15) (alfa 2a and alfa 2b injected alternately)
Outcomes Clinical and histological clearance at 8 weeks.
Weekly laboratory testing during treatment and at week 1 post-treatment.
AEs.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Alpsoy 1996 
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Allocation concealment
(selection bias)





Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Complete outcome data given for outcomes.
Selective reporting (re-
porting bias)





Methods Multi-centre, single-blinded, parallel group RCT. Modified ITT analysis.
Participants The Netherlands.
Inclusion criteria: primary, HP sBCC.
Exclusion criteria: patient taking immunosuppressive drugs, genetic skin cancer disorders, breastfeed-
ing or pregnant, tumour located at high-risk areas of the face, or on the scalp.
Age (mean in years): T1 = 63, T2 = 62, T3 = 64
Gender: male = 303, female = 298.
Interventions Sample size: 601 participants, 601 sBCC.
Period of inclusion: March 2008 to August 2010.
T1: MAL-PDT (n = 202, two treatment sessions with 1-week interval, surface prepared atraumatically
prior to treatment)
T2: Imiquimod 5 days per week for 6 weeks (n = 198)
T3: 5-FU twice daily for four weeks (n = 201)
Outcomes Primary outcome measure
Clinical clearance as assessed by blinded assessor at 3 and 12 months post-treatment, confirmed histo-
logically if deemed necessary.
Secondary outcome measures
Aesthetic outcome assessed by blinded observer on a four-point scale at 12 months post-treatment.
Compliance according to patient diary
Weekly and during-treatment patient-reported pain and burning according to VAS.
Arits 2013 
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Local adverse reactions according to a four-point scale.
AEs.
Notes Funded by a Grant of the Netherlands Organisation for Scientific Research.
No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Telephone randomisation.
Allocation concealment
(selection bias)






Unclear risk No blinding of participants and personnel during the study but unclear if this
would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Missing outcome data not balanced in numbers across intervention groups but
unclear if missing outcome data related to the nature of the interventions.
Selective reporting (re-
porting bias)
Unclear risk Retrospectively registered (ISRCTN 79701845). The trial registration stated
cosmetic outcome would be measured by participants and observers at 3 and
12 months' follow-up using the "Patient and Observer scale" and a "5-point
scale". However they reported an observer-rated 4-point scale at 12 months
only. The study group showed the 4-point scale had better reproducibility for
non-invasive scars in another study (Mosterd 2013) which may explain why





Methods Single-centre, single-blind, parallel-group RCT. ITT analysis.
Participants France.
Inclusion criteria: previously untreated BCC of the face, histologically confirmed, smaller than 4 cm in
diameter.
Exclusion criteria: BCC on scalp or neck. Participants who had total removal of BCC at biopsy, with five
or more BCCs, life expectancy below three years.
Age: mean 66 years (SD 12).
Gender: male = "50%", female = "50%".
Interventions Sample size: 347 patients, 347 BCC.
Period of inclusion: February 1982 to November 1988
Avril 1997 
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T1: SE (n = 174, 2 mm margin, with or without frozen section margin control)
T2: radiotherapy (n = 173, interstitial brachytherapy, superficial contact therapy or conventional thera-
py)
Outcomes Primary outcome measures: histological clearance at 4 years.
Secondary outcome measures: cosmetic results at 3,6,12,24,36 and 48 months. Assessed by 1) patient
using VAS 2) dermatologists rating scars using three-point scale, and 3) three blinded independent as-
sessors rating appearance using three-point scale.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Only stated that patients were randomly allocated.
Allocation concealment
(selection bias)





Unclear risk Unclear if participants or personnel blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Unable to truly blind due to nature of interventions but unclear if this would
influence study outcomes. For cosmetic outcomes however it was felt there




Low risk No missing outcome data.
Selective reporting (re-
porting bias)






Methods Multi-centre, open, parallel-group RCT. PP analysis.
Participants Europe.
Inclusion criteria: BCC size between 6 mm and 15 mm on face/scalp, < 20 mm on neck or < 30 mm on
trunk
Exclusion criteria: more than 10 lesions per patient, pigmented, morphoeaform or infiltrating, xeroder-
ma pigmentosum, porphyria, Gorlin's syndrome, arsenic exposure, allergy to MAL/topical photosensi-
tisers/excipients, participation in another trial within 30 days, pregnancy or breastfeeding, concomi-
tant treatment with immunosuppressive medication.
Age (mean in years): T1 = 62. T= 64.
Basset-Seguin 2008 
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Gender: male = 69, female = 46.
Interventions Sample size: 118 participants with 219 sBCC.
Period of inclusion: October 1999 to March 2000
T1: MAL-PDT (n = 60, initially debrided, one treatment session only)
T2: cryosurgery (n = 58, double freeze-thaw cycle, with freeze time of up to 20 seconds and thaw time of
2-3 x freeze time).
Participants with an incomplete response at 3 months received further treatment (T1: 2 further MAL-
PDT sessions; T2: repeat cryosurgery).
Outcomes Clinical clearance at 3 months post-treatment, and at 1,2,3,4, and years, assessed as complete or in-
complete resolution by assessor and confirmed histologically.
Cosmetic appearance as assessed by patient (3 months, 1 and 2 years) and assessor (3 months, 1,2,3,4
and 5 years) using four-point scale.
AEs at each follow-up visit up to 3 months post-treatment graded according to three-point severity
scale.
Notes No declarations of interest.
Risk of bias











Unclear risk No blinding of participants and personnel during the study but unclear if this
would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Per protocol analysis.
Selective reporting (re-
porting bias)
High risk Study prospectively registered (NCT00469417). Registration stated primary
outcome "number of patients in whom 75% or more of the BCC lesions have
responded completely at 3 months" but reported number of lesions with a
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Methods Multi-centre, non-inferiority, pragmatic parallel-group RCT. Modified ITT analysis.
Participants UK.
Inclusion criteria: HP, primary, previously untreated, nodular or superficial BCC at low-risk sites.
Exclusion criteria: morphoeic or recurrent BCC, Gorlin's syndrome.
Age (median in years): T1 = 69, T2 = 67.
Gender: males = 278, females = 189.
Interventions Sample size: 501 patients, 501 BCC
Period of inclusion: June 2003 to Feb 2007
T1: imiquimod 5 days per week for 6 weeks (n = 254)
T2: SE (n = 247, 4 mm margin)
Outcomes Primary outcome measure
Clinical clearance at 3 years from start of treatment.
Secondary outcome measures
Clinical clearance at years 1,2 and 5.
Time to first failure (stratified).
Cosmetic appearance as rated by participant and dermatologist using six-point scale.
Pain during treatment and at 16 weeks using six-point scale.
Number of days of pain.
Cost-effectiveness of imiquimod versus surgery.
Notes Funded by Cancer Research UK.
No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomisation.
Allocation concealment
(selection bias)
Low risk Research nurse was required to telephone RDSU to obtain the allocated treat-






Unclear risk No blinding of participants and personnel during the study but unclear if this
would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Unable to blind but unclear if this will affect judgement of BCC recurrence.
Bath-Hextall 2014  (Continued)
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Low risk More losses to follow-up in the SE arm (70 vs 48 by 5 years). Modified ITT and
sensitivity analysis were done which found no change to the results.
Selective reporting (re-
porting bias)





Methods Single-centre, parallel RCT. ITT analysis
Participants USA.
Inclusion criteria: HP BCCs with clearly visible margins for nodular with area of 0.5 cm2 to 1.5 cm2 or su-
perficial with an area of 0.5 cm2 to 2 cm2.
Exclusion criteria: none described in paper.
Age range (years): 37 to 81
Gender: not stated.
Interventions Sample size: 35 participants (7 nBCC, 28 sBCC)
Period of inclusion: not stated.
Five treatment schedules with the imiquimod 5% cream or vehicle. All participants continued treat-
ment until either 2 weeks after target tumour was clinically cleared or until 16 weeks.
T1: twice per day (n = 7)
T2: once per day (n = 4)
T3: three times per week (n = 4)
T4: twice per week (n = 5)
T5: once per week (n = 4)
T6: vehicle (n = 11)
Outcomes Complete response rate (histologic clearance of BCC at 6 weeks following treatment), safety evalua-
tions.
Notes Funded by a grant from 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)




Low risk Quote: "Double-blind" study.
Beutner 1999 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Complete outcome data.
Selective reporting (re-
porting bias)






Methods Single-centre, single-blinded, parallel-group RCT. ITT analysis.
Participants The Netherlands.
Inclusion criteria: HP sBCC of 4 mm or larger.
Exclusion criteria: tumours on the face or scalp, chronic NSAID use or Vitamin D supplementation in the
preceding 30 days.
Age (average in years): sBCC: T1 = 63, T2 = 65.5, T3 = 67.5, T4 = 61.5 ; nBCC: T1 = 78.5, T2 = 68.6, T3 = 71,
T4 = 66.
Gender: male = 89, female = 39.
Interventions Sample size: total: 128 participants, 128 BCCs
Period of inclusion: November 2011 to February 2013.
Treatment applied twice daily under occlusion for 8 weeks:
T1: diclofenac-3% gel (n = 32)
T2: calcitriol 3ug/g ointment (n = 32)
T3: diclofenac-3% gel and calcitriol 3ug/g ointment (n = 32)
T4: no topical treatment (n = 32)
Outcomes Primary outcome measure
Post-treatment percentage of cells expressing Ki-67 and Bcl-2, determined by blinded assessor.
Secondary outcome measures
Histologic tumour regression at 8 weeks.
Adverse events (including application site reactions, using VAS) and patient compliance at 8 weeks ac-
cording to patient diary.
Notes Funded by the Dutch Cancer Society.
Calcipotriol supplied by Galderma.
Brinkhuizen 2016 
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No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk No blinding of participants and personnel during the study but unclear if this
would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Pathologists who assessed histologic tumour regression were blinded. Un-




Unclear risk Attrition not clearly documented so unable to assess.
Selective reporting (re-
porting bias)
Low risk Study prospectively registered (NCT01358045). Primary outcome reported in
publication as stated in register. Secondary outcome reported in publication






Methods Single-centre, single-blinded, parallel-group RCT.
ITT and PP analysis.
Participants South Korea.
Inclusion criteria: maximum tumour depth of 2 mm, contraindications for surgical excision.
Exclusion criteria: greater than 5 eligible lesions or those located on the midface/nose/periorbital/ocu-
lar, greater than 15 mm, non-nodular subtype, allergy to trial agents, pregnancy or lactation, active sys-
temic infectious disease, immunosuppressive medication, history of melanoma/melasma/keloid, indi-
cation of poor compliance.
Age (mean in years): T1 = 66.9, T2 = 63.3.
Gender: male = 21, female = 18
Interventions Sample size: 39 patients, 42 nBCC
Inclusion period: March 2011 to September 2012.
T1: Er:YAG AFL MAL-PDT (n = 20)
T2: MAL-PDT (n = 19)
Choi 2016 
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Outcomes Primary outcome measures:
Blinded investigator assessment of clinical response rate 3 and 12 months after final treatment.
Recurrence rate at 12 months, based on clinical and histological findings.
Secondary outcome measures:
AEs immediately after treatment, at 1 week, 3 and 12 months.
Investigator assessment of cosmetic outcome at 12 months using a four-point scale.
Tertiary outcome measure:
Patient-reported pain intensity during PDT according to 11-point VAS.
Notes Funded in part by research funds from the Dong-A University.
No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation.
Allocation concealment
(selection bias)





Unclear risk Quote: "The patients may have been able to differentiate between the two
treatments because of the characteristics of Er:YAG pre-treatment". Unclear if
this would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Missing outcome data balanced in numbers across intervention groups.
Selective reporting (re-
porting bias)






Methods Single-centre, parallel-group, non-inferiority RCT. PP analysis.
Participants Ireland.
Inclusion criteria: superficial, nodular, infiltrative and morphoeic subtypes
Exclusion criteria: previously treated lesions, advanced BCC, SCC, bleomycin contraindication, chronic
renal failure, coagulopathy, epilepsy, pacemaker, pregnancy or lactation.
Clover 2016 
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Age (mean in years): T1: 66.8 ; T2: 63.8
Gender: male = 49, female = 50
Interventions Sample size: 86 participants; 105 BCCs
Inclusion period: not stated.
T1: electrochemotherapy (n = 45 patients, 60 lesions)
T2: surgical excision (n = 41 participants, 45 lesions)
Outcomes Recurrence rate at 1, 2, 3 and 4 years.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Shuffling of envelopes.
Allocation concealment
(selection bias)





Unclear risk Unblinded but strict protocol and unclear if this would influence study out-
comes.
Blinding of outcome as-
sessment (detection bias)
All outcomes





Unclear risk Fairly balanced number of dropouts between groups (19 lesions ECT vs 15 le-
sions SE) but almost 1/5th lost in one group and small overall numbers.
Selective reporting (re-
porting bias)
Unclear risk Study prospectively registered (EUDRACT 2010-019260-37). All expected out-






Methods Multi-centre, double-blind, parallel-group RCT. PP analysis
Participants USA.
Inclusion criteria: HP BCC (superficial or nodular), in good health, between 32 to 70 years of age.
Exclusion criteria: previously received therapy to test site, immunosuppressive or cytotoxic therapy
(within prior 4 weeks), exogenous interferon/interferon alfa-2b (Intron A), lesion in perioral or central
area of the face or penetrating to deep tissue, pregnancy.
Age (mean in years): T1 = 56, T2 = 57
Cornell 1990 
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Gender: male = 136, female = 29.
Interventions Sample size: 172 participants
Inclusion period: not stated.
Both given 3 days per week for 3 consecutive weeks:
T1: Intralesional injections 1.5 million IU of interferon alfa-2b (n = 123)
T2: placebo (vehicle for interferon preparation) (n = 42)
Outcomes Clinical clearance by blinded assessor using a four-point scale weekly after each of the treatment
weeks, then at 5, 9, 13 weeks after completion of treatment, then every 3 months up to 52 weeks.
Adverse events weekly after each of the treatment weeks, then at 5, 9, 13 weeks after completion of
treatment, then every 3 months up to 52 weeks.
Assessor- and patient-reported cosmetic outcome at week 16.
Histological assessment of efficacy by blinded assessor at 16 weeks.
Notes Supported by a grant from the Chering Coporation and a grant from Matt and Barbara Browning.
No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization quote: "by a computer-generated scheme".
Allocation concealment
(selection bias)





Unclear risk Quote: "Double-blind". Use of injection of vehicle in placebo arm however pa-
tients treated with interferon developed systemic symptoms which would like-
ly unblind them.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Total blinding of the examining physician was not possible because systemic
symptoms developed in more patients who received interferon than in the















Methods Single-centre, parallel-group RCT. PP analysis.
Edwards 1990 
Interventions for basal cell carcinoma of the skin (Review)









Cochrane Database of Systematic Reviews
Participants USA.
Inclusion criteria: nBCC or sBCC 0.5 cm to 1.5 cm diameter, with well-defined borders that could be eas-
ily excised.
Exclusion criteria: serious or debilitating illness, history of thromboembolic or cardiovascular disease,
radiation therapy to the test site area, history of arsenic ingestion, pregnancy, breast-feeding, immuno-
suppression as a result of medication or illness and receiving nonsteroidal anti-inflammatory medica-
tion. Morphoeic BCC, recurrent cancers, deeply invasive lesions, periorificial tumours and central facial
BCC.
Age range (years): 35 to 65
Gender: not stated.
Interventions Sample size: 65 participants
Period of inclusion: not stated.
T1: single injection of 10 million IU zinc chelate interferon alfa-2b (n = 33)
T2: 1 dose of 10 million IU of zinc chelate interferon alfa-2b per week for 3 weeks (n = 32)
Outcomes Clinical assessment at weeks 2, 8, 12 and 16.
Histological assessment at 16 weeks.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk Paper does not mention that participants were blinded. Probably not done but
unclear if this would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Paper does not mention that outcome assessors were blinded. Probably not




Low risk Only 2/65 (both from T2) did not complete the study (due to side effects).
Selective reporting (re-
porting bias)
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Methods Open-label phase III RCT. ITT analysis.
Participants Germany.
Inclusion criteria: at least one HP nBCC of maximum 1.5cm in diameter.
Exclusion criteria: all micronodular, infiltrative, superficial, multicentric or morphoeic BCCs, those lo-
cated within 0.5 cm of the eyes, pregnancy, skin disease/tattoo in the study area, clinically significant
or unstable medical conditions, or immunomodulatory medication.
Age: median 64 years (range 38 to 88)
Gender: male = 63, female = 27.
Interventions Sample size: 102 participants.
Period of inclusion: November 2001 to May 2005.
Imiquimod 5% applied thrice-weekly for:
T1: 8 weeks
T2: 12 weeks
Outcomes Primary outcome measure:
Histological and clinical clearance rate at 8 weeks post-treatment.
Secondary outcome measure:
Safety and cosmetic outcomes at 8 and 12 weeks.
Notes Supported by 3M.
No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Low risk Open-label, unblinded study but unlikely to influence outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Losses to follow-up not balanced between groups. Missing outcome data ad-
dressed but unclear if related to true outcome.
Selective reporting (re-
porting bias)
Unclear risk Study retrospectively registered (NCT00204555). All expected outcomes from
methods section reported.
Eigentler 2007  (Continued)
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Methods Prospective RCT - pilot study, abstract only
Participants USA.
Inclusion criteria: HP BCC on trunk or extremities.
Exclusion criteria: none described.
Age range (years): 29 to 88.
Gender: male = 16, female = 8.
Interventions Sample size: 24 participants. 24 HP nodular BCC.
Period of inclusion: not stated.
T1: one session of double-stacked PDL, 10 mm spot-size, 7.5 J/cm2
T2: no treatment
Outcomes Histological clearance and immediate / delayed adverse events.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk No losses to follow-up.
Selective reporting (re-
porting bias)
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Methods Single-centre, open-label, parallel RCT. ITT analysis.
Participants UK.
Inclusion criteria: adults with histologically-proven non-invasive and non-infected sBCC with a mini-
mum area and maximum depth of 2 mm.
Exclusion criteria: anogenital tumours, high-risk tumours, nodular/basosquamous/severe squamous
metaplastic or infiltrative, Gorlin's syndrome, tumours within 1 cm of hairline, metastatic/recurrent
tumours, involvement in other clinical trials, immunosuppressive treatment, corticosteroid therapy,
cryosurgery/cutaneous surgery, pregnant/breastfeeding, other dermatological disorders at target site.
Age: mean 68 (males) and 62 (females)
Gender: male = 17, female = 13
Interventions Sample size: 32 participants
Period of inclusion: not stated.
Imiquimod 5% applied:
T1: for 8 weeks with once daily dose for alternate weeks (n = 15)
T2: for 5 weeks, once daily dose fortnightly with 1-week interval (n = 16)
Outcomes Primary outcome measure:
Clinical clearance at weeks 19 and 52
Secondary outcome measures:
Weekly patient-reported tolerability using VAS.
Nurse-reported adverse events assessed using four-point severity scale at weeks 2, 4, 6 and 8.
AEs also assessed by telephone at weeks 1, 3, 5 and 7.
Notes Supported by 3M.
No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Single-blinded but unclear if this would influence performance.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote:"clinician assessing for clinical clearance at weeks 19 and 52 and the
statistician were blinded to the dosing regimen."
Ezughah 2008  (Continued)
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Low risk Reasons for missing outcome data unlikely to be related to true outcome.
Selective reporting (re-
porting bias)






Methods Multi-centre, randomised, double-blind,
placebo-controlled, parallel-group prospective studies performed in Australia (study 308) and the USA
(study 307). ITT analysis.
Participants Australia.
Inclusion criteria:aAdults with primary HP nodular BCC, suitable for simple excision.
Exclusion criteria: periorbital/perioral/nasal lesions, < 6 mm, > 15 mm (face or scalp), > 20 mm (extremi-
ties or neck), > 30 mm (trunk), pigmented/morphoeaform/infiltrating. Patients with porphyria, xeroder-
ma pigmentosum, arsenic exposure, allergy to study products, recent participation in a different trial,
poorly compliant or pregnant/breastfeeding, immunosuppressive medications.
Age (years): T1 = 66, T2 = 67.
Gender: male = 99, female = 32.
Interventions Sample size: 66 participants, 75 nBCCs.
Period of inclusion: October 2000 to September2002.
Lesion was prepared by gentle tumour surface debridement using a curette prior to application of MAL
or placebo. Number of treatment cycles determined by response:
T1: MAL-PDT (n = 66 participants, 75 lesions)
T2: placebo prior to illumination (n = 65 participants, 75 lesions).
Note these numbers are from both studies combined. Individual study data not presented.
Outcomes Efficacy evaluated histologically by blinded assessor at 3 and 6 months.
Clinical clearance according to a four-point scale.
Safety assessments during treatment, at 2 and 4 weeks, and at 3 months after each treatment cycle.
Assessor- and patient- rated cosmetic outcome according to four-point scale.
Notes Funded byPhotoCure ASA, Oslo, Norway.
The authors declare multiple conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation scheme prepared by PAREXEL Interna-
tional. Randomisation was stratified by centre.
Foley 2009a 
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Allocation concealment
(selection bias)





Low risk To ensure blinding to treatment, a study nurse was responsible for illumina-
tion and for monitoring adverse events during treatment sessions and at fol-
low-up.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Missing outcome data balanced in numbers between treatment groups.
Selective reporting (re-
porting bias)
Unclear risk These studies were reported together in the final publication and although
they were very similar in their design, they both had separate trial registra-
tions (NCT00472043 and NCT00472108) and there was no mention of combin-
ing the results of the studies in the trial registers. However it is not clear how






Methods Multi-centre, randomised, double-blind,
placebo-controlled, parallel-group prospective studies performed in Australia (study 308) and the USA
(study 307). ITT analysis.
Participants USA.
Inclusion criteria: adults with primary HP nodular BCC, suitable for simple excision.
Exclusion criteria: periorbital/perioral/nasal lesions, < 6 mm, > 15 mm (face or scalp), > 20 mm (extremi-
ties or neck), > 30 mm (trunk), pigmented/morphoeaform/infiltrating. Patients with porphyria, xeroder-
ma pigmentosum, arsenic exposure, allergy to study products, recent participation in a different trial,
poorly compliant or pregnant/breastfeeding, immunosuppressive medications.
Age (years): T1 = 66, T2 = 67.
Gender: male = 99, female = 32.
Interventions Sample size: 65 participants, 75 nBCCs.
Period of inclusion: October 2000 to September2002.
Lesion was prepared by gentle tumour surface debridement using a curette prior to application of MAL
or placebo. Number of treatment cycles determined by response:
T1: MAL-PDT (n = 66 participants, 75 lesions)
T2: placebo prior to illumination (n = 65 participants, 75 lesions).
Note these numbers are from both studies combined. Individual study data not presented.
Outcomes Efficacy evaluated histologically by blinded assessor at 3 and 6 months.
Foley 2009b 
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Clinical clearance according to a four-point scale.
Safety assessments during treatment, at 2 and 4 weeks, and at 3 months after each treatment cycle.
Assessor- and patient- rated cosmetic outcome according to four-point scale.
Notes Funded by PhotoCure ASA, Oslo, Norway.
The authors declare multiple conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation scheme prepared by PAREXEL Interna-
tional. Randomisation was stratified by centre.
Allocation concealment
(selection bias)





Low risk To ensure blinding to treatment, a study nurse was responsible for illumina-
tion and for monitoring adverse events during treatment sessions and at fol-
low-up
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Missing outcome data balanced in numbers between treatment groups.
Selective reporting (re-
porting bias)
Unclear risk These studies were reported together in the final publication and although
they were very similar in their design, they both had separate trial registra-
tions (NCT00472043 and NCT00472108) and there was no mention of combin-
ing the results of the studies in the trial registers. However it is not clear how






Methods Single-centre, parallel-group RCT. ITT analysis.
Participants Spain.
Inclusion criteria: HP nBCC of the eyelid
Exclusion criteria: previous BCC treatment, concomitant dermatological disease, immunocompro-
mised.
Age: mean 73.7 years (range 53-84)
Gender: male = 16, female = 11.
Interventions Sample size: 27 participants
Garcia-Martin 2011 
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Period of inclusion: not stated.
T1: 5% imiquimod applied once daily after initial curettage, five times per week for six weeks (n = 15)
T2: Radiotherapy, standard protocol (n = 12)
Outcomes Efficacy evaluated histologically at six weeks post-treatment.
Assessor and patient-evaluated cosmetic outcomes according to a three-point scale at six weeks post-
treatment.
Functional assessment.
Adverse effects and overall tolerability according to three-point rating scale at 3, 6, 12 and 24 months
post-treatment.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Randomised to imiquimod if born on even day of month and randomised to RT
if born on odd day of month.
Allocation concealment
(selection bias)





Unclear risk Not able to blind participants or personal but unclear if this would influence
performance.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk None lost to follow-up.
Selective reporting (re-
porting bias)






Methods Multi-centre phase II, double-blind, parallel-group vehicle-controlled RCT. ITT analysis.
Participants USA.
Inclusion criteria:aAdults with primary, HP sBCC measuring 0. 5 cm^2. to 2.0 cm^2.
Exclusion criteria: recurrent tumour, within 1 cm of hairline, eyes, nose, mouth or ears, in the anogeni-
tal area or on hands and feet, or within 5 cm of another BCC tumour.
Age: mean 59 years (range 35 to 85)
Geisse 2002 
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Gender: male = 82, female = 46
Interventions Sample size: 128 participants.
Period of inclusion: not stated.
Applied for 12 weeks:
T1: Imiquimod twice daily (n = 10)
T2: Imiquimod once daily (n = 31)
T3: Imiquimod 5 consecutive days per week (n = 26)
T4: Imiquimod 3 days per week (n = 29)
T5: Vehicle (n = 32)
Outcomes Clinical and histological clearance at six weeks post-treatment.
Histological clearance as per two blinded assessors.
Local skin reactions (descriptive and as per a four-point rating scale) and adverse events at each visit.
Total amount of Imiquimod applied
Number of patients taking rest periods.
Notes Supported by 3M.
Multiple authors received funding from or were employed by 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Compute- generated randomisation schedule.
Allocation concealment
(selection bias)





Low risk Double-blind study. Quote: "Imiquimod cream and vehicle cream were in iden-
tical packaging...Both patients and investigators were blinded to the content
of the treatment cream dispensed".
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk 125/128 patients completed study procedures and histological evaluations.
Selective reporting (re-
porting bias)
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Study characteristics
Methods Two identical multicentre phase III randomised, vehicle-controlled studies. ITT analysis.
Participants USA.
Inclusion criteria: adults with primary HP sBCC suitable for excision at least 0.5 cm2 in size with a maxi-
mum diameter of 2 cm, located on limbs, trunk, neck or head.
Exclusion criteria: lesions located on the facial H-zone or in the anogenital area, with no evidence of ag-
gressive growth pattern, dermatological disease in the target site other than BCC and syndromes pre-
disposing to BCCs.
Age (years): T1 = 58.4, T2 = 59.9, T3 = 59.4, T4 = 57.6
Gender: male = 445, female = 279
Interventions Sample size: 724 participants.
Period of inclusion: not stated.
For a six week period:
T1: imiquimod 5% cream 5 days per week
T2: vehicle 5 days per week
T3: imiquimod 5% cream 7 days per week
T4: vehicle 7 days per week
Outcomes Clinical clearance at 12 weeks post-treatment using a four-point rating scale with histological correla-
tion.
Local skin reactions assessed using 4-point rating scale, and adverse reactions at weeks 1,3, and 6 and
at post-treatment weeks 4 and 12.
Notes Supported by 3M.
Multiple authors received funding from or were employed by 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation schedule.
Allocation concealment
(selection bias)





Low risk Quote: "Study personnel and subjects were blinded to the study cream identi-
fication until the database was completed."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Insufficient information to make judgement.
Incomplete outcome data
(attrition bias)
Unclear risk Insufficient information to make judgement.
Geisse 2004 
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Methods Single-centre, parallel-group RCT.
Participants Denmark.
Inclusion criteria: adult with previously untreated HP nBCC with 1) diameter > 15 mm 2) high-risk facial
zones and/or 3) located on sun-damaged site.
Exclusion criteria: lactation/pregnancy, porphyria, known allergy to MAL cream, Gorlin syndrome, im-
munosuppressive treatment, Fitzpatrick skin type IV-VI, history of keloid and poor compliance.
Age: median 66 years (range 37-88).
Gender: male = 15, female = 17.
Interventions Sample size: 32 participants, 32 BCCs.
Period of inclusion: December 2010 to September 2011.
Preceded by debulking curettage:
T1: AFXL-PDT (n = 16)
T2: MAL-PDT (n = 16).
Outcomes Primary outcome measures:
Clinical response according to blinded assessor at 3,6,9 and 12 months, confirmed histologically if
deemed necessary.
Secondary outcome measures:
Pain scores during treatment rated on VAS scale. Assessor-rated cosmesis according to a three-point
scale at 3,6,9 and 12 months.
Assessor-rated adverse events according to a four-point scale at 3,6,9 and 12 months.
PpIX fluorescence measures (Methyl-amonolevulinate uptake) before and directly after treatment.
Notes The authors received multiple grants from Galderma International.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated list.
Allocation concealment
(selection bias)
Low risk Allocations contained in opaque, sequentially-numbered, sealed envelopes.
Haak 2015 
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Unclear risk Participants and personnel not blinded but unclear if this would influence per-
formance.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Unclear reasons for lost to follow-up.
Selective reporting (re-
porting bias)






Methods Single-centre, parallel-group RCT. PP analysis.
Participants UK.
Inclusion criteria: HP BCC, considered suitable candidate for treatment with radiotherapy.




Interventions Sample size: 105 participants.
Period of inclusion: not stated.
T1: cryosurgery (Cry-Owen, two freeze thaw cycles, except periocular lesions treated with thermocou-
ple-regulated Brymil cryospray) (n = 44)
T2: Radiotherapy, duration dictated by lesion thickness (n = 49)
Outcomes Investigator-assessed clinical evaluation of efficacy and cosmesis according to a three point scale at 1,
6, 12, 24 months.
Patient-evaluated pain and adverse event evaluation from 0 to 4 weeks.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to make judgement.
Hall 1986 
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Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Insufficient information to make judgement.
Selective reporting (re-
porting bias)






Methods Multi-centre, parallel-group, double-blinded RCT.
Participants Germany.
Inclusion criteria: HP, unpigmented BCC on trunk and extremities, maximum diameter 30 mm.
Exclusion criteria: Fitzpatrick skin type >III, pregnancy, previous BCC treatment within 4 weeks, coagu-
lation disorders or anticoagulant therapy, photosensitising medications, poor compliance.
Age (mean in years): T1 = 75.3, T2 = 68.4.
Gender: male = 27, female = 12.
Interventions Sample size: 39 participants, 100 sBCCs.
Period of inclusion: November 2012 to October 2013.
T1: PDL (n = 56)
T2: sham treatment (n = 44).
Outcomes Primary outcome measure:
Clinical and histological remission at 6 months post-treatment.
Secondary outcome measures:
Patient-recorded adverse events and pain intensity graded according to a VAS at 6 weeks and 6 months
post-treatment.
Patient satisfaction according to a 3 point scale at 6 weeks and 6 months post-treatment.
Notes Cynosure Multiplex-brand pulsed dye laser provided by Cynosure Inc.
No other conflicts of interests or funding declared.
Risk of bias
Karsai 2015 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation list was generated via a web-based program.
Allocation concealment
(selection bias)






Low risk All blinded except laser practitioner.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Blinded outcome assessor but residual dyspigmentation after laser treatment





Low risk Quote: "No patients dropped out or lost to follow-up".
Selective reporting (re-
porting bias)






Methods Single-centre, double-blinded, parallel-group, placebo controlled RCT. ITT and PP analysis.
Participants The Netherlands.
Inclusion criteria: adults with primary HP sBCC with a diameter between 4 mm and 20 mm, without co-
morbidities interfering with study treatment, and ability to understand instructions.
Exclusion criteria: recurrent BCC, breastfeeding/pregnant, serious co-morbidities, immunosuppression,
genetic skin cancer disorders, high-risk tumour site.
Age: not stated.
Gender: not stated.
Interventions Sample size: 42 participants
Period of inclusion: November 2014 to September 2015.
Applied twice daily for 6 weeks:
T1: topical sinecatechins ointment 10% (n = 21)
T2: placebo ointment (n = 21).
Outcomes Primary outcome measure:
Histological regression as assessed by two blinded investigators at 8 weeks.
Secondary outcome measures:
Patient-reported adverse events at weeks 1,4, and 6.
Kessels 2017 
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Decrease in expression of Ki-67 and Bcl-2 from baseline to week 8 according to immunohistochemistry
analyses
Notes Supported in part by Willpharma BV, the Netherlands, which supplied study medication.
No conflicts of interest declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a generated randomization list using random permuted blocks of
four". An independent statistician prepared the randomisation list.
Allocation concealment
(selection bias)






Low risk Patients and investigators, including the assessing pathologists, blinded to
treatment assignment until the end of the study. Placebo was of identical
colour and consistency as sinecatechins ointment to ensure blinding.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Numbers lost to follow-up balanced between groups.
Selective reporting (re-
porting bias)






Methods Multi-centre, single-blind, parallel-group RCT. ITT and PP analysis.
Participants The Netherlands.
Inclusion criteria: adults with primary HP sBCC.
Exclusion criteria: immunosuppressive drugs, genetic skin cancer disorder, previous treatment, por-
phyria, pregnancy/breastfeeding, known allergy to study materials, tumours located on H-zone on the
face, hairy scalp and convex or concave areas such as the ears/fingers.
Age (mean in years): T1 = 63.6, T2 = 65.9.
Gender: male = 75, female = 87.
Interventions Sample size: 162 participants
Period of inclusion: September 2013 to May 2015.
T1: MAL-PDT (n = 80, standard treatment repeated after 1 week)
T2: two-fold fractionated ALA-PDT (n = 82).
Kessels 2018 
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Outcomes Primary outcome measure:
Clinical clearance at 12 months, confirmed histologically if deemed necessary.
Secondary outcome measures:
Aesthetic outcome measured on a 4-point scale and independently scored by two blinded investigators
at 3 and 12 months.
Patient-reported adverse events on a 4-point scale 1 week after treatment.
Patient-reported pain on a VAS scale immediately and 1 week after treatment.
Notes Funded by a grant from the Health Foundation Limburg, the Netherlands.
No conflicts of interests declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Computer-generated lists in permuted blocks of six"
Allocation concealment
(selection bias)






Unclear risk Quote:"The patients could not be blinded for treatment allocation". Unclear if
this would influence performance.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote:"All study visits... were performed by two investigators who were blind-




Low risk Numbers lost to follow-up fairly balanced between both groups.
Selective reporting (re-
porting bias)
Low risk Study registered prospectively (NCT01491711). Primary outcome reported as
described in registration. Secondary outcomes in registration different from
publication (cosmetic outcome and adverse effects reported in publication;






Methods Single-centre, parallel RCT - pilot study.
Participants The Netherlands.
Inclusion criteria:nNodular, primary BCC anywhere except periocular/hairy scalp areas, measuring < 20
mm.
Kuijpers 2006 
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Exclusion criteria: pigmented BCC, contraindications to surgery, hypersensitivity to daylight, known al-
lergy to study materials, porphyria, more than 5 BCCs per patient.
Age: mean 68.4 years (range 39-87).
Gender: male = 24, female = 15
Interventions Sample size: 39 patients, 43 HP nBCC.
Period of inclusion: not stated.
In each group, half of the tumours were debulked using curettage prior to PDT:
T1: ALA-PDT (n = 22)
T2: MAL-PDT (n = 21)
Outcomes Histological clearance accorded to blinded assessor at 8 weeks post-treatment.
Pain reported using visual analogue scale and descriptive terms, during and after treatment.
Notes No declarations of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Low risk Participants were blinded to allocation.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk No patients dropped out or lost to follow-up.
Selective reporting (re-
porting bias)





Methods Single-centre, parallel-group RCT. PP analysis.
Participants The Netherlands.
Kuijpers 2007 
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Inclusion criteria: adults with HP primary BCC (nodular or superficial) in the head and neck area, < 20
mm.
Exclusion criteria: recurrent BCC, other histological subtypes, > 20 mm, contraindications to surgery or
cryosurgery, > 5 BCCs.
Age: mean 67 years (range 34-92).
Gender: male = 50, female = 38.
Interventions Sample size: 88 participants, 100 HP BCCs.
Period of inclusion: March 1996 and January 1999.
T1: SE ( n = 49, 3 mm margin)
T2: cryosurgery (n = 51, after debulking with curette, using two cycles and cone-spray technique).
Outcomes Histological evidence of recurrence within 5 mm of the scar at 5 years.
Adverse events.
Notes No declarations of interest.
Risk of bias











Unclear risk No blinding of participants and personnel during the study but unclear if this
would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk No blinding of outcome assessors but unclear if this would influence study














Methods Single-centre, parallel RCT.
Participants Germany.
Landthaler 1989 
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Inclusion criteria: HP BCC and SCC
Exclusion criteria: not stated.
Age: median age 71-75 for both T1 and T2.
Gender: T1: 93 = males, 71 = female; T2: 94 = male, 61 = female.
Interventions Sample size: 319 participants (BCC and SCC)
Period of inclusion: 1980-1983
T1: 60 Gy total (n = 142 BCCs, 24 SCC, sGy on 20 consecutive days)
T2 48 Gy total (n = 148 BCCs, 20 SCCs, 4Gy 3 x/week for 12 sessions).
Outcomes Recurrence rate at 3 years.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Low numbers lost to follow-up.
Selective reporting (re-
porting bias)





Methods Multi-centre, open-label, parallel-group RCT. ITT and PP analysis.
Participants Australia and New Zealand.
Inclusion criteria: adults with primary HP sBCC on the head, neck, trunk of limbs, with a surface area of
between 5 mm2 to 20 mm2.
Marks 2001 
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Exclusion criteria: recurrent, previously treated, within 1 cm of the hairline/anogenital/facial ori-
fices/distal extremities.
Age: mean 61 years (range 23 to 83).
Gender: male = 72, female = 27.
Interventions Sample size: 99 participants.
Period of inclusion: Not stated.
All groups treated with 5% imiquimod for six weeks:
T1: twice per day (n = 3)
T2: once per day (n = 33)
T3: twice per day for 3 days each week (n = 30)
T4: once per day for 2 days each week (n = 33)
Outcomes Histological assessment of efficacy at 6 weeks, and patient-reported adverse events on a three-point
scale including characterisation of local reactions.
Notes Supported by 3M Pharmaceuticals, by whom some authors were employed.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information given to make judgement.
Allocation concealment
(selection bias)





Unclear risk No blinding of participants and personnel during the study but unclear if this
would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Missing outcome data balanced in numbers between treatment groups.
Selective reporting (re-
porting bias)





Methods Multi-centre, open-label, parallel-group RCT. ITT and PP analysis.
Participants USA.
Miller 1997 
Interventions for basal cell carcinoma of the skin (Review)









Cochrane Database of Systematic Reviews
Inclusion criteria: Single HP BCCs, 6 mm to 15 mm in diameter, with well-defined margins, at least 50
mm away from another malignancy.
Exclusion criteria: lesions that had already received treatment, those at high-risk sites (e.g. eyelids,
nose, ears and central part of the face), tumours considered to be more appropriately treated with
Mohs micrographic surgery, lesions with deep tissue involvement, morphoeic lesions, basal cell nevus
syndrome, hypersensitivities or allergies to 5-FU, sulphites, epinephrine, bovine collagen, history of au-
toimmune disease or immunosuppression, pregnant or lactating women.
Age: Mean 61 yrs (range 29 - 86).
Gender: male = 97 male and female = 25.
Interventions Sample size: 122 participants.
Period of inclusion: Not stated.
Intralesional sustained-release 6fluorouracil/epinephrine injectable gel (5FU/epi gel)
T1: 1.0 ml 5 FU/epi gel once weekly for 6 weeks (n = 20)
T2: 0.5 ml 5-FU/epi gel once weekly for 6 weeks (n = 21)
T3: 1.0 ml 5-FU/epi gel twice weekly for 3 weeks (n = 18)
T4: 0.5ml 5-FU/epi gel twice weekly for 3 weeks (n = 19)
T5: 0.5 ml 5-FU/epi gel twice weekly for 4 weeks (n = 21)
T6: 0.5 ml 5-FU/epi gel 3 times weekly for 2 weeks (n = 17)
Outcomes Clinical investigator-led examinations at 1, 4, 8 and 12 weeks. Patient-reported assessment of adverse
effects at 1, 4, 8 and 12 weeks. Participant- and investigator-reported evaluation of cosmetic appear-
ance according to a five-point scale. Clinical and histological regression assessed at 12 weeks.
Notes No declarations of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information given to make judgement.
Allocation concealment
(selection bias)





Unclear risk Study does not mention blinding of participants and personnel during the
study but unclear if this would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Study does not mention blinding of participants and personnel during the




Unclear risk Most participants completed the study (116/122).
Miller 1997  (Continued)
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Selective reporting (re-
porting bias)





Methods Randmonised, multinational, multi-centre, non-inferiority RCT. PP analysis.
Participants Germany, UK.
Inclusion criteria: One to three non-aggressive BCC with less than or equal to 2 mm thickness, 0.5 cm to
2 cm diameter, on face/scalp, neck/trunk or extremities.
Exclusion criteria: patients with porphyria, photodermatoses, intolerances to ingredients, recent treat-
ments potentially influencing the ocutome.
Age: 66.5 in MAL group (+/- 11.5 SD), 67.3 in ALA group (+/- 11.6 SD).
Gender: male = 131, female = 100.
Interventions Sample size: 281 participants
Period of inclusion: January 2014 to November 2015
One obligatory PDT cycle with 2 PDT sessions 1 week apart, and a second PDT cycle in case of partial or
no response 12 weeks after the first cycle:
T1: BF-200 ALA PDT (n = 121)
T2: MAL PDT (n = 110)
Outcomes Primary outcome measure: overall complete clinical repose of all lesions in each patient at 12 weeks
Secondary outcome measures: clinical clearance rate of individual lesions at weeks 4 and 12. Cosmetic
outcome as rated by patient satisfaction on a four-point scale. Patient-reported local adverse reactions
as rated on a three-point scale, pain as rated on a ten-point scale and adverse events on a four-point
scale.
Notes Supported by Biofrontera.
Multiple conflicts of interest declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a validated program that automates the random assignment of treat-
ments to randomizations numbers."
Allocation concealment
(selection bias)
Low risk Randomization schedule was generated by Accovion






Unclear risk Participants not blinded but unclear if this would influence study outcomes.
Morton 2018 
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Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Observer-blinded. Quote: "To guarantee the blind status of investigators as-
sessing efficacy and safety, a second investigator or delegated person was to





Low risk Numbers lost to follow-up relatively small and balanced between groups.
Selective reporting (re-
porting bias)






Methods Single-centre, parallel group RCT. ITT analysis.
Participants The Netherlands.
Inclusion criteria: adults with previously untreated HP nBCC with a largest diameter of 20 mm
Exclusion criteria: pregnancy, life expectancy of < 5 years, known skin cancer syndromes, phototox-
ic/photosensitive drugs, hypersensitivity to light or ALA cream, recurrent or pigmented BCC, histologi-
cal subtypes other than nodular BCC, localisation on concave areas or hairy skin.
Age: mean 64.7 years +/- 13
Gender: male = 75, female = 74
Interventions Sample size: 149 participants with 173 BCC
Period of inclusion: August 2002 and February 2006.
3 weeks prior to PDT lesions underwent partial debulking curettage under local anaesthesia:
T1: ALA-PDT (n = 83)
T2: SE (n = 88, 3mm margin)
Outcomes Clinical recurrence at 3,6,12,18 months and 2,3,4, and 5 years (confirmed histologically as no recur-
rence within 5 mm of the scar).
Notes No declarations of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Patients and treating physicians unblinded but unclear if this would influence
performance.
Mosterd 2008 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Quote: "Dermatologists other than the research physician conducted the on-
cological follow-up in most cases."




Unclear risk Missing outcome data presented. Fairly large dropouts over the study- unclear
if related to true outcomes.
Selective reporting (re-
porting bias)





Methods Multi-centre, parallel, double-blinded RCT. ITT analysis.
Participants UK.
Inclusion criteria: adults with HP BCC of any type except morphoeic, measuring at least 0.5cm diame-
ter.
Exclusion criteria: pregnant or lactating patients, those with known sensitivities, immunosuppression,
recent 5-FU or topical tretinoin treatments, history of recurrent BCC after surgery/cryosurgery/radio-
therapy.
Age: Range 32-95 years.
Gender: male = 50, female = 44.
Interventions Sample size: 94 participants.
Period of inclusion: not stated.
T1: Zycure cream, containing 0.005% of solasodine glycosides every 12 hours for 8 weeks (n = 62)
T2: Vehicle (control) every 12 hours for 8 weeks (n = 32)
Outcomes Primary outcome measure: histologically-confirmed clearance of test lesion BCC at 8 weeks.
Secondary outcome measures: physician's global evaluation of response to treatment, assessment of
local irritation and cosmetic outcome on a four-point scale, and adverse events at screening and end of
treatment.
Notes Sponsored by GlycoMed Sciences Lt
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to make judgement.
Punjabi 2008 
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Low risk The investigator, pharmacist, and the patients were blinded to treatment.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Large difference in proportion of patients withdrawing between groups.









Methods Multi-centre RCT. PP analysis.
Participants UK.
Inclusion criteria: previously untreated nodular BCC in adults
Exclusion criteria: more than 10 lesions, midface region/orbital/ears, lesions < 6 mm or > 15 mm on the
face/scalp, > 20 mm on limbs/neck or > 30 mm on trunk, pigmented/morpheaform BCC, porphyria, Gor-
lin syndrome, arsenic exposure, involved in other study, poor compliance, immunosuppression, preg-
nancy or breastfeeding.
Age: Mean 69 in T1 (40-95) and 67 in T2 (38-82)
Gender: male = 61, female = 40
Interventions Sample size: 103 participants, 105 BCC
Period of inclusion: October 1999 to September 2000
T1: MAL-PDT (n = 52, 75J/cm2 red light, 570 nm to 670 nm)
T2: SE (n = 49, with 5 mm margin)
Outcomes Primary outcome measure: clinical clearance at 3 months.
Secondary outcome measures: sustained response rate at 12 and 24 months. Patient and assessor-re-
ported cosmetic outcome at 3, 12 and 24 months on a four-point rated scale.
Notes Supported by PhotoCure ASA.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer randomisation
Rhodes 2004 
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Allocation concealment
(selection bias)
Low risk Quote: "The randomization list was kept centrally, and investigators called or
faxed to the monitor when a new patient was included to find out the treat-





Unclear risk Unable to blind due to nature of interventions but unclear if this would influ-
ence study outcomes. For cosmetic outcomes however it was felt there would
be a high risk of bias.
Blinding of outcome as-
sessment (detection bias)
All outcomes





Unclear risk Large number of dropouts but unclear if related to study interventions.
Selective reporting (re-
porting bias)












Interventions T1: recombinant IFN-beta
T2: placebo
T1: 1 MU three times a week.
Outcomes Early treatment failure at 16 weeks and recurrence at 2 years.
Notes Translated for 2007 review. No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to make judgement.
Rogozinski 1997 
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Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Insufficient information to make judgement.
Selective reporting (re-
porting bias)





Methods Single-centre, double-blind parallel-group RCT. ITT analysis. Pilot study.
Participants USA.
Inclusion criteria: at least one HP, non-superficial BCC measuring at least 0.7 cm in diameter, in a
healthy individual.
Exclusion criteria: systemic disease, women of childbearing age, facial BCCs.
Age: not stated
Gender: not stated.
Interventions Sample size: 13 participants, 17 BCCs.
Period of inclusion: not stated.
Applied twice daily for 4 consecutive weeks:
T1: 5% 5-FU in PC vehicle (n = not stated)
T2: 5% 5-FU in a petrolatum base (n = not stated)
Outcomes Clinical assessment on four-point scale by blinded investigator, cosmetic appearance, AEs and labora-
tory assessments at 4, 8, 12 and 16 weeks. Histological assessment by blinded assessor at week 16.
Notes No declarations of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information given to make judgement.
Allocation concealment
(selection bias)
Unclear risk Insufficient information given to make judgement.
Romagosa 2000 
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Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "lesions were evaluated by a blinded investigator","specimens were
evaluated by a dermatopathologist who was blinded with respect to whether




Low risk No missing outcome data.
Selective reporting (re-
porting bias)





Methods Single-centre, parallel group. ITT analysis.
Participants Iran.
Inclusion criteria: HP BCC.
Exclusion criteria: indication for Mohs surgery
Age: mean 57.3 years (range 21 - 84 years)
Gender: male = 31, female = 24
Interventions Sample size: 55 participants, (69 lesions)
Period of inclusion: not stated.
T1: SE (n = 24, 4 mm margin)
T2: curettage (n = 20)
T3: curettage and cautery (n = 25)
Outcomes Recurrence rate at 28 months
Notes No declarations of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomisation" but no further details given.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to make judgement
Salmanpoor 2012 
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Unclear risk Insufficient information to make judgement
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Insufficient information to make judgement
Selective reporting (re-
porting bias)





Methods Multi-centre, parallel, double-blinded RCT
Participants Finland.
Inclusion criteria: HP sBCC.
Exclusion criteria:
pigmented, morpheaform, infiltrative or nodular basal cell carcinomas;





Age (mean (range)) T1: 71 (47–91); T2: 74 (51–91); T3: 74 (57–91).
Gender: unclear from numbers presented.
Interventions Sample size: 98 HP BCC from 57 participants.




Outcomes Histological clearance at three months.
Pain, post-treatment reactions and cosmetic outcomes (including photobleaching).
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Salmivuori 2019 
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Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Insufficient information to make judgement.
Selective reporting (re-
porting bias)






Methods Multi-centre, phase III, parallel-group, double-blind, vehicle-controlled RCT. ITT analysis.
Participants Finland, France, Germany, Italy, Spain.
Inclusion criteria: adults with HP sBCC on limbs, trunk, neck or head. Minimum area 0.5 cm2 and maxi-
mum diameter 2 cm.
Exclusion criteria: clinically significant, unstable medical conditions, pregnancy, metastatic tumours or
high probability thereof, tumours located within 1 cm of the hairline, nose, mouth, ears and eyes, with
no evidence of morphoeic, metaplastic, infiltrative or desmoplastic features, participants with derma-
tological disease in target tumour site.
Age (median): T1 = 67, T2 = 68
Gender: male = 101, female = 65
Interventions Sample size: 166 participants
Period of inclusion: not stated.
Once daily application for six weeks:
T1: imiquimod 5% (n = 84)
T2: vehicle (n = 82)
Outcomes Clinical clearance at 12 weeks post-treatment, confirmed by blinded histopathological assessment. In-
vestigator-reported skin quality assessment at week 12 post-treatment.
Adverse events at weeks 2, 4 and 6 and post-treatment weeks 4 and 12.
LSR at all post-treatment visits, assessed according to four-point scale.
Notes Supported by 3M.
Schulze 2005 
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Multiple authors received funding from or were employed by 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer generated randomisation schedule"
Allocation concealment
(selection bias)
Low risk Quote: "Subjects, study personnel and the sponsor’s clinical research team





Low risk Blinding of participants and key study personnel ensured, and unlikely that
the blinding could have been broken.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Missing outcome data balanced in numbers across intervention groups, with
similar reasons for missing data across groups.
Selective reporting (re-
porting bias)





Methods Mult-icentre, open-label, dose-response RCT. ITT analysis. First of two studies included in the paper
(see Shumack 2002b for 12-week study).
Participants Australia and New Zealand
Inclusion criteria: adult with single, primary, HP, nBCC (measuring 0.5 cm2 to 1.5 cm2), greater than 1
cm from eyes, nose, mouth, ear and hairline.
Exclusion criteria: BCC with morphoeic infiltrating and micronodular patterns.
Age (mean in years): T1 = 72, T2 = 66, T3 = 69, T4 = 63
Gender: male = 81, female = 18
Interventions Sample size: 99 participants
Period of inclusion: Not stated
Topical 5% imiquimod applied for six weeks:
T1: twice daily, seven days per week (n = 1)
T2: once daily, seven days per week (n = 35)
T3: twice daily, three alternating days per week (n = 31)
T4: once daily, three alternating days per week (n = 32)
Shumack 2002a 
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Outcomes Clinical and histological clearance at six weeks post-treatment.
Safety and efficacy evaluations at 1, 2, 4 and 6 weeks.
Local skin reactions according to four-point scale at all visits.
Notes Supported by 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Unclear risk Open-label but unclear if this would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk 15/92 discontinued study but unclear in which treatment arms.
Selective reporting (re-
porting bias)





Methods Multi-centre, open-label, dose-response RCT. ITT analysis. Second of two studies included in the paper
(see Shumack 2002a for 6-week study).
Participants USA.
Inclusion criteria: adult with single, primary, HP, nBCC (measuring 0.5 cm2 to 1.5 cm2), greater than 1
cm from eyes, nose, mouth, ear and hairline.
Exclusion criteria: BCC with morphoeic infiltrating and micronodular patterns.
Age (mean in years): T1 = 53, T2 = 63, T3 = 63, T4 = 58, T5 = 62
Gender: male = 63, female = 29
Interventions Sample size: 92 participants
Period of inclusion: Not stated.
Imiquimod or vehicle for 12 weeks:
T1: imiquimod twice daily, seven days per week (n = 4)
Shumack 2002b 
Interventions for basal cell carcinoma of the skin (Review)









Cochrane Database of Systematic Reviews
T2: imiquimod once daily, seven days per week (n = 21)
T3: imiquimod once daily for 5 consecutive days per week (n = 23)
T4: imiquimod once daily for 3 alternating days per week (n = 20)
T5: Vehicle (n = 24)
Outcomes Clinical and histological clearance at six weeks post-treatment.
Safety and efficacy evaluations at 1, 2, 4, 6, 8, 10 and 12 weeks.
Local skin reactions according to four-point scale at all visits.
Notes Supported by 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Unclear risk Open-label but unclear if this would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Only 3 patients discontinued study.
Selective reporting (re-
porting bias)





Methods Multi-entre RCT. Modified ITT analysis.
Participants Australia.
Inclusion criteria: adults with HP sBCC, 4 mm to 15 mm diameter, maximum thickness 4 mm.
Exclusion criteria: recurrent or atypical lesions, immunosuppression, and prior, concomitant or antici-
pated therapy with the potential to confound the study results. women of childbearing potential were
also excluded.
Mean age years 59 (34 to 86)
Siller 2010 
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Gender: male = 88, female = 32
Interventions Sample size: 60 participants
Period of inclusion: April to December 2005
Topical application by investigator using micro-pipette
T1: ingenol mebutate gel 0.0025% (n = 16)
T2: ingenol mebutate gel 0.01% (n = 16)
T3: ingenol mebutate gel 0.05% (n = 16)
T4: identical vehicle (n = 12)
Outcomes Clinical response (according to a six-point scale), and histological response at day 85. Local skin reac-
tions on a three-point scale and with descriptive analysis.
Notes Supported by Peplin Ltd.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk An independent clinical research organisation used a computer-generated
randomisation schedule with a block size of eight. Participants assigned to
treatment or vehicle in a ratio of 1:2
Allocation concealment
(selection bias)





Unclear risk Both the investigator and the participants were blinded. The authors state that
complete blinding could not be guaranteed because of the skin responses ex-
pected with active treatment. The active and vehicle gels were physically in-
distinguishable, and identical packaging used to maintain blinding.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk The post-treatment excision specimen at day 85 looked at by central patholo-




Low risk All 60 patients completed follow-up.
Selective reporting (re-
porting bias)






Methods Multi-centre, unblinded, parallel-group RCT. ITT analysis.
Participants The Netherlands.
Inclusion criteria: HP primary or recurrent BCC located on the face, at least 1cm diameter, located in
the H-zone or high-risk/aggressive histopathological subtype.
Smeets 2004 
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Exclusion: life expectancy less than 3 years.
Age: mean 67.7 years (SD 12.65)
Gender: male (n = 224), female (n = 150)
Interventions Sample size: primary BCC 374 participants (408 lesions) and recurrent BCCs 191 participants (204 le-
sions).
Period of inclusion: October 1999 to January 2001
T1: MMS (n = 204)
T2: SE (n = 204, 3 mm margin)
Outcomes Recurrence at 30 months and 5 years and incomplete excision rate. Cost-effectiveness after 5 years.
Participant assessment of cosmetic outcome at 6 and 18 months, some lesions also retrospectively as-
sessed by investigators and laymen.
Notes Supported by the Dutch Fund for Investigative Medicine
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly assigned using computer programme.
Allocation concealment
(selection bias)





Unclear risk Blinding not possible but unclear if this would influence performance.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Quote: "For practical reasons, the research physician was not blinded to the















Methods Single-centre parallel RCT. ITT analysis.
Participants Norway.
Inclusion criteria: HP BCC, clinical thickness less than 1mm, diameter less than 3 cm, fewer than six le-
sions per patient
Soler 2000 
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Exclusion criteria: not stated.
Age (mean, in years): T1 = 62.4, T2 = 62
Gender: male = 39, female = 44
Interventions Sample size: 83 participants and 245 lesions.
Inclusion period: study dates not reported.
All lesions in both groups were treated with the same drug (topical application of 20% ALA). Three
hours later the cream was removed and light source applied. Two different light sources used:
T1: laser light (n = 41 participants, 111 lesions, 630 nm)
T2: broadband light (n = 42 participants, 134 lesions, 570 nm to 740 nm)
Outcomes Clinical response at 3 and 6 months after treatment according to a three-point scale. Adverse events at
one week, patient-reported pain during and throughout follow-up. Cosmetic outcome according to a
four-point scale.
Notes No declarations of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of random sequence generation not given.
Allocation concealment
(selection bias)
Low risk Quote: "The primary investigator was provided with the randomization num-
bers in locked envelopes, one envelope for each patient." Allocation in blocks





Unclear risk Investigator and patients unblinded but unclear if this would influence study
outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk No missing outcome data for outcomes of interest.
Selective reporting (re-
porting bias)





Methods RCT. Conference abstract.
Participants Australia
Spelman 2014 
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Inclusion criteria: HP sBCC in adults, 4 mm to 15 mm diameter and < 1 mm thick on trunk/extremities
Exclusion criteria:
Age: 60.8 (mean)
Gender: male = 35; female = 40
Interventions Sample size: 75 participants
Period of inclusion: April 2011- March 2012
Ingenol mebutate 0.05% gel applied for three consecutive days with:
T1: full occlusive aluminium disk (n = 27)
T2: semi-occlusive dressing with OpsiteTM (n = 24)
T3: no occlusion (n = 24)
Outcomes Complete histological clearance at day 120. AEs and local skin responses.
Notes No declarations of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Unclear risk Insufficient information to make judgement.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Insufficient information to make judgement.
Selective reporting (re-
porting bias)






Methods Multi-centre (two studies), parallel, open-label. ITT analysis.
Participants Two studies in Europe.
Sterry 2002a 
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Inclusion criteria: adults with HP primary sBCC on limbs, trunk, neck or head, measuring 0.25 cm2 to 1.5
cm2 if sBCC
Exclusion criteria: previous treatment to target tumour, dermatological conditions interfering with lo-
cal assessments, tumours located on hands and feet, anogenital area. High-risk areas within 1 cm of
hairline, eyes, nose, mouth or ears were excluded if sBCC but included if nBCC.
Age: mean 63 years (+/- 13.8 SD)
Gender: male = 59, female = 34
Interventions Sample size: 93 with sBCC
Period of inclusion: not stated
All treated with imiquimod 5% for 6 weeks:
T1: 3 times per week with occlusion (n = 23)
T2 3 times per week without occlusion (n = 25)
T3: twice per week with occlusion (n = 21)
T4: twice per week without occlusion (n = 24)
Outcomes Primary outcome measure: histological confirmation of response at 6 weeks.
Secondary outcome measures: safety and efficacy at 1, 2, 4, 6 and 6 weeks post-treatment. AEs rated on
four-point scale Clinical evaluation at 6 weeks.
Notes Funded by 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A computer-generated randomisation schedule assigned patients in blocks of
four to each dosing regimen.
Allocation concealment
(selection bias)
Unclear risk Quote: "Study personnel were blinded to this randomization schedule until af-





Unclear risk Participants and personnel not blinded but unclear if this would influence
study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Reasons for withdrawals detailed and balanced between groups.
Selective reporting (re-
porting bias)
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Study characteristics
Methods Multi-centre (two studies), parallel, open-label. ITT analysis.
Participants Two studies in Europe.
Inclusion criteria: adults with HP primary nBCC on limbs, trunk, neck or head, measuring 0.5 cm2 to 2
cm2
Exclusion criteria: previous treatment to target tumour, dermatological conditions interfering with lo-
cal assessments, tumours located on hands and feet, anogenital area. High-risk areas within 1 cm of
hairline, eyes, nose, mouth or ears were excluded if sBCC but included if nBCC.
Age: mean 63 years (+/- 13.8 SD)
Gender: male = 59, female = 34
Interventions Sample size: 90 with nBCC
Period of inclusion: not stated
All treated with imiquimod 5% for 6 weeks:
T1: 3 times per week with occlusion (n = 23)
T2 3 times per week without occlusion (n = 24)
T3: twice per week with occlusion (n = 22)
T4: twice per week without occlusion (n = 21)
Outcomes Primary outcome measure: histological confirmation of response at 6 weeks.
Secondary outcome measures: Safety and efficacy at 1, 2, 4, 6 and 6 weeks post-treatment. AEs rated
on four-point scale Clinical evaluation at 6 weeks.
Notes Funded by 3M.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A computer-generated randomisation schedule assigned patients in blocks of
four to each dosing regimen.
Allocation concealment
(selection bias)
Unclear risk Quote: "Study personnel were blinded to this randomization schedule until af-





Unclear risk Participants and personnel not blinded but unclear if this would influence
study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Reasons for withdrawals detailed and balanced between groups.
Sterry 2002b 
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Selective reporting (re-
porting bias)





Methods Multi-centre, parallel-group RCT. PP analysis.
Participants UK, Germany, Switzerland and Australia
Inclusion criteria: adults with HP sBCC, suitable for excision, with no evidence of aggressive growth pat-
terns.
Exclusion criteria: more than 5 lesions, lesions in mid-face region, lesions with a largest diameter <
8 mm or > 20 mm, recurrent lesions, lesions in areas of severe sun damage, lesions proximal to cur-
rent/previous SCC, pigmented/morphoeaform/infiltrating lesions, pregnancy or breastfeeding, con-
traindications to MAL-PDT.
Age: mean 63.8 years (range 31 to 92)
Gender: male = 194, female = 132
Interventions Sample size: 196 participants, 246 sBCC(1.4 lesions per participant).
Period of investigation: not stated.
T1: MAL-PDT (n = 100)
T2: SE (n = 96)
Outcomes Primary outcome measures: Clinical response at 3 months and investigator-assessed cosmetic out-
come according to a four-point scale at 12 months.
Secondary outcome measures: Clinical response at 12 months, investigator-assessed cosmetic out-
come according to a four-point scale at 3, 6 and 12 months.
Other outcomes: AEs at each visit.
Notes Funded by Galderma R&D, Sophia Antipolis, France.
The investigating authors received payments for the project, and two are Galderma employees.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A block of numbered randomisation cards were provided to each site. Whenev-
er a patient was considered eligible, the investigator had to scratch a randomi-
sation card, following an ascending number order, to disclose the procedure
assigned to the patient.
Allocation concealment
(selection bias)




Unclear risk Unable to blind due to nature of treatments but unclear if this would influence
performance.
Szeimies 2008 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Unable to blind due to nature of treatments but unclear if this would influence





Low risk Reasons for missing outcome unlikely to be related to true outcome
Selective reporting (re-
porting bias)





Methods Single-centre, parallel, pilot RCT.
Participants USA.
Inclusion criteria: HP superficial, nodular, multicentric BCC measuring 0.4 cm to 3 cm on trunk and ex-
tremities in Caucasian patients with Fitzpatrick skin types I and II.
Exclusion criteria: morphoeaform, infiltrating and recurrent BCCs or those on the head and neck, feet
or genitals.
Age: range 46 to 84 years, median age 62 (SD +/- 12 years).
Gender: Male = 10, female = 10.
Interventions Sample size: 17 participants with 20 HP BCC.
Period of inclusion: not stated.
T1: PDL 7 mm spot-size, single pulses, 15 J/cm2 (n = 8).
T2: PDL 10 mm spot-size, stacked pulses, 7.5 J/cm2 (n = 8).
T3: Control group (no treatment) (n = 7).
Outcomes Histological clearance and adverse events at 0 to 157 days.
Notes No declarations of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to make judgement.
Allocation concealment
(selection bias)





Low risk Participants were blinded to treatment allocation.
Blinding of outcome as-
sessment (detection bias)
Low risk No mention of blinding but unlikely to have affected interpretation of histol-
ogy for primary outcome.
Tran 2012 
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Low risk No losses to follow-up.
Selective reporting (re-
porting bias)






Methods Single-centre parallel-group RCT. PP analysis.
Participants Sweden.
Inclusion criteria: non-morphoeic HP BCC suitable for PDT or cryosurgery, in patients aged 20 to 90
years.
Exclusion criteria: pregnancy and lactation, severe malignancies, daily intake of vitamins E or C, beta
carotene, iron preparations, non-steroidal anti-inflammatory agents or strong analgesics in higher than
specified doses. BCC on nose, morphoeic growth, porphyria, abdominal pain of unknown aetiology,
photosensitivity, treatment of BCC with topical steroids within the last month.
Age: Range 42 to 88 years
Gender: male = 44, female = 44
Interventions Sample size: 88 participants
Period of inclusion: not stated
T1: ALA-PDT (n = 47, 20% weight-based ALA/water in oil cream applied, irradiation 6 hours later)
T2: cryosurgery (n = 41, liquid nitrogen using a spray technique. Two freeze thaw cycles of 25 to 30 sec-
onds with 2 to 4 minutes thaw time)
Outcomes Histological resolution at three months.
Clinical and histopathological resolution at 12 months. Blinded-assessor rated cosmetic outcome ac-
cording to two three-point scales.
Tolerability as assessed by discomfort according to a VAS and self-reporting of analgesia used.
Notes Supported by Johnson & Johnson Medical GmbH, Norderstedt, Germany, and the Swedishand the Nor-
wegian Cancer Societies.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Allocation concealed by regional cancer registry.
Wang 2001 
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Unclear risk Quote: "No blinding regimen was possible due to the nature of the treatment
procedures". Unclear if this would influence study outcomes.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Quote: "No blinding regimen was possible due to the nature of the treatment





Low risk No missing outcome data.
Selective reporting (re-
porting bias)
Unclear risk Study not registered. All expected outcomes from methods section reported.
Wang 2001  (Continued)
AEs: advere events;ALA: aminolevulinic acid; BCC: basal cell carcinoma; nBCC: nodular BCC; sBCC: superficial BCC; HP: histologically
proven; IFN: interferons; ITT: intention-to-treat; IU: international unit; MAL: methyl aminolevulinate; MMS: Mohs micrographic surgery;
NSAIDs: non-steroidal anti-inflammatories; MU: megaunits; PC: phosphatidyl choline;PDL: pulsed dye laser; PDT: photodynamic therapy;
PP: per protocol;RCT: randomised controlled trial; SCC: squamous cell carcinoma; SE: surgical excision; T1: treatment group 1; T2:
treatment group 2; T3: treatment group 3; 5-FU: 5-fluorouracil; 5-FU/epi: 5-fluorouracil/epinephrine; VAS: visual analogue scale.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Al-Niaimi 2015 No outcomes of interest measured - study measured outcomes relating to number of sections and
stages.
Arits 2014 No outcomes of interest measured - study addressed cost-effectiveness. Arits 2013 study is includ-
ed which measured outcomes of interest.
Berroeta 2007 Not clear if biopsy-proven BCC.
Butler 2009 No outcomes of interest measured, study addressed stages and defect size.
Čarija 2016 Not an RCT, intra-patient study.
Cho 2013 Not an RCT.
de Haas 2006 Not all BCCs histologically proven.
Dessinioti 2014 Not an RCT.
EudraCT 2013-000092-33 Not all BCCs histologically proven.
Genouw 2018 Not an RCT, intra-patient randomised study.
Groselj 2018 Not an RCT.
Huang 2004 No outcomes of interest measured. This study was about the utility of preoperative tumour curet-
tage in Mohs micrographic surgery for primary or recurrent BCC. The end points were per cent sur-
face area increase from tumour surface area to wound surface area; actual surface area increase
from tumour surface area to wound surface area; and number of layers removed to clear tumour.
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Study Reason for exclusion
Ibbotson 2018 Not all BCCs histologically proven.
Lippert 2013 Included previously treated lesions.
Lu 2017 Included several tumour types. Data related to BCC alone not available.
Lui 2004 Included Gorlin syndrome patients.
Migden 2015 Included previously treated lesions.
NCT01033019 No outcomes of interest measured.
Nguyen 2018 No outcomes of interest measured.
Quirk 2010 Not an RCT.
Radiotis 2014 Not an RCT.
Schleier 2007 Included participants with Gorlin syndrome.
Sekulic 2012 Not an RCT
Spencer 2006 Adjuvant therapy study.
Tang 2012 Included participants with Gorlin syndrome.
van der Geer 2012 No outcomes of interest measured.
Vijlder 2012 Not all lesions histologically proven.
Wettstein 2013 Not all lesions histologically proven.
Zane 2017 Not all lesions histologically proven.
BCC: basal cell carcinoma;RCT: randomised controlled trial.
 




Interventions 5- Fluorouracil/adrenaline injectable gel.
Outcomes Unknown
Notes This trial was identified from the National Research Register in our old review searches but no more
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Methods Single-centre, randomised, parallel RCT.
Participants Iran.
Inclusion criteria: pathologically documented BCC; maximum tumour diameter of 30 mm.
Exclusion criteria: skins with Fitzpatrick type of higher than 3; coagulation disorders or recent re-
ceiving of anticoagulant agents; consumption of light-sensitive drugs.
Interventions T1: 585-nanometer PDL laser with power of 9 joules, in 450 microseconds, for 2 treatment sessions
with 3-week intervals ; T2 585-nanometer PDL laser with power of 9 joules, in 450 microseconds,
followed by cryosurgery with one unit of liquid nitrogen (CRY-ACW) using spray method during two
freeze cycles each of which being 4 ± 2 minutes, for 2 sessions with intervals of 3 weeks.
Outcomes Primary: tumour remission 6 months after the last treatment session.




Methods Single-centre, randomised, parallel RCT.
Participants UK.
Participant inclusion criteria
1. Patients referred for PDT as judged appropriate by dermatologists in local area
2. Patients will have BCCs, Bowen's disease or actinic keratoses and will be randomised depending
on diagnosis.
Interventions Two treatment arms in the study, randomised in double-blind fashion to receive either topical
20% ALA or 20% ALA, 2% EDTA cream. Both groups will then receive light treatment to the areas to
which the cream has been applied. Comparison of the two groups will be by change in size of skin
lesion by any tolerance of procedure.
Outcomes Response of skin lesion clinically by size change at 3-month follow-up.









Interventions 72 participants. Unclear BCC subtype. Unclear if HP.
T1: 635 nm Ella light once a week for 4 weeks.
T2: imiquimod pre-treatment and 635 nm Ella light once a week for 4 weeks.
Kang 2018 
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Outcomes Immune index changes, clinical efficacy, cosmetic effect and adverse reactions.











T1: adriamycin combined with cisplatin.
T2: cisplatin.
Outcomes Quote: "Observe and compare the clinical effects, adverse reactions, serum VEGF level, pain score
and self-efficacy of two groups."





Methods Multi-centre, randomised, parallel RCT.
Participants Cuba.
Inclusion criteria
1. Clinical and histological diagnosis of BCC
2. > 18 years of age.
3. Lesions between 1.5 cm2 to 10.0 cm2.
4.Lesions of any subtype, localisation and size
5. Non recurrent lesion.
6. Without previous specific treatments.
Interventions Study group (CIGB-128-A). Perilesional treatment with CIGB-128-A (dose of 10.5 MIU) 2 times per
week for 4 weeks Study group (CIGB-128-A). Perilesional treatment with CIGB-128-A (dose of 10.5
MIU) 2 times per week for 6 weeks Study group (CIGB-128-A). Perilesional treatment with CIGB-128-
A (dose of 10.5 MIU) 2 times per week for 8 weeks Control group (CIGB-128-A). Perilesional treat-
ment with CIGB-128-A (dose of 10.5 MIU) 3 times per week for 4 weeks Study group (CIGB-128-
A). Perilesional treatment with CIGB-128-A (dose of 10.5 MIU) 3 times per week for 6 weeks Study
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Clinical response (Size of the lesion. RECIST criteria. Complete Response (CR); Partial Response
(PR); Stable Disease (SD) and Progression Disease (PD)). Measuring time: at baseline and at week 16
after starting the treatment.
Secondary outcomes
Clinical response time (time to reach partial or complete response). Measuring time: weeks 1, 4, 8,
12 and 16. Quality of scarring; Will be evaluated since the clinical standpoint, in patients that re-
spond completely to treatment. Measuring time: at a week 16 and annually for 10 years. Time to re-
currence (time elapsing from the first day provided the absence of neoplastic cells according to the
evaluation histological or clinical (patient refusal to biopsy end or biopsy no useful), until appears
an injury histologically demonstrated in the treated site). Measuring time: annually for 10 years.
Presence of clinical adverse effects. Anti-IFN alpha and gamma antibodies.
Notes Date of first enrolment: 01/02/2013. Recruitment status: Pending. No reply to email to trial registra-
tion contact.
RPCEC00000147  (Continued)
ALA: aminolevulinic acid; BCC: basal cell carcinoma; EDTA: Ethylenediaminetetraacetic acid; HP: histologically proven; PDL: pulsed dye
laser; PDT: photodynamic therapy; RCT: randomised controlled trial; VEGF: Vascular endothelial growth factor.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Electrochemotherapy versus standard radiotherapy for the treatment of basal cell carcinoma.
Methods Single-centre, randomised, parallel RCT.
Participants Denmark.
Age > 18 with HP BCC.
Aiming for 52 participants.
Interventions T1: bleomycin electrochemotherapy.
T2: standard radiotherapy (no further detail given).
Outcomes Primary: evaluate tumour response and compare efficacy of electrochemotherapy versus standard
radiotherapy (time point: 3 months).







Study name Surgical excision versus combined treatment with curettage and imiquimod for nodular basal cell
carcinoma: an open, non-inferiority, randomized controlled trial
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Primary HP nBCC ≥ 4 mm and ≤ 20 mm in diameter.
Aiming for 145 participants.
Interventions T1: Standard surgical excision (including a 3-mm clinically tumour-free margin)
T2: Imiquimod 5% cream with prior curettage
Outcomes Primary: proportion of participants tumour-free [Time Frame: At 1 year after end of treatment]
Secondary: 5-year cumulative probability of recurrence-free survival after end of treatment [Time
Frame: At 5 years after end of treatment].
Compliance [Time Frame: At 3 months after end of treatment ].
Cosmetic appearance [ Time Frame: At 1 and 5-year after end of treatment ].
Patient satisfaction [ Time Frame: At 1 and 5-year after end of treatment ].
Level of Pain [ Time Frame: 2 weeks after end of treatment ].
Cost-effectiveness [ Time Frame: At 5-year after end of treatment ].
Adverse events [ Time Frame: Up to 3 months after end of treatment ].
Starting date January 2016.
Contact information Principal Investigator: Klara Mosterd, MD, PhD Maastricht University Medical Centre.




Study name A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety
and efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the treatment of superficial basal cell
carcinoma (sBCC) With photodynamic therapy (PDT).
Methods Multi-centre, randomised, parallel RCT.
Participants USA.
Aiming for 186 participants (over 18 years old) across 15 centres.
Interventions Experimental: BF-200 ALA
Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).
Placebo comparator: vehicle
Topical application of vehicle to BF-200 ALA containing no active ingredient.
Outcomes Primary:
Composite clinical and histological response of the participant's Main Target Lesion as assessed 12
weeks after the start of the last PDT cycle that included treatment of the main target lesion. [Time
Frame: 12 weeks after the start of the last PDT cycle that included treatment of the main target le-
sion]
The composite clinical and histological response rate of the participant's main target lesion is the
percentage of participants with clinically and histologically cleared main target lesion 12 weeks af-
ter the start of the last PDT cycle that included treatment of the main target lesion (Visit 5 or Visit 8).
Starting date 2018.
Contact information b.schmitz@biofrontera.com
Notes Study aiming to complete 2024.
NCT03573401 
Interventions for basal cell carcinoma of the skin (Review)









Cochrane Database of Systematic Reviews
ALA: aminolevulinic acid; BCC: basal cell carcinoma; nBCC: nodular basal cell carcinoma; HP: histologically proven; PDT: photodynamic
therapy; RCT: randomised controlled trial.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Mohs micrographic surgery vs surgical excision





Statistical method Effect size
1.1 Recurrence at 3 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.2 Recurrence at 5 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1: Mohs micrographic surgery vs














M-H, Random, 95% CI
0.64 [0.16 , 2.64]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MMS Favours SE
 
 
Analysis 1.2.   Comparison 1: Mohs micrographic surgery vs














M-H, Random, 95% CI
0.61 [0.18 , 2.04]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MMS Favours SE
 
 
Comparison 2.   Imiquimod vs surgical excision





Statistical method Effect size
2.1 Recurrence at 3 years 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
2.2 Recurrence at 5 years 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
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Statistical method Effect size
2.3 Cosmetic outcome (good/excellent) 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
2.3.1 Observer rated at 3 years 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
2.3.2 Participant rated at 3 years 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
2.4 Pain (moderate/severe) 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
2.4.1 During treatment 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected



















M-H, Random, 95% CI
10.30 [3.22 , 32.94]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod cream Favours SE
 
 














M-H, Random, 95% CI
7.73 [2.81 , 21.30]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod cream Favours SE
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Analysis 2.3.   Comparison 2: Imiquimod vs surgical excision, Outcome 3: Cosmetic outcome (good/excellent)
Study or Subgroup
2.3.1 Observer rated at 3 years
Bath-Hextall 2014

















M-H, Random, 95% CI
1.70 [1.35 , 2.15]
1.00 [0.94 , 1.06]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours SE Favours imiquimod
 
 





















M-H, Random, 95% CI
1.36 [0.98 , 1.88]
0.47 [0.29 , 0.77]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod cream Favours SE
 
 
Comparison 3.   Radiotherapy vs surgical excision (with or without frozen section margin control)





Statistical method Effect size
3.1 Recurrence at 3 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.2 Recurrence at 4 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.3 Cosmetic outcome (good) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.3.1 Participant rated at 4 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.3.2 Observer rated at 4 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 3.1.   Comparison 3: Radiotherapy vs surgical excision (with or














M-H, Random, 95% CI
19.11 [1.12 , 325.78]
Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours radiotherapy Favours SE
 
 
Analysis 3.2.   Comparison 3: Radiotherapy vs surgical excision (with or














M-H, Random, 95% CI
11.06 [1.44 , 84.77]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours radiotherapy Favours SE
 
 
Analysis 3.3.   Comparison 3: Radiotherapy vs surgical excision (with or
without frozen section margin control), Outcome 3: Cosmetic outcome (good)
Study or Subgroup
3.3.1 Participant rated at 4 years
Avril 1997

















M-H, Random, 95% CI
0.76 [0.63 , 0.91]
0.48 [0.37 , 0.62]
Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours SE Favours radiotherapy
 
 
Comparison 4.   Curettage vs surgical excision




Statistical method Effect size
4.1 Recurrence at 2 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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M-H, Random, 95% CI
2.40 [0.49 , 11.77]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours curettage Favours SE
 
 
Comparison 5.   Curettage and cautery vs surgical excision




Statistical method Effect size
5.1 Recurrence at 2 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.96 [0.15 , 6.28]
Risk Ratio
M-H, Random, 95% CI
0.002 0.1 1 10 500
Favours C&C Favours SE
 
 
Comparison 6.   Curettage and cautery vs curettage




Statistical method Effect size
6.1 Recurrence at 2 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.40 [0.08 , 1.97]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours C&C Favours curettage
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Comparison 7.   Low dose radiotherapy vs high dose radiotherapy




Statistical method Effect size
7.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.82 [0.39 , 1.72]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours low dose Gy Favours high dose Gy
 
 
Comparison 8.   Radiotherapy vs cryosurgery




Statistical method Effect size
8.1 Recurrence at 2 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.11 [0.03 , 0.43]
Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours radiotherapy Favours cryosurgery
 
 
Comparison 9.   Curettage and cryosurgery vs surgical excision





Statistical method Effect size
9.1 Recurrence at 3 years (le-
sions)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.2 Recurrence at 5 years (le-
sions)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.3 Cosmetic outcome (good) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.3.1 Participant rated at 1 year 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
Interventions for basal cell carcinoma of the skin (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
9.3.2 Obsever rated at 1 year 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 9.1.   Comparison 9: Curettage and cryosurgery vs














M-H, Random, 95% CI
3.36 [0.73 , 15.40]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours curettage/cryo Favours SE
 
 
Analysis 9.2.   Comparison 9: Curettage and cryosurgery vs














M-H, Random, 95% CI
2.78 [0.93 , 8.34]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours curettage/cryo Favours SE
 
 
Analysis 9.3.   Comparison 9: Curettage and cryosurgery vs surgical excision, Outcome 3: Cosmetic outcome (good)
Study or Subgroup
9.3.1 Participant rated at 1 year
Kuijpers 2007

















M-H, Random, 95% CI
0.88 [0.78 , 0.98]
0.28 [0.16 , 0.47]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours SE Favours curettage/cryo
 
 
Comparison 10.   MAL-PDT vs surgical excision





Statistical method Effect size
10.1 Recurrence at 3 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Statistical method Effect size
10.2 Cosmetic outcome (good/excel-
lent)
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.2.1 Participant rated at 1 year 2 309 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.09, 1.27]
10.2.2 Observer rated 1 year 2 256 Risk Ratio (M-H, Random, 95% CI) 1.87 [1.54, 2.26]
10.3 Pain 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
10.4 Early treatment failure (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
26.47 [1.63 , 429.92]
Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours MAL-PDT Favours SE
 
 
Analysis 10.2.   Comparison 10: MAL-PDT vs surgical excision, Outcome 2: Cosmetic outcome (good/excellent)
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 4.24 (P < 0.0001)





Heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 1 (P = 0.55); I² = 0%







































M-H, Random, 95% CI
1.17 [1.01 , 1.34]
1.18 [1.08 , 1.30]
1.18 [1.09 , 1.27]
2.08 [1.38 , 3.12]
1.81 [1.46 , 2.25]
1.87 [1.54 , 2.26]
Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours surgery Favours MAL-PDT
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M-H, Random, 95% CI
2.20 [0.60 , 8.03]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MAL-PDT Favours SE
 
 














M-H, Random, 95% CI
11.65 [0.67 , 202.74]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MAL-PDT Favours SE
 
 
Comparison 11.   ALA-PDT vs surgical excision





Statistical method Effect size
11.1 Recurrence at 3 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
11.2 Recurrence at 5 years (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
11.3 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
10.87 [2.63 , 44.95]
Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours ALA-PDT Favours SE
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M-H, Random, 95% CI
11.91 [2.90 , 48.95]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours ALA-PDT Favours SE
 
 














M-H, Random, 95% CI
3.18 [0.66 , 15.32]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours ALA-PDT Favours SE
 
 
Comparison 12.   ALA-PDT vs MAL-PDT





Statistical method Effect size
12.1 Cosmetic outcome (good/very
good)
2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
12.2 Pain (visual analogue score) 2   Mean Difference (IV, Random, 95% CI) Subtotals only
12.2.1 Cycle 1 2 313 Mean Difference (IV, Random, 95% CI) 0.56 [-0.76, 1.88]
12.2.2 Cycle 2 2 300 Mean Difference (IV, Random, 95% CI) 0.43 [-0.18, 1.05]
12.3 Pain (numerical rating scale) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
12.3.1 Cycle 1 1   Mean Difference (IV, Random, 95% CI) Totals not selected
12.3.2 Cycle 2 1   Mean Difference (IV, Random, 95% CI) Totals not selected
12.4 Early treatment failure 2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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M-H, Random, 95% CI
1.19 [0.98 , 1.46]
1.07 [0.84 , 1.36]
Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours MAL-PDT Favours ALA-PDT
 
 






Heterogeneity: Tau² = 0.59; Chi² = 2.33, df = 1 (P = 0.13); I² = 57%





Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 1 (P = 0.67); I² = 0%













































IV, Random, 95% CI
1.54 [-0.23 , 3.31]
0.10 [-0.44 , 0.64]
0.56 [-0.76 , 1.88]
0.94 [-1.48 , 3.36]
0.40 [-0.24 , 1.04]
0.43 [-0.18 , 1.05]
Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours MAL-PDT Favours ALA-PDT
 
 



























IV, Random, 95% CI
-0.37 [-1.13 , 0.39]
0.88 [0.09 , 1.67]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours ALA-PDT Favours MAL-PDT
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M-H, Random, 95% CI
0.75 [0.17 , 3.24]
0.95 [0.37 , 2.49]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours ALA-PDT Favours MAL-PDT
 
 
Comparison 13.   BF-200 ALA-PDT vs MAL-PDT




Statistical method Effect size
13.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
2.82 [0.31 , 25.68]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours BF-200 ALA-PDT Favours MAL-PDT
 
 
Comparison 14.   HAL-PDT vs MAL-PDT




Statistical method Effect size
14.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
2.00 [0.19 , 20.93]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HAL-PDT Favours MAL-PDT
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Comparison 15.   HAL-PDT vs BF-200 ALA-PDT




Statistical method Effect size
15.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.71 [0.13 , 3.97]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours HAL-PDT Favours BF-200-PDT
 
 
Comparison 16.   MAL-PDT vs cryosurgery





Statistical method Effect size
16.1 Recurrence at 3 years (le-
sions)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
16.2 Recurrence at 5 years (le-
sions)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
16.3 Cosmetic outcome (good/
excellent)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
16.3.1 Participant rated at 1
year
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
16.3.2 Observer rated at 1 year 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
16.4 Pain 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
16.5 Early treatment failure (le-
sions)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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M-H, Random, 95% CI
1.14 [0.65 , 1.98]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MAL-PDT Favours cryosurgery
 
 














M-H, Random, 95% CI
1.08 [0.62 , 1.86]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours MAL PDT Favours cryosurgery
 
 
Analysis 16.3.   Comparison 16: MAL-PDT vs cryosurgery, Outcome 3: Cosmetic outcome (good/excellent)
Study or Subgroup
16.3.1 Participant rated at 1 year
Basset-Seguin 2008

















M-H, Random, 95% CI
1.23 [1.07 , 1.41]
1.46 [1.14 , 1.88]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours cryosurgery Favours MAL-PDT
 
 














M-H, Random, 95% CI
1.12 [0.68 , 1.84]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MAL-PDT Favours cryosurgery
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M-H, Random, 95% CI
0.57 [0.14 , 2.33]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PDT Favours cryosurgery
 
 
Comparison 17.   ALA-PDT vs cryosurgery





Statistical method Effect size
17.1 Cosmetic outcome (good/ex-
cellent)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
17.2 Pain 1   Mean Difference (IV, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
1.72 [1.26 , 2.34]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours cryosurgery Favours MAL-PDT
 
 


















IV, Random, 95% CI
11.00 [-1.12 , 23.12]
Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours ALA-PDT Favours cryosurgery
 
 
Comparison 18.   Imiquimod cream vs MAL-PDT





Statistical method Effect size
18.1 Recurrence at 3 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
18.2 Recurrence at 5 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
Interventions for basal cell carcinoma of the skin (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
18.3 Cosmetic outcome (good/ex-
cellent, observer rated at 1 year)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
18.4 Pain (moderate/severe) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
18.5 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.44 [0.32 , 0.62]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod Favours MAL-PDT
 
 














M-H, Random, 95% CI
0.42 [0.31 , 0.57]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod Favours MAL-PDT
 
 
Analysis 18.3.   Comparison 18: Imiquimod cream vs MAL-PDT, Outcome














M-H, Random, 95% CI
0.98 [0.84 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours MAL-PDT Favours imiquimod
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M-H, Random, 95% CI
0.60 [0.41 , 0.87]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod Favours MAL-PDT
 
 














M-H, Random, 95% CI
0.64 [0.37 , 1.09]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod Favours MAL-PDT
 
 
Comparison 19.   5-FU cream vs MAL-PDT





Statistical method Effect size
19.1 Recurrence at 3 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
19.2 Recurrence at 5 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
19.3 Cosmetic outcome (good/ex-
cellent, observer rated at 1 year)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
19.4 Pain (moderate/severe) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
19.5 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.65 [0.49 , 0.86]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours 5-FU cream Favours MAL-PDT
 
 
Interventions for basal cell carcinoma of the skin (Review)









Cochrane Database of Systematic Reviews














M-H, Random, 95% CI
0.67 [0.53 , 0.84]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours 5-FU cream Favours MAL-PDT
 
 
Analysis 19.3.   Comparison 19: 5-FU cream vs MAL-PDT, Outcome














M-H, Random, 95% CI
0.92 [0.78 , 1.09]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours MAL-PDT Favours 5-FU cream
 
 














M-H, Random, 95% CI
0.41 [0.26 , 0.63]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours 5-FU cream Favours MAL-PDT
 
 














M-H, Random, 95% CI
0.77 [0.47 , 1.26]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours 5-FU cream Favours MAL-PDT
 
 
Comparison 20.   Laser ALA-PDT vs broadband light ALA-PDT





Statistical method Effect size
20.1 Cosmetic outcome (good/excellent,
observer rated at 6 months)
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Statistical method Effect size
20.2 Pain 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
20.2.1 Discomfort during/after illumina-
tion
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
20.2.2 Discomfort during 1st week after
treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 20.1.   Comparison 20: Laser ALA-PDT vs broadband light ALA-PDT,














M-H, Random, 95% CI
0.91 [0.82 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours Broad band Favours laser
 
 
Analysis 20.2.   Comparison 20: Laser ALA-PDT vs broadband light ALA-PDT, Outcome 2: Pain
Study or Subgroup
20.2.1 Discomfort during/after illumination
Soler 2000

















M-H, Random, 95% CI
1.09 [0.87 , 1.35]
0.93 [0.70 , 1.22]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LL Favours BL
 
 
Comparison 21.   AFXL MAL-PDT vs MAL-PDT





Statistical method Effect size
21.1 Cosmetic outcome (good/excel-
lent)
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
21.1.1 Observer rated at 1 year 2 57 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.54, 2.31]
21.1.2 Participant rated at 1 year 1 23 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.75, 1.17]
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Statistical method Effect size
21.2 Early treatment failure 2 71 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.17, 0.84]
 
 
Analysis 21.1.   Comparison 21: AFXL MAL-PDT vs MAL-PDT, Outcome 1: Cosmetic outcome (good/excellent)
Study or Subgroup





Heterogeneity: Tau² = 0.20; Chi² = 2.97, df = 1 (P = 0.08); I² = 66%
Test for overall effect: Z = 0.31 (P = 0.76)







































M-H, Random, 95% CI
0.95 [0.81 , 1.11]
1.54 [0.64 , 3.68]
1.12 [0.54 , 2.31]
0.94 [0.75 , 1.17]
0.94 [0.75 , 1.17]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MAL-PDT Favours AFXL MAL-PDT
 
 






Heterogeneity: Tau² = 0.00; Chi² = 0.20, df = 1 (P = 0.66); I² = 0%
Test for overall effect: Z = 2.39 (P = 0.02)
























M-H, Random, 95% CI
0.40 [0.17 , 0.91]
0.20 [0.01 , 3.86]
0.38 [0.17 , 0.84]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours AFXL-PDT Favours MAL-PDT
 
 
Comparison 22.   MAL-PDT vs placebo





Statistical method Effect size
22.1 Cosmetic outcome (good/excellent, ob-
server rated at 6 months))
1   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
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Statistical method Effect size
22.2 Pain (frequency reported as local AE) 1   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed




Analysis 22.1.   Comparison 22: MAL-PDT vs placebo, Outcome 1:














M-H, Random, 95% CI
1.05 [0.91 , 1.21]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours Placebo Favours MAL-PDT
 
 














M-H, Random, 95% CI
3.94 [1.17 , 13.32]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours MAL-PDT Favours Placebo
 
 














M-H, Random, 95% CI
0.36 [0.24 , 0.54]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours MAL-PDT Favours Placebo
 
 
Comparison 23.   Imiquimod cream vs 5-FU cream





Statistical method Effect size
23.1 Recurrence at 3 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Statistical method Effect size
23.2 Recurrence at 5 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
23.3 Cosmetic outcome (good/ex-
cellent, observer rated at 1 year)
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
23.4 Pain (moderate/severe) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
23.5 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.68 [0.47 , 0.99]
Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours imiquimod cream Favours 5-FU cream
 
 














M-H, Random, 95% CI
0.62 [0.44 , 0.87]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours imiquimod cream Favours 5-FU cream
 
 
Analysis 23.3.   Comparison 23: Imiquimod cream vs 5-FU cream,














M-H, Random, 95% CI
1.07 [0.90 , 1.26]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours 5-cream Favours imiquimod cream
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M-H, Random, 95% CI
1.46 [0.89 , 2.38]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours imiquimod cream Favours 5-FU cream
 
 














M-H, Random, 95% CI
0.83 [0.47 , 1.46]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours imiquimod cream Favours 5-FU cream
 
 
Comparison 24.   Imiquimod vs radiotherapy





Statistical method Effect size
24.1 Cosmetic outcome (excellent, participant rated
at 6 weeks)






Analysis 24.1.   Comparison 24: Imiquimod vs radiotherapy, Outcome














M-H, Random, 95% CI
25.19 [1.66 , 382.13]
Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours radiotherapy Favours imiquimod cream
 
 
Comparison 25.   Imiquimod cream under occlusion vs no occlusion





Statistical method Effect size
25.1 Early treatment failure 2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
25.1.1 sBCC 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Statistical method Effect size
25.1.2 nBCC 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 25.1.   Comparison 25: Imiquimod cream under





















M-H, Random, 95% CI
0.93 [0.53 , 1.61]
0.90 [0.57 , 1.44]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours occlussion Favours no occlusion
 
 
Comparison 26.   Imiquimod cream vs vehicle




Statistical method Effect size
26.1 Early treatment failure 5 1145 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.19, 0.32]
 
 









Heterogeneity: Tau² = 0.05; Chi² = 9.22, df = 4 (P = 0.06); I² = 57%
Test for overall effect: Z = 10.19 (P < 0.00001)







































M-H, Random, 95% CI
0.18 [0.07 , 0.46]
0.29 [0.20 , 0.44]
0.20 [0.16 , 0.25]
0.22 [0.14 , 0.33]
0.35 [0.24 , 0.52]
0.25 [0.19 , 0.32]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours imiquimod cream Favours vehicle
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Comparison 27.   Imiquimod 5 weeks vs 8 weeks




Statistical method Effect size
27.1 Recurrence at 1 year 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
4.57 [1.16 , 18.05]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours 5 weeks Favours 8 weeks
 
 
Comparison 28.   Imiquimod 8 weeks vs 12 weeks




Statistical method Effect size
28.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.94 [0.55 , 1.62]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours 8 weeks Favours 12 weeks
 
 
Comparison 29.   5-FU in PC vs 5-FU in petrolatum




Statistical method Effect size
29.1 Early treatment failure (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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M-H, Random, 95% CI
0.23 [0.03 , 1.81]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours FU in PC Favours 5-FU in petr
 
 
Comparison 30.   5-FU/epinephrine gel (1.0 mL once a week for 6 weeks vs 0.5 mL once a week for 6 weeks




Statistical method Effect size
30.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 30.1.   Comparison 30: 5-FU/epinephrine gel (1.0 mL once a week for 6














M-H, Random, 95% CI
2.10 [0.21 , 21.39]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours high dose Favours low dose
 
 
Comparison 31.   5-FU/epinephrine gel(1.0 mL twice a week for 3 weeks vs 0.5 mL twice a week for 3 weeks)




Statistical method Effect size
31.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 31.1.   Comparison 31: 5-FU/epinephrine gel(1.0 mL twice a week for 3














M-H, Random, 95% CI
0.26 [0.03 , 2.14]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours high dose Favours low dose
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Comparison 32.   5-FU/epinephrine gel(0.5ml twice a week for 4 weeks vs 0.5 mL three times a week for 2 weeks.




Statistical method Effect size
32.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 32.1.   Comparison 32: 5-FU/epinephrine gel(0.5ml twice a week for 4 weeks
vs 0.5 mL three times a week for 2 weeks., Outcome 1: Early treatment failure
Study or Subgroup
Miller 1997











M-H, Random, 95% CI
4.09 [0.21 , 79.88]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours 2x/wk for 4w Favours 3xwk for 3 w
 
 
Comparison 33.   Electrochemotherapy vs surgical excision





Statistical method Effect size
33.1 Recurrence at 3 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
33.2 Recurrence at 5 years 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
3.79 [0.44 , 32.32]
Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours ECT Favours SE
 
 














M-H, Random, 95% CI
4.86 [0.60 , 39.63]
Risk Ratio
M-H, Random, 95% CI
0.002 0.1 1 10 500
Favours ECT Favours SE
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Comparison 34.   Ingenol vs vehicle (day 1+2)





Statistical method Effect size
34.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
34.1.1 Ingenol 0.05% vs vehicle 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
34.1.2 Ingenol 0.01% vs vehicle 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
34.1.3 Ingenol 0.0025% vs vehicle 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 34.1.   Comparison 34: Ingenol vs vehicle (day 1+2), Outcome 1: Early treatment failure
Study or Subgroup
34.1.1 Ingenol 0.05% vs vehicle
Siller 2010
34.1.2 Ingenol 0.01% vs vehicle
Siller 2010





















M-H, Random, 95% CI
0.42 [0.18 , 0.97]
0.78 [0.49 , 1.23]
1.00 [0.77 , 1.30]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours ingenol Favours vehicle
 
 
Comparison 35.   Ingenol vs vehicle (day 1+8)





Statistical method Effect size
35.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
35.1.1 Ingenol 0.05% vs vehicle 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
35.1.2 Ingenol 0.01% vs vehicle 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
35.1.3 Ingenol 0.0025% vs vehicle 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 35.1.   Comparison 35: Ingenol vs vehicle (day 1+8), Outcome 1: Early treatment failure
Study or Subgroup
35.1.1 Ingenol 0.05% vs vehicle
Siller 2010
35.1.2 Ingenol 0.01% vs vehicle
Siller 2010





















M-H, Random, 95% CI
0.75 [0.39 , 1.43]
1.20 [0.79 , 1.83]
1.05 [0.67 , 1.64]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours ingenol Favours vehicle
 
 
Comparison 36.   Ingenol under occlusion vs no occlusion





Statistical method Effect size
36.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
36.1.1 Full occlusion vs no occlusion 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
36.1.2 Semi-occlusion vs no occlusion 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 36.1.   Comparison 36: Ingenol under occlusion vs no occlusion, Outcome 1: Early treatment failure
Study or Subgroup
36.1.1 Full occlusion vs no occlusion
Spelman 2014

















M-H, Random, 95% CI
0.65 [0.31 , 1.34]
1.36 [0.80 , 2.33]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours occlusion Favours no occlusion
 
 
Comparison 37.   Solasodine glycoside cream vs vehicle




Statistical method Effect size
37.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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M-H, Random, 95% CI
0.45 [0.30 , 0.67]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours BEC-5 cream Favours vehicle
 
 
Comparison 38.   Valproic acid gel + Tazarotene gel vs placebo + Tazarotene




Statistical method Effect size
38.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 38.1.   Comparison 38: Valproic acid gel + Tazarotene














M-H, Random, 95% CI
0.62 [0.31 , 1.22]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours Baceca + Tazarotene Favours placebo + Tazarotene
 
 
Comparison 39.   Diclofenac gel vs calcitriol ointment




Statistical method Effect size
39.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.55 [0.39 , 0.77]
Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours diclofenac Favours calcitriol
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Comparison 40.   Diclofenac gel vs diclofenac+calcitriol




Statistical method Effect size
40.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.87 [0.56 , 1.35]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours diclofenac Favours diclofen+calcitri
 
 
Comparison 41.   Calcitriol ointment vs calcitriol+diclofenac




Statistical method Effect size
41.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
1.58 [1.19 , 2.11]
Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours calcitriol Favours diclofen+calcitri
 
 
Comparison 42.   PDL one session vs PDL two sessions




Statistical method Effect size
42.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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M-H, Random, 95% CI
0.83 [0.60 , 1.13]
Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours two sessions Favours one session
 
 
Comparison 43.   PDL 7mm spot-size single pulses vs PDL 10mm spot-size stacked pulses




Statistical method Effect size
43.1 Early treatment failure (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 43.1.   Comparison 43: PDL 7mm spot-size single pulses vs PDL














M-H, Random, 95% CI
0.33 [0.10 , 1.12]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours 10mm stacked Favours 7mm single
 
 
Comparison 44.   PDL vs sham laser




Statistical method Effect size
44.1 Early treatment failure (lesions) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.22 [0.14 , 0.37]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours PDL Favours sham]
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Comparison 45.   PDL vs no treatment




Statistical method Effect size
45.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.36 [0.15 , 0.86]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PDL Favours no treatment
 
 
Comparison 46.   Interferon alpha 2b vs placebo




Statistical method Effect size
46.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 














M-H, Random, 95% CI
0.20 [0.12 , 0.32]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours Interferon Favours Placebo
 
 
Comparison 47.   Interferon beta vs placebo




Statistical method Effect size
47.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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M-H, Random, 95% CI
0.55 [0.34 , 0.87]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours Interferon Favours Placebo
 
 
Comparison 48.   Interferon alpha 2a+2b vs interferon alpha 2a




Statistical method Effect size
48.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
 
 














M-H, Random, 95% CI
0.80 [0.27 , 2.41]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours IFN 2a+2b Favours IFN 2a
 
 
Comparison 49.   Interferon alpha 2a+2b vs interferon alpha 2b




Statistical method Effect size
49.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
 
 














M-H, Random, 95% CI
0.80 [0.27 , 2.41]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours IFN 2a+2b Favours IFN alpha2b
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Comparison 50.   Interferon alpha 2b vs interferon alpha 2a




Statistical method Effect size
50.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
 
 














M-H, Random, 95% CI
1.00 [0.36 , 2.75]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours IFN 2b Favours INF 2a
 
 
Comparison 51.   3x a week vs single dose protamine zinc chelate IFN alpha 2b




Statistical method Effect size
51.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 51.1.   Comparison 51: 3x a week vs single dose protamine














M-H, Random, 95% CI
0.41 [0.19 , 0.92]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours 3 x week Favours single dose
 
 
Comparison 52.   Topical sinecatechin vs placebo




Statistical method Effect size
52.1 Early treatment failure 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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M-H, Random, 95% CI
1.05 [0.89 , 1.25]
Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours sinecatechin Favours placebo
 
 










Not stated. Not stated. Not stated. Only 2 patients experienced pain and ulceration in the
single-session group. There was no significant differ-





Not stated. Not stated. Not stated. Transient local discomfort at injection site (requiring






Not stated. Weekly post-treatment
patient-reported maxi-
mum score for pain and
burning sensation on a
visual analogue scale (0–
10) for six weeks, and
maximum score during
the first and second pho-
todynamic therapy ses-
sions. Categorised as 0-3


















Maximum duration of pain and burning sensation:
Imiquimod group = 6 weeks, Fluorouracil group = 4






Not stated. AEs at each follow-up
visit up to three months
post-treatment accord-








Local pain in 33% in cryosurgery group compared to











During treatment and at
16 weeks using six-point
scale. Number of days of







More patients reported pain during treatment in im-
iquimod group
Table 1.   Pain table 
Interventions for basal cell carcinoma of the skin (Review)









































Not stated. Weekly patient-reported
pain score on a VAS (0–
10).
Not stated. Pain at application site most likely to occur in the
combination therapy group (40.6%) as compared to













Not stated. All patients experienced mild to moderate pain during
PDT illumination. After illumination had ceased, the
pain intensity immediately lessened, resolving over
the next few hours. VAS scores (11-point scale) during
illumination were similar with Er:YAG AFL-PDT (4.632





















Composite weekly median VAS scores for tolerabili-
ty are low, suggesting little discomfort in both study







Not stated. Adverse effects noted
at each follow-up visit
and rated as mild/mod-
erate/severe.
Not stated. Burning more common than stinging or other skin
pain. 29% in treatment arm compared to 12% in
placebo group. Pain = 18% and 5%, respectively,





















50% of the patients in the radiotherapy group com-
pared to 60% in the imiquimod group reported symp-
toms of discomfort with blinking during treatment.
One patient complained of slight pain in the lower
eyelid during radiotherapy treatment.
Geisse 2002
(Imiquimod
BD / OD /
Rest peri-
od of up to
Patient-reported adverse
effects at each visit.
Not stated. Pain and tenderness at the target site were reported
less frequently than itching.
Table 1.   Pain table  (Continued)
Interventions for basal cell carcinoma of the skin (Review)










































Pain scores during LED il-
lumination, scored from
0-10.
Not stated. “AFXL pre-treatment did not influence median pain
scores during LED illumination and pain intensities
were similar at first and second illumination: first
treatment AFXL-PDT median 3 (IQR 2–55) vs MAL-PDT
35 (25–5), second treatment AFXL-PDT 35 (3–65) vs
MAL-PDT 3 (3–45), (P>0519). The presumed enhanced
uptake of MAL did not affect the pain level during illu-
mination. Pain scores were similar during AFXL-PDT
and MAL-PDT and rated as mild to moderate.”
Karsai 2015
(PDL / sham)
Not stated. Pain intensity using a VAS
(0 cm = ‘no pain’ to 10
cm = ‘maximal pain’) at
every visit.
Not stated. “The following median values were indicated on the
pain intensity scale (ordinal scale 0–10) among pa-
tients at the four treatment sessions surveyed (mini-
mum–maximum): Laser treatment: 2 (0–6), 3 (0–6), 3
(0–8) and 4 (0–9); Sham treatment: 0 (0–1), 0 (0–1), 0














cluding pain were record-
ed in personal diary kept
by patients once a week
during treatment.
Not stated. A burning sensation was reported in the treatment
group in 5% of patients, at week four compared to 1%






Not stated. Pain and burning sensa-
tion
were scored using a
numerical rating scale
(score 0–10),
directly after both illumi-
nations and 1 week later.
The maximum
pain scores for both illu-
minations were assessed.
Not stated. “After the second illumination, mean pain scores were
significantly higher in the two-fold ALA-PDT group
compared with patients treated with MAL-PDT, with
mean pain scores of 3.36 +- 2.57 and 2.48 +- 2.57 re-
spectively (P=0.039). None of the patients discontin-
ued treatment because of pain. 16.4% in the ALA-PDT
group vs 5.8% in the MAL-PDT group reported the use





Not stated. Patient description of





Majority of pain was reported as burning or stinging
(59 and 41% respectively); also described as throb-
bing, lingering or tingling. Intensity and character was
the same between groups. Generally pain was experi-
enced during illumination and sporadically after, with
the second cycle reported as the worst. No radiation
reported.
Table 1.   Pain table  (Continued)
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Marks 2001
(Imiquimod
BD / OD / BD
for 3 days /
OD for 2
days)
Not stated. Three-point rating scale
applied by assessor
based on descriptive
terms used by patient.
Not stated. Pain more frequent in the BD group (100%) > OD























At each treatment visit,
patients were asked to
report injection site
pain, including burning


































during PDT was assessed
for each PDT session (on
a numerical rating pain
scale).
Ranking of the subjective
sensations
pain, burning and itching
was done by the patient.
Pain during
PDT assessed with a nu-
merical rating pain scale
ranging
from 0 (no pain at all) to
10 (worst possible pain).
Not stated. Pain was one of the most frequently reported reac-
tions, experienced by 100% patients undergoing MAL-
PDT and 97.1% patients undergoing BF 200 ALA-PDT.
Local pain experienced during each session showed
little variation between both treatments and was










Local skin reactions dur-
ing and after treatment
at each clinic visit were
documented, and rated













14% in the MAL-PDT group experienced pain, com-













mented at every study
visit.
Not stated. Pain was one of the three most frequent symptomatic
adverse effects and two patients discontinued treat-
ment due to pain.
Table 1.   Pain table  (Continued)
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mented at every study
visit.
Not stated. Pain at the application site was most common in in-
genol mebutate gel group 0.05% (n=2, treatment arm
B), and 1 patient experienced pharyngolaryngeal pain






Not stated. Pain reported during
treatment and in fol-
low-up period (patient
questionnaires).
Not stated. 83% of patients in the laser group and 76% in the
broadband group reported some discomfort during
and after illumination. Types of pain included stinging
and burning sensation. There was no significant dif-
















mented at every study
visit.
Not stated. One patient reported continuous stinging and pain
at the application site; one reported irritation and an-
other reported irritation and pruritus.
Table 1.   Pain table  (Continued)
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mented at every study
visit.
Not stated. Post procedural pain was reported in 3 of the surgical
participants and none of the MAL-PDT group. Pain was
reported in 2 and 1 of the participants in the MAL-PDT













Pain recorded in first
week after treatment us-
ing 115-mm visual ana-
logue scale (VAS) for pain
indication and analgesia
diary.
Not stated. Overall VAS scores low for both treatment modalities,
and insignificantly higher in PDT group (43 +/- 31mm
SD in PDT group, 32 +/- 27mm SD in cryosurgery








Not stated. Not stated. Not stated. 8 patients in the placebo group experienced pain in
comparison to 6 in the treatment group.
Table 1.   Pain table  (Continued)

























Not stated. In the group who received
two sessions of treatment, 4
patients experienced dyspig-








None reported. Local skin redness reported
as moderate or severe in all
treatment groups.
Patients treated with im-
iquimod or 5-FU more often
reported moderate to severe
local swelling, erosion, crust
formation and itching of the
Unexpected serious adverse ef-
fects in 1) Imiquimod group in-
clude wound infection (n = 1) and
influenza-like symptoms (n = 8)
and 2) in 5-FU group include two
local wound infections, erysipelas
of the lower extremity (n = 1), leg
ulcer (n = 1).
Adverse reactions more com-
mon in last treatment weeks.
Table 2.   Adverse e<ects table 
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skin than patients treated
with MAL-PDT.
The erysipelas and ulcer were
treated with ambulant compres-
sion therapy and antibiotics. None






Not stated. Main adverse characteristics
of surgical scars were "de-
formations" and "constric-
tions", affecting 25% and 5%
of patients respectively by
year 4. Radiodystrophy and
necrosis affected 41% and
5% of the radiotherapy group
at 4 years respectively.
Three ophthalmic complica-
tions were observed: 1 ectropi-
on, 1 cataract - after surgery. One









None reported. Crusting: MAL PDT = 35%,
cryosurgery = 47%.
Erythema: MAL PDT = 30%,
cryosurgery 21%.
Blisters: cryosurgery only = 21%.
Suppuration: cryosurgery group
only.
Most were transient, resolv-
ing in 5 days.
More likely to experience
severe AE in MAL-PDT
group and moderate AE in
cryosurgery group, although
























Itching: Imiquimod =211, SE
= 129.
Weeping: Imiquimod = 160,
SE = 81.
Higher frequency adverse ef-
fects more common in imiquimod
group include 1) Mild/moderate
events: occurrence of new tu-
mours, redness and swelling at
tumour site, cold/influenza-like
symptoms, headache, scab at tu-
mour site, spots close to trial tu-
mour, discomfort and bleeding, 2)
Severe events: cold/flu, inflamma-
tory reactions.
Other high-frequency adverse ef-
fects, more common in SE group
include 1) Mild/moderate events:
Pain and swelling at tumour site
and 2) Severe events: Heat attack /
heart failure and pneumonia.
In the imiquimod group, 38
(15%) participants needed a
dose reduction.
No deaths or serious adverse




















= 6, calcitriol =
2, combination
= 8)
Erythema: diclofenac = 21,
calcitriol = 20, combined
treatment = 22
Other commonly reported AEs in
all groups include swelling, ero-
sions, pruritus.
Other less frequent AEs include
crust formation, vesicles, scaling,
and paraesthesia.
Adverse effects were mostly
mild to moderate.
No serious adverse effects
were considered to be relat-
ed to the study medication.
Three patients had serious
adverse effects requiring hos-
pitalisation.
No adverse effects were re-
ported in the control group.
Table 2.   Adverse e<ects table  (Continued)
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None reported. Crusting: Er-YAG AFL-PDT =
17, MAL-PDT = 14
Erythema, burning sensation at
application site, hyperpigmenta-
tion and itching more frequent in
Er:YAG AFL-PDT group.
Other reactions include scale, bul-
lae, oozing and bleeding.







None reported. Erythema and oedema oc-
curred in 92% of participants.
Reporting of vesicles, ero-
sions, ulcerations, desqua-




ed in 9% of participants. Most
AEs were judged by physi-
cians as moderate severity
and by patients as moderate
(17%) to severe (54%).
Authors reported "no differences
between treatment arms in ad-
verse events".
Data for AEs were not pre-








None reported. Purpura immediately after
laser treatment: 100% PDL
group.
Late AEs in PDL group: blister
(21.4%), dyspigmentation (21.4%)













Mild erythema (at week 1):
8-week group = 69%, 5 week
group = 69%.
Other reactions include pain,
swelling, weeping, broken skin and
scabbing.
Erythema decreased in both
groups at week 5.
One patient on 8 week course
developed severe erythema
and soreness and was unable
to apply 7th treatment.
The severity of local site reac-
tions was greatest in the first
half of the treatment phase











due to local ad-
verse event.
Burning: MAL-PDT = 19,
placebo = 8.
Erythema: MAL-PDT = 14,
placebo = 4.
Other reactions include stinging of
skin, crusting and bleeding (more
frequent in treatment group).
Severe events: cholangiocarcino-
ma, cholelithiasis, carotid stenosis,
pulmonary oedema and acute MI,
melanoma, femoral artery surgery.
One serious AE deemed not
treatment-related.
All were mild-to-moderate








None reported. Blink discomfort (during
treatment): Imiquimod =
60%, radiotherapy = 50%.
Intense conjunctival irritation
13.3% imiquimod group, discom-
fort 8.3% radiotherapy group.
After treatment, radiothera-
py group reported ectropion,
dry eye and loss of eyelash-
es. imiquimod group report-
ed no post-treatment AEs.
Table 2.   Adverse e<ects table  (Continued)
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effects (BD = 1,









Itching: 5xpw = 62%, OD =
61%, 3xpw = 38%, BD = 30%,
vehicle = 13%.
Pain: BD = 30%, OD = 16%,
3xpw = 10%, 5xpw = 8%, vehi-
cle = 0.
Tenderness: BD = 20%, OD =
16%, 5xpw = 8%, 3xpw = 7%,
vehicle = 6%.
Other reactions include erythe-
ma, scabbing, erosion, excoria-
tion/flaking, ulceration, vesicles,
induration and oedema.
Severe erythema and scabbing
occurred more commonly in the
twice-daily treatment groups.
AEs occurred in all treatment
groups, as did local skin re-
actions (all of those deemed
related to study drug were in
the OD group).
Six serious AEs, all unrelated














ment due to AE
or local site re-
action.
Erythema: most frequently
observed and most intense
LSR: 5xpw = 87, 7xpw = 92,
vehicle = 48.
Itching: 5xpw = 16%, 7xpw =
26%.
Burning: 5xpw = 6%, 7xpw =
9%.
Other reactions include oedema,
induration, vesicle, erosion, ulcer-
ation, scabbing and flaking.
The incidence of headache
was statistically higher in the
Imiquimod 5xpw group compared
to the corresponding vehicle group
(P = 0.027), although this differ-
ence was not seen in the 7xpw
group.
Local site reactions reached
maximum intensity at week
3, and most were mild.
Local site reactions were ex-
perienced in all groups but
more likely in imiquimod
groups, and these were sta-
tistically more likely to be se-
vere (P = 0.001).
AEs occurred more frequent-
ly during treatment than af-
ter and were more likely to
occur in the imiquimod 7xpw
group than the 5xpw group
or the vehicle groups (64%
compared to 58% and 36%
(combined vehicle groups).
Local site reactions were ex-
perienced more commonly in
7xpw Imiquimod group com-
pared to the 5xpw group (P =
0.002).
AEs considered possibly or
probably related to treat-
ment include local site reac-
tions and lymphadenopa-
thy in the 7xpw Imiquimod
group.
All local site reactions were
significantly more likely to
be intense than 7xpw group
than 5xpw group (P < 0.5).
Table 2.   Adverse e<ects table  (Continued)
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Overall the severe AEs experi-
ence by participants were in
the 7xpw Imiquimod group.
A decrease in WCC and neu-






Not stated. Immediate skin reactions
(white micro-spots at the sur-
rounding skin surface and
minor pinpoint bleeding)
seen in all AFXL group.
Pigmentary changes and
scarring similar in both
groups.
Minor bleeding and bruising in de-
bulked areas.
Scarring was the most fre-






Not stated. Crusting (lasted an aver-
age of 10 days): intervention
group only.
Hyperpigmentation: inter-
vention group only (21 of 56
cases, 37%).
Hypopigmentation: interven-
tion group only (did not man-
ifest until after the third ses-
sion; its rate increased with
the number of sessions) seen
in 52 of 56 cases (93%).
Purpura in 100% of the laser
group.
Not stated. Purpura was considered a
desired concomitant effect
and was seen for an average
of 6 days.
Hyper- and hypopigmenta-
tion persisted until the end

















Other reactions include oedema,
erosions, bullae and squamae.
Statistically significant differ-








Not stated. Erythema: MAL-PDT = 65,
ALA-PDT = 73.
Wounds/erosions: MAL-PDT =
64, ALA-PDT = 72.
Vesicles: MAL-PDT = 66, ALA-
PDT = 72.
All significantly higher after
ALA-PDT compared with MAL-
PDT.
Other reactions include swelling,
crusts, scaling and pruritus.
Four serious AEs unrelated to
study treatment (three hospitaliza-
tions owing to transient ischaemic
attack, chemotherapy for lung car-
cinoma and dizziness, and one pa-
tient died owing to cancer).
AE incidence higher during
treatment period than after
treatment.
Table 2.   Adverse e<ects table  (Continued)
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No serious unexpected adverse







Not stated. Secondary wound infec-
tion requiring systemic an-
tibiotics: curettage and
cryosurgery group = 3 pa-
























Erythema: BD = 66.7%, OD =
27.3%, BDx3pw, = 13.3 %, OD
x3pw = 9.1%.
Itching: BD =33.3%, OD =
66.7%, BDx3pw, = 36.7%, OD
x3pw = 45.5%.
Weeping: decreased as the
dosing frequency decreased
BD = 66.7% OD = 12.1%
BDx3pw, = 3.3%, OD x3pw =
0%.
Other reactions include scabbing,
flaking, erosion, ulceration, oede-
ma and induration.
One patient died as the result of a
coincidental cerebrovascular acci-
dent.
Local skin reactions occurred




In the twice-every-day group,
all the local skin reactions
were assessed as severe by
both the patient and the in-
















Not stated. Local tissue reactions were
confined to the treatment
site and included erythema,
swelling, desquamation, ero-
sions and eschar in most pa-
tients.
Hyperpigmentation was ob-
served in 83% of treated pa-
tients but typically cleared
during the FU period.
Ulcerations at the treatment
site occurred in 47% of pa-
tients; only one patent had a
residual scar.
Not stated. There were no clinically sig-
nificant serious or unexpect-
ed adverse effects or changes
in any lab values or physi-
cal examination findings as
judged by the investigator
to be related to the adminis-
tration of 5-FU/epi gel. The
number of events per regi-










AEs in the BF
200 ALA group








Most frequently reported re-
actions included pain, ery-
thema, pruritus and oedema;
most frequently at mild to
moderate intensity.
Frequencies were compara-
ble between the groups and
revealed no statistically sig-
nificant differences.
There were ten serious AEs, none
of which were related to the study
medication.
 
Table 2.   Adverse e<ects table  (Continued)
Interventions for basal cell carcinoma of the skin (Review)















None reported. Not stated. Secondary wound infection was
observed once after ALA-PDT treat-
ment. No serious complications
such as wound dehiscence or
necrosis were observed in either














  There were four serious adverse
effects in treatment group (3 un-
related, 1 unlikely to be related to
treatment), and 2 in the vehicle
group (one unrelated and one un-
likely related to treatment).
No SAEs were considered
likely or related to the treat-
ment and there was no signif-










Erythema: MAL-PDT = 7, SE =
1.
Skin infection: MAL-PDT = 0,
SE = 3.
Three patients had skin infections
after SE (none in PDT group).
Other local adverse effects includ-
ed crusting and itching.
There were three deaths, all un-
related to treatment, and one pa-
tient was diagnosed with breast
cancer during treatment.
More patients with MAL-PDT
than SE experienced adverse










Not stated. Local irritation, erythema,
ulceration, tenderness were
common but well-tolerated.

















tion, vesicles, erosion, ulcer-
ation, scaling/flaking and
scabbing/crusting were all
significantly more likely to




cant changes in skin quality as-
sessment scores for hypo- or irreg-
ular pigmentation, and skin sur-
face texture.
Severe AE more common in treat-
ment group but none due to treat-
ment. No deaths.
Central and peripheral nervous
system disorders e.g. headache,
gastrointestinal disorders and res-
piratory system disorders were al-
so reported.
Local skin reactions were
more intense in the im-
iquimod group (statistically
significant).
Local skin reactions in-
creased at week 2 and












fects (OD 7 day
dosing group),
one discon-
Erythema and scabbing com-
monly reported.
Influenza-like symptoms, proba-
bly related to drug noted in 10 pa-
tients.
Fatigue in the OD 7 day group.
AEs occurred in all dosing
groups (42% possibly / prob-
ably due to study treatment).
Table 2.   Adverse e<ects table  (Continued)
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ing to local skin
reaction (2 in
OD 5 day group,
4 in OD 7 day
group, 2 in BD 7
day group).
2 discontin-
ued due to AEs
(1 = pain and
drainage at tar-




Erythema and scabbing com-
monly reported.
Two patients in the BD 7 day group
and one in the OD 7 day group re-
ported severe local skin reactions.
Influenza-like symptoms, proba-
bly related to drug, were noted in 5
patients.
Local skin reactions occurred
in all study groups, and were
the most commonly reported





















The most common reactions
were erythema and flak-
ing/scaling/dryness, which
occurred in a minimum of 75
and 50% respectively, of all




bing/crusting, vesicles all more
common in ingenol mebutate gel
0.05% group. Most were mild to
moderate reactions, although 2
were severe (ingenol mebutate gel
0.01 and 0.05% respectively).
Other skin reactions include itch,
weeping/exudate, scarring.
Other adverse effects include liver
function derangement, diarrhoea,
erythema, flaking, headache,
oedema, pustules at application
site, pustular rash, scabbing and
telangiectasia.
No serious AE.
Severe AE included mild/mod
erythema extending beyond
treatment site and headache.
10 severe local skin reac-
tions seen in Arm A in ingenol
mebutate gel 0.01% / ingenol




Not stated. AEs in SE group include
wound infection, necrosis of
graKs or flaps or post-opera-
tive bleeding.
33 patients died due to conditions
not related to the treatment.
12% complications in MMS








Not stated. During the 1st week after
treatment, 68% patients
in the laser group and 74%
of those in the broadband
group also reported some
degree of discomfort (sting-
ing, itching, pain, suppura-
tion headache, sensation of
warmth or blushing).
Not stated. No serious AEs reported in
the 6-month follow-up peri-
od.











Not stated. Local skin reactions in 11.3 full ODr
group, 7,5 in semi-ODr group and
8.9 in no-ODr group.
The majority of AEs were not
considered treatment relat-
ed. The percentage of AEs
was similar across all treat-
Table 2.   Adverse e<ects table  (Continued)
Interventions for basal cell carcinoma of the skin (Review)






















ment groups, the most com-
mon being application site
pain. The majority of treat-
ment-related AEs were in the
ALU group, and in this group
the majority only tolerated
one treatment due to the






















and one due to












Itching, burning and hy-
popigmentation most fre-
quently reported AEs.
Two severe application site reac-
tions were considered due to the
medication (in 2xpw without oc-
clusion group and in 3xpw with oc-
clusion group).
Fever and influenza-like symptoms
were infrequently reported.
Four patients experienced serious
adverse effects unrelated to the
medication.
AEs occurred in all treatment
groups with 59% reporting at
least one.
32% reported application site
reactions, which occurred
more often in groups treated

























Bleeding, itching and irrita-
tion most frequently report-
ed AEs.
Erythema was the most fre-
quently reported local skin
reaction and was most com-
mon in the 3xpw group.
Five experienced severe appli-
cation site reactions considered
probably related to the study drug.
In groups receiving 3xpw treat-
ment, severe local skin reactions
were most common.
Four experienced severe AEs unre-
lated to study drug.
70% reported adverse ef-
fects. 42% reported appli-
cation site reactions; local
skin reactions occurred in all
treatment groups, most fre-













MAL-PDT = 37%, SE = 0%.
Wound infection: MAL-PDT =
0%, SE = 5.2%.
Other reported AEs included ery-
thema, post-procedural pain, milia
and wound dehiscence.
21 serious AEs were reported; none




higher in MAL-PDT group
than in SE group (37% versus
14.6%).
All AEs were mild to moder-
ate severity except one se-





Not stated. Both treatment group par-
ticipants developed eschars
at 2 weeks, followed by mild
Not stated.  
Table 2.   Adverse e<ects table  (Continued)
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erythema at 1 month and hy-





Not stated. Infections: SE = 2,
cryosurgery = 3.
In the cryosurgery group,
90% complained about mod-
erate to severe swelling of
the treatment area, followed
by leaking from the defect.







Not stated. Not stated. There were two patient deaths,
and both were unrelated to the
BCC or the treatment.
One patient reported pain radi-
ating from treatment site (PDT
group) and one developed bacteri-










Not stated. Erythema (17/25 and 20/25 in
the two treatment groups).
Itch (18 versus 15 patients), ulcera-
tion (11 versus 16 patients) and lo-
cal pain (8 versus 6 patients).
No significant differences be-
tween the two groups. Exten-
sion phase outcomes not re-
ported.
Table 2.   Adverse e<ects table  (Continued)
MAL: methyl aminolevulinate; PDL: pulsed dye laser; PDT: photodynamic therapy; SE: surgical excision; xpw: times per week.
 
 
Curettage & cryosurgery compared to surgical excision for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from a single-centre in The Netherlands
Intervention: curettage & cryosurgery
Comparison: surgical excision
Anticipated absolute effects* (95% CI)Outcomes
Risk with surgical
excision















Study populationRecurrence at 3
years









Study populationRecurrence at 5
years









Table 3.   Curettage and cryosurgery compared to surgical excision for basal cell carcinoma of the skin 
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No study addressed this outcome not estimable - - -
Pain No study addressed this outcome not estimable - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
Table 3.   Curettage and cryosurgery compared to surgical excision for basal cell carcinoma of the skin  (Continued)
1 Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm.
2 Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI and downgraded one
level for serious risk of bias as unable to truly blind due to the nature of interventions.
3 Downgraded one level for serious imprecision as only a single study with a small sample size.
4 3-point scale: bad, fair, good.
 
 
ALA-PDT compared to surgical excision for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from a single-centre in the Netherlands
Intervention: ALA-PDT
Comparison: surgical excision
Anticipated absolute effects* (95% CI)Outcomes
















Study populationRecurrence at 3
years










Table 4.   ALA-PDT compared to surgical excision for basal cell carcinoma of the skin 
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Study populationRecurrence at 5
years












No study addressed this outcome. not estimable - - -
Pain No study addressed this outcome. not estimable - - -
Study populationEarly treatment
failure









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
Table 4.   ALA-PDT compared to surgical excision for basal cell carcinoma of the skin  (Continued)
1 Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI.
2 Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm.
 
 
PDT compared to cryosurgery for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from France, UK, Sweden, Italy, Belgium and Austria
Intervention: MAL-PDT
Comparison: cryosurgery






































Table 5.   MAL-PDT compared to cryosurgery for basal cell carcinoma of the skin 
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Study populationCosmetic out-
come (good/














excellent) 604 per 1000 882 per 1000
(689 to 1000)
































ported as AE dur-
ing the follow-up
period.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
AE: adverse event; CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
Table 5.   MAL-PDT compared to cryosurgery for basal cell carcinoma of the skin  (Continued)
1 Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm.
2 Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions.
3 4-point scale: poor (extensive occurrence of scarring, atrophy, or induration), fair (slight to moderate occurrence of scarring, atrophy or
induration), good (no scarring, atrophy or induration and moderate redness or increase in pigmentation compared with adjacent skin),
excellent (no scarring, atrophy, or induration and slight or no redness or change in pigmentation compared with adjacent skin).
4 Includes participants with multiple lesions which means diJerences between groups could be over-estimated.
 
 
5-FU cream compared to MAL-PDT for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from seven hospitals in the Netherlands
Intervention: 5-FU cream
Comparison: MAL-PDT
Anticipated absolute effects* (95% CI)Outcomes














Table 6.   5-FU cream compared to MAL-PDT for basal cell carcinoma of the skin 
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Study populationRecurrence at
3 years

































Blinded observer-rated at 1
year on 4-point scale.3
Study populationPain (moder-
ate/severe)










paring the week of treat-
ment with highest frequen-
cy of reported moderate/se-
vere pain (treatment cycle













*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
Table 6.   5-FU cream compared to MAL-PDT for basal cell carcinoma of the skin  (Continued)
1 Downgraded one level for serious imprecision as only a single study with a small sample size.
2 Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm.
3 4-point scale: poor, fair, good, excellent.
 
 
Imiquimod cream compared to 5-FU cream for low-risk BCC
Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from seven hospitals in the Netherlands
Intervention: imiquimod cream
Comparison: 5-FU cream
Table 7.   Imiquimod cream compared to 5-FU cream for basal cell carcinoma of the skin 
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paring the week of treat-
ment with highest fre-
quency of reported mod-
erate/severe pain (week













*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
Table 7.   Imiquimod cream compared to 5-FU cream for basal cell carcinoma of the skin  (Continued)
1 Downgraded one level for serious imprecision as only a single study with a small sample size.
2 Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI.
3 Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm.
4 4-point scale: poor, fair, good, excellent.
 
 
PDT compared to cryosurgery for low-risk BCC
Table 8.   ALA-PDT compared to cryosurgery for basal cell carcinoma of the skin 
Interventions for basal cell carcinoma of the skin (Review)
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Patient or population: adults with basal cell carcinoma of the skin
Setting: secondary care with outpatients from a single hospital in Sweden
Intervention: ALA-PDT
Comparison: cryosurgery






















No study addressed this outcome. not es-
timable




No study addressed this outcome. not es-
timable


























MD 11mm higher (1.12










Pain during treatment assessed
by VAS (115mm, where 115mm
corresponds to 'unbearable
pain' and 0mm corresponds to
'no pain'.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; VAS: visual analogue scale.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
Table 8.   ALA-PDT compared to cryosurgery for basal cell carcinoma of the skin  (Continued)
1 Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions.
2 Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI.
3 4-point scale: blemished, acceptable, good, excellent.
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A P P E N D I C E S
Appendix 1. Skin Group Specialised Register (CRS) search strategy
(basal cell* and (cancer* or epithelioma* or carcinoma* or naev* or nev* or tumor* or tumour* or neoplasm*)) or bcc or "gorlin syndrome"
or ((rodent or Jacob*) and ulcer*) or basalioma or nmsc or (keratinocyte* and (cancer* or carcinoma*)) or nonmelanoma or "non
melanoma" or "basal keratinocyte*"
Appendix 2. CENTRAL (Cochrane Library) search strategy
#1 MeSH descriptor: [Carcinoma, Basal Cell] explode all trees
#2 MeSH descriptor: [Neoplasms, Basal Cell] explode all trees
#3 MeSH descriptor: [Basal Cell Nevus Syndrome] explode all trees
#4 (basal cell* next (cancer* or epithelioma* or carcinoma* or naev* or nev* or tumor* or tumour* or neoplasm*)):ti,ab,kw
#5 bcc:ti,ab,kw
#6 gorlin syndrome:ti,ab,kw
#7 (rodent next ulcer*):ti,ab,kw
#8 (jacob* next ulcer*):ti,ab,kw
#9 basalioma*:ti,ab,kw
#10 nmsc:ti,ab,kw
#11 (keratinocyte* and (cancer* or carcinoma*)):ti,ab,kw
#12 nonmelanoma skin cancer*:ti,ab,kw
#13 non melanoma skin cancer*:ti,ab,kw
#14 basal keratinocyte*:ti,ab,kw
#15 {or #1-#14}
Appendix 3. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.




9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Carcinoma, Basal Cell/
12. (basal cell$ and (cancer$ or epithelioma$ or carcinoma$ or naev$ or nev$ or tumor$ or tumour$ or neoplasm$)).mp.
13. exp Neoplasms, Basal Cell/
14. bcc.ti,ab.
15. gorlin syndrome.mp.





21. (keratinocyte$ and (cancer$ or carcinoma$)).mp.
22. nonmelanoma skin cancer$.mp.
23. non melanoma skin cancer$.mp.
24. basal keratinocyte$.mp.
25. or/11-24
26. 10 and 25
[Lines 1-10: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing
version (2008 revision); Ovid format, from section 3.6.1 in Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-
I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS,
Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6. Cochrane, 2019. Available from:
www.training.cochrane.org/handbook]
Appendix 4. Embase (Ovid) search strategy
1. exp Basal Cell Carcinoma/
Interventions for basal cell carcinoma of the skin (Review)
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2. (basal cell$ and (cancer$ or epithelioma$ or carcinoma$ or naev$ or nev$ or tumor$ or tumour$ or neoplasm$)).mp.
3. bcc.ti,ab.
4. gorlin syndrome.mp.




9. (keratinocyte$ and (cancer$ or carcinoma$)).mp.
10. nonmelanoma skin cancer$.mp.







18. (crossover$ or cross over$).tw.
19. placebo$.tw.
20. (doubl$ adj blind$).tw.
21. allocat$.tw.
22. trial.ti.
23. randomized controlled trial.sh.
24. random$.tw.
25. or/15-24
26. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
27. human/ or normal human/
28. 26 and 27
29. 26 not 28
30. 25 not 29
31. 14 and 30
[Lines 15-25: Based on terms suggested for identifying RCTs in Embase (section 3.6.2) in Lefebvre C, Glanville J, Briscoe S, Littlewood
A, Marshall C, Metzendorf M-I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J,
Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6. Cochrane,
2019. Available from: www.training.cochrane.org/handbook]
Appendix 5. CINAHL (EBSCO) search strategy
S1TI basal cell and (cancer* or epithelioma* or carcinoma* or naev* or nev* or tumor* or tumour* or neoplasm*)) or AB basal cell and
(cancer* or epithelioma* or carcinoma* or naev* or nev* or tumor* or tumour* or neoplasm*))
S2 (MH "Carcinoma, Basal Cell") OR (MH "Neoplasms, Basal Cell+")
S3 TI ((non melanoma or nonmelanoma) and skin cancer*) or AB ((non melanoma or nonmelanoma) and skin cancer*)
S4 "gorlin syndrome"
S5 Jacob* nr1 ulcer*
S6 (rodent next ulcer*)
S7 TI bcc or AB bcc
S8 TX basalioma*
S9 TI nmsc or AB nmsc
S10 TX (keratinocyte* nr2 (cancer* or carcinoma*))
S11TI basal keratinocyte* or AB basal keratinocyte*
S12 TX random*
S13 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S14 S12 AND S13
Appendix 6. LILACS search strategy
Searched on the advanced search page with ti and ab fields only, and using the Controlled clinical trials topic-specific query filter.
("basal cell" or "basal cells" or "rodent ulcer" or "rodent ulcers" or "jacobs ulcer" or "jacobs ulcers" or basalioma or nmsc or "non melanoma
skin cancer" or "non melanoma skin cancers"):ti,ab
W H A T ' S   N E W
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Date Event Description
9 September 2020 New citation required and conclusions
have changed
This update included studies of many more interventions, with
several new studies of non-surgical interventions compared to
surgical interventions and other non-surgical interventions. It al-
so includes long-term follow-up data from previously included
studies. These new data have led to new and updated conclu-
sions.
19 February 2020 New search has been performed Since the 2007 review, we have identified 26 new randomised
controlled trials. This updated review now has a total of 52 stud-
ies that randomised 6690 participants.
 
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 2, 2003
 
Date Event Description
22 May 2008 Amended Converted to new review format.




C O N T R I B U T I O N S   O F   A U T H O R S
JT was the contact person with the editorial base, JT co-ordinated contributions from the co-authors, and wrote the final draK of the review.
JT, FB-H, and SH screened papers against eligibility criteria.
JT, FB-H, and SH obtained data on ongoing and unpublished studies.
JT, FB-H, and SH appraised the quality of papers.
JT, FB-H, and SH extracted data for the review and sought additional information about papers.
JT, FB-H, and SH entered data into RevMan.
FB-H, JT, SH and JL-B analysed and interpreted data.
FB-H and JT worked on the methods sections.
JT and HW draKed the clinical sections of the background and responded to the clinical comments of the referees.
JL-B responded to the methodology and statistics comments of the referees.
JT is the guarantor of the update.
Disclaimer
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Skin
Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, National Health Service (NHS), or the Department of Health.
D E C L A R A T I O N S   O F   I N T E R E S T
Jason Thomson: none known
Sarah Hogan: none known
Jo Leonardi-Bee: none known
Hywel C Williams and Fiona J Bath-Hextall were involved in the SINS trial that compared topical imiquimod versus surgery and is a trial
that is included in this review (Bath-Hextall 2014). The trial was funded by Cancer Research UK, a UK cancer charity. They were not involved
in extracting data from the trial nor commenting on the evidence from this trial. Neither the charity, Fiona J Bath-Hextall or Hywel Williams
have any links with industry.
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S O U R C E S   O F   S U P P O R T
Internal sources
• Cochrane Skin, UK
External sources
• The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of Cochrane Skin.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We have amended the primary and secondary outcomes of this updated review to reflect the outcomes that are important for both
clinicians and patients as well as to conform to the recommendations from Cochrane. Specifically, we have separated "recurrence at 3 to
5 years" to "recurrence at 3 years" and "recurrence at 5 years". The reason for this was because "3 to 5 years" is a wide time range and we
did not feel it would be appropriate to compare three-year outcomes with five-year outcomes. This was not such a concern for the 2007
review as very few studies had long term follow-up data, but for this review we were aware that many more studies would have follow-
up data up to five years.
We have also amended the cosmetic outcome. In the 2007 review this outcome was "Aesthetic appearance to participants/observer:
atrophy, scarring, changes in pigmentation" and was categorised as an "adverse eJect". We did not feel this was appropriate and have
changed this to "cosmetic outcome (participant- and observer-rated)", and aKer discussion with HW, who had not seen the results, if
multiple time points were reported, we included the time point closest to one year (but not less than one year) following treatment, as this
is the minimum time taken for a scar to mature. Additionally, on Cochrane Skin's advice we have made the cosmetic outcome a primary
outcome so as to include both a benefit and harm as primary outcomes.
We have renamed the secondary outcome "discomfort to participants in terms of pain during treatment and thereaKer" to "pain during
treatment and thereaKer" to make it clearer and more specific. All adverse eJects data were recorded but due to the heterogeneous nature
of these data and the way they were presented, we did not perform analyses or present them in the 'Summary of findings' tables. Instead
we collated all these into a separate adverse eJects table.
In methods, a section has been added detailing the addition of GRADE assessments of the certainty of evidence as well as 'Summary of
findings' tables and how they were produced.
Due to the large number of studies and to improve readability of the review, we excluded studies that did not measure any of our outcomes
of interest in accordance with MECIR C40.
We decided to include studies that compared an active treatment against a no treatment arm. The reason we departed from the protocol
on this was because we did not have a strong justification for excluding such studies and we were challenged on this by two of our peer-
reviewers.
JT, SH and J-LB are new authors since the last review. JB and WB are not authors on this update.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antineoplastic Agents  [therapeutic use];  Carcinoma, Basal Cell  [surgery]  [*therapy];  Cryotherapy;  Photochemotherapy;  Radiotherapy;
  Randomized Controlled Trials as Topic;  Skin Neoplasms  [surgery]  [*therapy];  Treatment Outcome
MeSH check words
Adult; Humans
Interventions for basal cell carcinoma of the skin (Review)
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